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LITERATURE REVIEW
EFFECTS OF POOR MATERNAL NUTRITION
The concept of fetal programming is explained in the developmental origins of adult
disease theory. This theory suggests that alterations in fetal nutrition and endocrine status may
result in developmental adaptations that permanently change the structure, physiology, and
metabolism of the offspring. Therefore, poor nutrition during fetal life can predispose offspring
to metabolic, endocrine, and cardiovascular disease (Barker and Clark, 1997). Programming
involves resetting fetal development to accommodate the environment into which the fetus
expects to be born, similar to the maternal and placental endocrine, and metabolic environment
(Gluckman and Harding, 1997). Programming due to an inadequate environment in-utero allows
the fetus short-term survival. However, these permanent changes can be harmful if the post-natal
environment does not match that of the intrauterine environment, and can lead to disease in adult
life (Kanaka-Gantenbein, 2010). Intrauterine growth retardation (IUGR) can result from changes
in fetal programming due to poor maternal nutrition and can be detrimental to post-natal growth
(Wu et al., 2006).
Intrauterine growth retardation is defined as the impaired growth and development of the
mammalian embryo/fetus or its organs during pregnancy (Wu et al., 2006). It is associated with
many negative consequences, permanently affecting growth and development of the offspring
(Wu et al., 2006). This can result in impaired growth, decreased milk production, and decreased
feed efficiency. Offspring with IUGR tend to have decreased birth weight and decreased organ
weight due to the changes in energy allocation as a result of programming (Barker, 2006).
Development of permanent lifetime health problems such as altered insulin secretion, insulin
resistance, and cardiovascular disease in adult life is a concern for IUGR offspring (Da Silva et
1

al., 2001). As IUGR progeny reach reproductive age, they tend to have poor reproductive
performance and delayed onset of puberty (Da Silva et al., 2002). These long-term effects can
be very costly for animal producers since there is a high mortality rate of IUGR animals.
Intrauterine growth retardation is a problem in the agriculture industry and is considered
an obstacle in achieving the main goals of animal production such as, enhancing efficiency of
feed/forage utilization, and improving quality of meats, eggs, milk, and fiber (Wu et al., 2006).
Body composition and growth rate are altered in IUGR animals, influencing the tenderness and
palatability of meat. Fast growing animals tend to have a greater number of muscle fibers with
smaller cross sectional areas, hence produce better quality meat (Gondret et al., 2005). For
example, the concentration of glycogen and rate of glycolysis in muscle affects the production of
lactic acid, meat pH and its water holding capacity, and the amount of intramuscular fat
determines the rate of lipid peroxidation, which can cause changes in meat color and taste (Fang
et al., 2002; Wu et al., 2006). The slower growth rate associated with IUGR animals, leads to an
increase in fat and decrease in protein accretion.
Intrauterine growth retardation can be caused by many factors including, genetics,
environmental stress, and poor maternal nutrition, due to under or over feeding, which will be the
focus of this literature review (Wu et al., 2006).

The intrauterine environment is an important

determinant of fetal growth since it is dependent upon placental transfer from the mother
(Wilson, 2002). Changes to maternal nutritional status can hinder fetal growth, since the fetus is
fully dependent on transfer of oxygen and nutrients across the placenta for substrate supply
(Gluckman and Harding, 1997). Poor maternal nutrition causes substrate limitation that can
result in impaired fetal development leading to health problems in adulthood (Gluckman and
Harding, 1997). Wallace et al. (2004) demonstrated that overfeeding, like underfeeding, once
2

pregnancy is established, retards fetal growth in sheep. Therefore, both maternal under-nutrition
and over-nutrition can result in permanent negative consequences in the offspring (Wu et al.,
2006).
For example, ruminants, such as cattle and sheep, graze in pastures and rangelands
consuming forages. The quality of forage on rangeland can be poor, especially during the winter
and periods of drought, and is insufficient for optimal nutrition of growing, gestating, and
lactating animals (Fontaneli et al., 2005). This is a problem since the gestating period for ewes is
normally during winter when forage quality and quantity are declining (Hoaglund et al., 1992).
Therefore, under-nutrition at the fetal level can occur, resulting in decreased fetal growth
(Mellor, 1993; Vonnahme et al., 2003; Wu et al., 2006). It has been shown that nutrient uptake
of grazing ewes in the western United States is usually less than 50% of the National Research
Council (NRC, 1985) recommendations and is considered nutrient-restriction (Thomas and Kott,
1995).
Maternal over-nutrition is just as detrimental to the fetus as under-nutrition. Overnutrition is an increase in either protein or energy, or a combination of both. Long et al. (2010)
produced a maternal obese sheep model where ewes were fed 150% NRC recommendations
from 60 d before conception until parturition, resulting in a 30% body weight (BW) increase by
breeding and a 52% BW increase by 135 d of gestation. An energy rich environment during fetal
programming such as these has been reported to lead to the development of excess abdominal fat
and insulin resistance, demonstrating that similar to under-nutrition, over-nutrition can also
predispose offspring to developing diseases in adult life (Kanaka-Gantenbein, 2010).
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Flushing, the practice of increasing energy intake to enhance the rate of ovulation in
animals so that the number of embryos/fetuses is greater, is one case where management to
increase the number of offspring can result in programming changes during fetal life (Cole,
1990). Multi-fetal pregnancies increase total placental weight, but placental mass per fetus is
reduced, affecting fetal growth (Wootton et al., 1983; Redmer et al., 2004). High prolificacy in
sheep is desirable because it increases the profitability of lamb production, but an increased
number of fetuses in-utero results in decreased birth weight (Gootwine et al., 2006). This can
result in negative consequences, that have permanent effects in post-natal life (Wallace et al.,
2004). Overfeeding, during part or even all of gestation, can have negative pregnancy outcomes
(Han et al., 2000; Nissen et al., 2003). Thus, the management scheme to increase the number of
offspring can result in reduced birth weight and cause post-natal problems (Gootwine et al.,
2006).
Poor maternal nutrition results in many negative consequences, but the timing of insult
during gestation can have different effects on offspring post-natal growth. Many studies have
determined the effects of poor maternal nutrition during specific periods of gestation including
pre-gestation, early gestation, mid-gestation, late gestation, or a combination of these periods.
The first half of gestation in sheep and humans is critical for placental growth and
vascularization, and fetal organogenesis (Stegeman, 1974; Reynolds and Redmer, 1995;
Schneider, 1996). Nutrient -restriction only during mid-gestation can result in variable placental
and fetal growth, but if extended throughout gestation, fetal growth can be compromised
(Redmer et al., 2004). Gardner et al. (2005) reported that under-nutrition, confined to early
gestation might have an impact on adult cardiovascular function in sheep. Functional
development of the pancreas, in sheep, takes place during mid to late gestation, so under4

nutrition during late gestation affects both the development and function of the pancreas. This
can impair glucose tolerance later in life (Wallace and Bassett, 1966). Ford et al. (2009) reported
increased pancreatic weight at mid-gestation in offspring born to ewes overfed starting 60 d
before conception. Ford et al. (2007) demonstrated hyperglycemia and altered insulin secretion
after a glucose tolerance test in lambs born to ewes nutrient-restricted starting at d 28 of
gestation. Over-nutrition, beginning before conception and lasting throughout gestation, can
decrease fetal pancreatic weight by late gestation and increase leptin concentrations of offspring
(Long et al., 2010; Zhang et al., 2011). Gardner et al. (2005) reported that under-nutrition
confined to late gestation alters glucose-insulin homeostasis of the adolescent, providing
evidence of post-natal effects due to poor maternal nutrition during gestation, such as glucose
intolerance and insulin resistance. These authors also demonstrated reduced expression of
glucose transporter (GLUT) 4, in these animals, causing reduced glucose uptake in adipose tissue
(Gardner et al., 2005). Overall, these reports demonstrate that nutritional insult at any time
during gestation can negatively influence post-natal growth and metabolism of the offspring.
Altered hormonal sensitivity is a common feature of the pathophysiology of IUGR,
which could cause the long-term consequences associated with IGUR (Gluckman and Harding,
1997). Many hormones regulate fetal growth including insulin-like growth factors (IGF)-I and II, and insulin. Placental glucose transfer is a major pathway in the regulation of fetal growth
since it is responsible for regulating insulin release from the pancreas (Gluckman and Harding,
1997). Insulin, in turn regulates fetal IGF-I release (Gluckman and Harding, 1997). The role of
IGF-II is more prominent in embryonic growth, whereas IGF-I is prominent in late gestational
and post-natal growth (Gluckman and Harding, 1997). Studies have demonstrated that maternal
nutritional status before and in early pregnancy influences not only fetal growth rate, but also
5

development of the fetal glucose-insulin axis, and thus, post-natal glucose tolerance and insulin
sensitivity (Bloomfield et al., 2013). Given that programming affects insulin sensitivity, it may
explain the origin of the association between IUGR and diabetes in humans (Gluckman and
Harding, 1997). The release of leptin from adipose tissue is regulated by insulin, and leptin
regulates energy expenditure and food intake, making it an important hormone in the growth
process. Both insulin and leptin are critical hormones in nutrient storage, especially related to
adiposity. Therefore, programming due to poor maternal nutrition can lead to changes in
hormones of the somatotropic axis as well as the insulin-glucose axis and leptin concentrations,
causing permanent changes in offspring development and potentiating disease later in life.
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SOMATOTROPIC AXIS
Overview
The somatotropic axis is a multilevel hormonal system consisting of neuropeptides from
the hypothalamus, including growth hormone releasing hormone (GHRH) and somatostatin
(SRIF); growth hormone (GH) produced from the anterior pituitary gland; IGF-I and -II and their
binding proteins (IGFBP), produced from the liver, and peripheral tissues including adipose,
skeletal muscle, and bone (Skaar et al., 1994; Renaville et al., 2002). This axis is important in
the regulation of growth, development, energy, and protein metabolism (Gerrard and Grant,
2006). Measures of the somatotropic axis can be predictive of nutritional status and growth rate
of individual animals (Rausch et al., 2002; Govoni et al., 2011).
Somatotrope cells, in the anterior pituitary gland, produce and secrete GH (Tuggle and
Trenkle, 1996). Growth hormone is regulated by two hypothalamic hormones, GHRH and SRIF
(Kazmer et al., 2000; Sosa et al., 2009). The arcuate (ARC) nucleus of the hypothalamus
releases GHRH, allowing it to bind to its receptor on the somatotrope cells of the anterior
pituitary gland and stimulate GH release. Somatostatin, produced by the neurons of the anterior
periventricular nucleus, inhibits the release of GH from the somatotrope cells.
Upon secretion, GH is released into circulation where it can bind to GH binding protein
(GHBP), which can then bind to hepatic GH receptors (GHR; Baumann, 1994). Growth
hormone can also act on other tissues such as adipose, bone, and muscle, by binding to specific
cell surface receptors. It is a major regulator of metabolism and post-natal longitudinal growth
by acting in both indirect and direct manners (Breier, 1999). Growth hormone stimulates
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synthesis of IGF in tissues, and in turn, IGF (-I and –II) mediate many actions of GH (Renaville
et al., 2002)
Insulin-like growth factor-I and -II act in an endocrine manner in circulation as well as an
autocrine/paracrine manner locally. Once released from the liver into circulation, IGF can bind
to one of six IGFBP. These binding proteins act as carriers of IGF and increase IGF half-life
(Renaville et al., 2002). Most IGF binds to IGFBP-3 and an acid labile subunit (ALS), forming a
tertiary complex. Over the years, our laboratory has demonstrated how IGF-I, IGFBP-2, and
IGFBP-3 respond to changes in growth, development and nutritional status (Rausch et al., 2002;
Govoni et al., 2003, 2004).
Locally produced IGF can exhibit autocrine and paracrine effects on bone, muscle, and
adipose tissue through interactions of cell surface IGF receptors (Jones and Clemmons, 1995).
Insulin-like growth factors have a major role in skeletal muscle regeneration and hypertrophy as
well as mammary gland cell proliferation, survival during pregnancy and lactation (Hadsell,
2004; Clemmons, 2009). Growth hormone has insulin-antagonistic properties and fluxes of GH
can cause insulin resistance (Holt, 2003). In contrast, IGF-I has insulin-like effects and increases
insulin sensitivity (Annunziata et al., 2011).
These hormones of the somatotropic axis all contribute to the overall growth rate and
metabolism of animals, making the study and knowledge of this axis essential to the
understanding of post-natal growth and development. It is also important to understand how
factors such as age and nutrition can influence the somatotropic axis, therefore affecting growth.
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Growth hormone
Growth hormone is a 22 to 23 kDa protein that exhibits structural homology among
species with prolactin and placental lactogen (Goffin et al., 1996). Growth hormone and the
GHR belong to a large family of cytokine peptides and their receptors (Bazan, 1990). Most GH
circulates in the blood as a monomer, but other variant forms arise from alternate splicing during
transcription (Baumann, 1999). Growth hormone is composed of four anti-parallel helical
bundles connected by loops of varying length (Frank and Messina, 2002). The human, rat,
bovine, and ovine GH gene sequences are similar, all containing 2.6 to 3.0 kilobase pairs and
five exons and four introns (Barta et al., 1981; DeNoto et al., 1981; Tuggle and Trenkle, 1996).
The ovine gene has been determined to be more similar to the bovine gene than other species. In
most species such as cattle and pigs, there is one GH gene, but in sheep, multiple copies of the
GH gene have been found (Gootwine et al., 1998). Sheep have two alleles at the ovine gene
locus: the GH1 allele with a single GH copy and the GH2 allele that has two GH copies of the
GH coding region (GH2-N and GH2-Z; Valinsky et al., 1990; Gootwine et al., 1993). These two
copies of GH2 are almost identical in nucleotide sequence, but only GH2-N is found in the
anterior pituitary gland (Gootwine et al., 1998). Ewes with an extra copy of the GH gene have
been shown to have a greater ovulation rate and increased plasma GH, but also developed more
heath problems (Adams and Briegel, 2005).
Growth hormone receptor is a type I glycoprotein, cytokine receptor that is known to
utilize the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling
pathway (Bazan, 1990; Brooks et al., 2008). The full length GHR of various species are in the
range of 600 amino acids in length and contain large cytoplasmic domains (Frank and Messina,
2002). Alternatively spliced forms of the GHR gene exist and encode receptors different from
9

the full-length GHR (Frank and Messina, 2002). One of these isoforms circulates as a high
affinity GHBP (Frank and Messina, 2002).
In humans, about 50% of circulating GH is associated with GHBP (Baumann et al.,
1988). Two independent mechanisms derive GHBP. Growth hormone binding protein is
composed of a soluble form of the GHR extracellular domain (Frank and Messina, 2002) and can
stimulate and inhibit GH action (Baumann, 2001). Most GHBP exists in a 1:1 ratio of
GH:GHBP (Frank and Messina, 2002). In circulation, GHBP increases the half-life of bound
GH and acts to stabilize GH bioavailability (Baumann, 2001).
Both GHR and GHBP are derived from the same gene either by alternate mRNA splicing
or by proteolytic cleavage of the GHR protein (Baumann, 1994). The extracellular domain of
the receptor consists of two fibronectin type III β sandwich domains connected by a helical
transmembrane linker (Brooks et al., 2008). The intracellular domain is composed of two motifs,
Box I and Box 2. These motifs bind the tyrosine kinase, JAK2 and several tyrosine residues that
are substrates for phosphorylation by JAK2 (Brooks et al., 2008). Box 1 is a proline rich
sequence found in the cytoplasmic domain of the GHR membrane and Box 2 is a short acidic
section, 30 residues long (Murakami et al., 1991; Frank and Messina, 2002). Growth hormone
receptor is N-glycosylated and spans the membrane surface. The GH molecule has two binding
sites for the extracellular domain of the GHR and forms a 1GH:2GHR complex by sequential
homodimerization (Breier, 1999). Site 1 has a higher affinity for GH binding than site 2 and
interacts with the first receptor, leaving the second site to interact with the second receptor
(Cunningham et al., 1991). The GHR-GHR dimerized receptor is the activated form of GHR and
is required for stabilization of the GH complex (Frank and Messina, 2002).
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Growth hormone binding to the GHR activates a number of intra-cellular pathways
including mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase
(Pl3K) cascade (Figure 1). Growth hormone receptor association with JAK2 is critical to GH
action (Frank and Messina, 2002). Other tyrosine kinases are activated in response to GH
including focal adhesion kinase (FAK; Zhu et al., 1998). Growth hormone receptor signaling
results in activation of STAT molecules by recruiting the STAT molecule to the tyrosine
phosphorylated receptor or JAK, allowing tyrosine phosphorylation of the STAT src homology 2
(SH2) domain (Davey et al., 1999). Growth hormone promotes the tyrosine phosphorylation and
DNA-binding capacity of STAT1, 3, 5a, and 5b (Campbell and Scanes, 1995). Activation of
JAK2 by GH is also required for the MAPK cascade, through recruiting adaptor protein Shc,
which then binds growth factor receptor-bound protein 2 (Grb2), and son of Sevenless (SOS)
activating Ras, Raf and in turn, Mek. The Pl3K cascade is activated by adaptor protein insulinreceptor substrate (IRS), leading to activation of Akt. These pathways lead to cell proliferation
and gene transcription (Kelly et al., 2001).
There has been detection of GHR mRNA and immunoreactivity in most post-natal tissues
with the greatest abundance in liver and adipose tissue (Breier, 1999). Pituitary-specific
transcription factor-1 (PIT-1) binding directs cell specific gene expression in somatotrope cells
(Dasen and Rosenfeld, 2001). Pituitary specific transcription factor-1 is required for the
development and maintenance of somatotrope cells and regulation of GH by activating
transcription of GH1. This leads to increased GH1 mRNA and GH protein, replenishing GH
stores (Lin-Su and Wajnrajch, 2002). Within the anterior pituitary gland, the GHRH receptor
(GHRH-R) is co-expressed with PIT-1 (Mayo et al., 2000). Transcription of GHRH-R gene can
be stimulated by PIT-1, increasing receptor concentration on somatotropes (Mayo et al., 2000).

11

Regulation of growth hormone secretion
The regulation of GH secretion and its action on peripheral tissues is thought to be the
most fundamental determinant of body size (Butler and Le Roith, 2001). Growth hormone is
regulated by nutrition and by the hormonal and genetic milieu that controls the timing and rate of
growth (Butler and Le Roith, 2001). Growth hormone secretion from somatotrope cells in the
anterior pituitary gland occurs under control of a complex neuroendocrine system involving two
hypothalamic hormones from the median eminence (Tuggle and Trenkle, 1996; Sosa et al.,
2009). Growth hormone releasing hormone stimulates GH release and SRIF inhibits it (Tuggle
and Trenkle, 1996; Sosa et al., 2009). The secretory pattern of GH is pulsatile in most species
and is dependent on the interaction between GHRH and SRIF at the somatotrope level (Muller et
al., 1999). This pattern of GH release is important in determining growth rate in mammals
(Butler and Le Roith, 2001). Neurons in the ARC nucleus and anterior periventricular nucleus
produce GHRH and SRIF, respectively (Devesa et al., 1992).
Growth hormone releasing hormone was originally isolated from a human pancreatic
tumor and identified as a hypothalamic peptide that stimulates the release of GH from the
pituitary (Guillemin et al., 1982). It stimulates GH synthesis through increasing intracellular
cyclic adenosine monophosphate (cAMP) concentrations, activating protein kinase (PK) A
(Mayo et al., 2000). Growth hormone releasing hormone also has mitogenic effects on
somatotropes and is required for their normal proliferation during development (Cella et al.,
1994), most likely through activation of MAPK (Mayo et al., 2000). Growth hormone releasing
hormone receptor is a class II G protein coupled receptor mainly found on pituitary somatotrope
cells (Mayo, 1992; Gaylinn et al., 1993). It is 423 amino acids long and consists of seven
transmembrane domains. After GHRH is released from the ARC nucleus of the hypothalamus, it
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Figure 1. Growth hormone (GH) signal transduction pathways.

Growth hormone binds to growth hormone receptor (GHR) activating the phosphatidylinositol 3kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Binding activates Janus
kinase (JAK) 2, causing phosphorylation of other substrates such as signal transducers and
activators of transcription (STAT) molecules, focal adhesion kinase (FAK), insulin receptor
substrate (IRS) -1/2, and Shc. Phosphorylation of IRS-1/2 leads to the PI3K pathway and
activation of Akt. The MAPK pathway is activated by phosphorylation of Shc, which recruits
growth factor receptor-bound protein 2 (Grb2) and son of Sevenless (SOS), activating Ras, then
Raf and Mek, leading to proliferation. Tyrosine phosphorylation of STAT molecules promotes
their DNA-binding capacity (Modified and reprinted from Postel-Vinay and Kelly, 1996 with
permission from Elsevier.
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binds to the GHRH-R located on somatotrope cells. Binding of GHRH activates a stimulatory
G-protein (Gs) by catalyzing binding of GTP to the α subunit (Lin-Su and Wajnrajch, 2002).
Adenylyl cyclase is stimulated and increases intracellular cAMP. A sodium (Na+) channel in the
somatotrope opens in response to receptor activation, causing depolarization to take place. As a
result, a voltage-gated calcium (Ca2+) channel opens and the influx of Ca2+ causes release of GH
from secretory granules (Petersenn and Schulte, 2000; Lin-Su and Wajnrajch, 2002).
Not only does the binding of GHRH to its receptor stimulate GH secretion, but GH
synthesis is stimulated as well. This occurs in response to the increase in cAMP stimulating
PKA to phosphorylate and activate cAMP response element-binding protein (CREB; Petersenn
and Schulte, 2000). Growth hormone production increases due to an increase in transcription of
the GH1 gene and GHRH receptor gene (Mayo et al., 1995; Muller et al., 1999; Petersenn and
Schulte, 2000).
Somatostatin acts in opposition to GHRH by inhibiting GH release. Somatostatin is
synthesized as a 116 amino acid precursor, cleaved by endopeptidases, resulting in two forms
secreted from the hypothalamus: SRIF-28 and SRIF-14 (Krantic et al., 2004). These two forms
are produced in different proportions by neurons and secretory cells through the differential
processing of a common pro-SRIF precursor (Patel and O’Neil, 1988). Both SRIF-14 and SRIF28 are found in the periphery and central nervous system, with SRIF-14 as the predominant form
(Krantic et al., 2004). Both monomers and dimers of SRIF-14 exist in circulation (Devesa et al.,
1992). The two forms of SRIF have overlapping physiological functions. The main function of
SRIF is to inhibit hormone secretion, particularly GH secretion. Administration of SRIF-28 in
cattle has been reported to effectively inhibit GHRH induced GH release, proving SRIF
involvement in regulation of GH (Kazmer et al., 2000). Somatostatin regulates potassium (K+)
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channels causing hyperpolarization of the plasma membrane, decreasing Ca2+ influx (Benali et
al., 2000). This reduces intracellular Ca2+, thus inhibits GH release (Benali et al., 2000). The
actions of SRIF are mediated by the coupling of G high affinity plasma membrane receptors to
adenylyl cyclase, K+, Ca2+ channels, and protein tyrosine phosphatase, with the help of G
proteins (Koch and Schonbrunn, 1988).
Once GH is released from the anterior pituitary gland, it circulates in the blood and exerts
many biological functions. Growth hormone can act on many tissues including liver, muscle,
adipose, and bone, to stimulate production of IGF-1 locally (Isaksson et al., 1987). Circulating
IGF acts to mediate the local autocrine/paracrine effects of GH (Butler and Le Roith, 2001).
Growth hormone also acts directly on adipose tissue by decreasing lipogenesis and insulin
sensitivity (Renaville et al., 2002). Many of the effects of GH on growth and metabolism are
mediated indirectly via control of the synthesis of other growth factors, such as IGF (Butler and
Le Roith, 2001). This makes GH the main regulator of growth via the production of systemic
and local IGF-I production (Monzavi, 2002).
Insulin-like growth factors
Insulin-like growth factor-I and -II are single-chain homologous polypeptides, similar in
structure to insulin, that regulate proliferation and differentiation of many different cell types and
exert insulin-like metabolic effects (Cohick and Clemmons, 1993; Hwa et al., 1999). Most
tissues of the body produce IGF, with the liver being the predominant source of production
(Cohick and Clemmons, 1993). The human IGF-I gene is located on the long arm of
chromosome 12 (Brissenden et al., 1984; Tricoli et al., 1984). It has multiple promoters and
contains six exons, four of which can be alternatively spliced (Rotwein et al., 1986; Smith et al.,
2002). The mature IGF-I is a single 7.5 kDa chain, 70 amino acids in length with three disulfide
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bridges (Rotwein et al., 1986). Insulin-like growth factor-I has four domains: A, B, C, and D.
The A and B domains are structurally homologous to insulin A and B chains and C is similar to
the connecting C peptide in pro-insulin (Humbel, 1989). The amino acid sequence of the mature
form of ovine IGF-I is highly homologous to the human, mouse, and rat sequences (Dickson et
al., 1991), only differing from human and porcine sequences at a single amino acid residue
(Tavakkol et al., 1988). Dickson et al. (1991) found that the DNA sequence of the ovine gene is
highly homologous to that of human IGF-I, with the nucleotide sequence of the coding regions
exhibiting 89 to 100% homology, and the exon-intron boundaries showing co-incident, splice
consensus sequences. Bovine IGF-I was found to be identical to human IGF-I by Honegger and
Humbel (1986). Insulin-like growth factor-II is similar to IGF-I in structure, but only has 67
amino acids (Rotwein et al., 1986). The IGF-II gene is about 30 kilobases long and has three
promoters. The liver, as well as other tissues, produce IGF-II, but it is not regulated by GH
(Clemmons, 2006; Kaplan and Cohen, 2007). Insulin-like growth factor-II has an important role
in embryonic and fetal growth, but less of a role in post-natal life, when the role of IGF-I is more
prominent (Annunziata et al., 2011). Both IGF-I and –II are conserved among species.
The IGF can interact with type I and type II IGF receptors, and insulin receptors. The
type I IGF receptor is a heterotetrameric glycoprotein, tyrosine kinase receptor that spans the cell
membrane and mediates the effects of IGF-I and -II (Le Roith, 1996; Baserga et al., 1997).
Insulin-like growth factor-I binds with high affinity to the type I IGF receptor. Insulin and IGFII can also bind to this receptor, but with lower affinity (Le Roith, 2003; Himpe and Kooijman,
2009). The type I IGF receptor is homologous to the insulin receptor and is a disulfide-linked
dimer composed of two α and two β subunits in each half (Le Roith, 1996). The precursor
peptide of the type I IGF receptor is 1,367 amino acids and when cleaved produces the subunits
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(Le Roith, 1996). The α subunits are extracellular and modified by N-glycosylation and the β
subunits anchor the receptor in the membrane and contain a tyrosine kinase domain in their
cytoplasmic portion (Le Roith, 1996).
The type II IGF receptor is structurally distinct from the type I IGF and insulin receptors
in that it contains a short cytoplasmic region that lacks tyrosine kinase activity (Le Roith, 1996).
It is a monomeric, 250 kDa, transmembrane protein. Insulin-like growth factor-II binds with
high affinity to the type II IGF receptor, IGF-I binds with less affinity, and insulin does not bind
to this receptor (Shimasaki and Ling, 1991). In addition to binding IGF-II, it can also bind
mannose-6-phosphate-containing ligands, and interact with G protein pathways (Nissley and
Lopaczynski, 1991; Ikezu et al., 1995). Within each of the 15 contiguous extracellular repeats of
the receptor, there are eight conserved cysteine residues with similar disulfide bonding (Le
Roith, 1996). This receptor has anti-proliferative and pro-apoptotic activities by sequestering
IGF-II and reducing its interaction with the type II IGF receptor (Hankins et al., 1996;
O’Gorman et al., 2002; Pollak, 2008). Hybrid receptors can also be formed due to the close
similarity between the insulin receptor and type I IGF receptor and can bind both IGF-I and IGFII with high affinity, and insulin with lower affinity (Soos et al., 1993).
Upon IGF-I binding to the α subunit of the type I IGF receptor, activation of the intrinsic
tyrosine kinases of the β subunit and three tyrosine residues that act as docking sites for signaling
proteins, occurs (Himpe and Kooijman, 2009). The signaling proteins then recruit other
substrates leading to activation of different signaling cascades, including the PI3K pathway and
the MAPK pathway, that stimulate cell proliferation and survival (Figure 2; Le Roith, 2003;
Himpe and Kooijman, 2009). There are two main substrates involved in signal transduction
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Figure 2. Insulin-like growth factor (IGF) -I signal transduction pathways.

Insulin-like growth factor (IGF) -I or -II binds to the type I IGF receptor (IGFIR),
autophosphorylating the β subunit tyrosine kinases. This activates two major pathways:
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). Tyrosine
residues act as docking sites for signaling proteins. The PI3K pathway is activated by
phosphorylation of insulin-receptor substrate (IRS) -I, resulting in an increase of
phosphatidylinositol 3, 4, 5-triphosphate (PIP3), which binds to Akt. The MAPK pathway is
activated by binding of Shc to the receptor and recruitment of growth factor receptor-bound
protein 2 (Grb2) and son of Sevenless (SOS), activating Ras then Raf and Mek, eventuating in
the activation of extracellular signal-regulated kinase (ERK) -1/2. Proliferation can then be
induced (Modified and reprinted with permission from: Bikle, 2008).
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of type I and insulin receptors: IRS-1 and Shc (Le Roith, 1996). Activation of the PI3K pathway
occurs by binding of the SH2 domain of its regulatory subunit to IRS-1, which IGF type I
receptor phosphorylates before binding (Vincent and Feldman, 2002). The concentrations of
phosphatidylinositol 3, 4, 5-triphosphate (PIP3) are increased and bind to the pleckstrin
homology domain of protein kinase B (AKT/PKB) and phosphoinositide-dependent kinase-1
(PDK-1). This kinase phosphorylates residue Thr308 on AKT/PKB as well as other proteins,
including p70 ribosomal protein S6 kinase, PKC and PKA.
Another pathway involves isoforms of the MAPK family, extracellular signal-regulated
kinase (ERK) -1 and -2. This pathway is activated by binding of Shc and recruitment of Grb2,
which binds SOS, a guanine nucleotide exchange factor, that activates Ras (Himpe and
Kooijman, 2009). Then Ras activates Raf, in turn activating Mek-1/2, then activating ERK-1
and ERK-2 (Himpe and Kooijman, 2009). This pathway causes cell differentiation and
migration to occur (Yoshida et al., 2006).
Insulin-like growth factor binding proteins
Insulin-like growth factor binding proteins maintain IGF in circulation and transport them
to target tissues where they can promote cell growth, proliferation, differentiation, and cell
survival through binding to the type I IGF receptor (Denley et al., 2005). These proteins increase
the half life of IGF and mediate their metabolic clearance rate (Firth and Baxter, 2002). There
are six mammalian IGFBP (IGFBP-1 to 6) derived from distinct genes (Firth and Baxter, 2002).
The precursor forms of all six IGFBP have secretory signal peptides, 20 to 39 amino acids in
length and the mature proteins are extracellular (Firth and Baxter, 2002). In their soluble form,
the IGFBP have greater affinity for the IGF than the type I receptor does, potentially inhibiting
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the biological effects of the hormone (Denley et al., 2005). Insulin-like growth factor binding
protein-1 through -5 bind both IGF-I and IGF-II with similar affinities, but IGFBP-6 has a higher
affinity for IGF-II than IGF-I (Headey et al., 2004; Siwanowicz et al., 2005).
The IGFBP family is classified as cysteine rich proteins (16 to 20 cysteines in the prepeptides) with similar amino acid sequences. The cysteines are located at the N-terminal third
and at the C-terminal third of the proteins. There are three domains, of approximately equal
length, that make up the IGFBP; a conserved N-terminal domain, a variable linking domain (L
domain), and a conserved C-terminal domain (Bach et al., 2005). The N and C-terminal domains
are both necessary in IGF binding and they are connected by the L domain that is not involved in
binding (Bach et al., 2005).
The N-terminus contains 80 to 93 amino acid residues after the signal peptides and has
58% similarity among IGFBP. Of the 16 to 20 cysteines in the pre-peptides, this domain consists
of 12 cysteins (Duan, 2002). There are intra-domain disulfide bonds in the N-terminus, but no
inter-domain disulfide bonds due to an even number of cysteine residues (Bach et al., 2005).
Sub-domains form between cysteines that are close together in the primary sequence, two of
these sub-domains are within the N-terminus domain. The first sub-domain consists of the first
six cysteines and the second sub-domain contains the next four cysteines (Hwa et al., 1999). The
local motif (GCGCCxxC) in the N-terminal domain is well conserved, except in IGFBP-6 where
a GCAEAEGC sequence is substituted, but is still able to maintain high affinity for IGF (Hwa et
al., 1999). This motif is considered important in high affinity IGF binding, which is the only
function of this domain (Hwa et al., 1999; Bach et al., 2005).
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The second domain, the L domain, separates the N-terminal domain from the C-terminal
domain. This domain is not conserved and is not involved directly with IGF binding (Bach et al.,
2005). Post-translational modifications, such as glycosylation and phosphorylation of IGFBP,
occur in this mid-region (Firth and Baxter, 2002). Insulin-like growth factor binding protein -3
has three potential sites of N-glycosylation at an asparagine residue that is part of the consensus
sequence Asn-X-Ser/Thr, located at Asn89, Asn109, and Asn172 (Firth and Baxter, 1999). Insulinlike growth factor binding protein-5 and -6 are O-glycosylated, but there is no consensus
sequence for predicting sites for O-glycosylation (Neumann and Bach, 1999). Glycosylation
does not affect IGFBP high-affinity binding to IGF, but modifies other properties such as
stability and susceptibility to proteolysis and circulating half-life (Marinaro et al., 2000; Firth
and Baxter, 2002). Post-translational modification by phosphorylation occurs in IGFBP-1, -3,
and -5 (Coverley and Baxter, 1997). Phosphorylation allows cells to regulate the activities of
numerous intracellular proteins, such as proteins involved in the cell cycle, signal transduction
pathways and in gene expression (Jones et al., 1991). Phosphorylation occurs predominantly at
serine residues in the mid-region of the proteins. Phosphorylation of IGFBP-3 may affect
interactions with ALS or cell surface (Coverley, 2000).
The C-terminal domain is highly conserved and 34% homologous among IGFBP. This
domain consists of six cysteines and studies indicate intra-domain disulfide bond formation
among the residues (Duan et al., 2002). Due to the level of homogeneity between the last five
cysteines in the C-terminal, the tertiary structure of this domain should be almost identical in all
IGFBP. The C-terminal domain in IGFBP-3 and -5 contains an 18 amino acid region where
ALS can bind (Firth and Baxter, 2002). The C-domain has a wide range of functions including
IGF-independent actions such as growth inhibition, promotion of apoptosis, and modulation of
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cell migration (Bach et al., 2005). This domain of IGFBP-1 and -2 contain RGD motifs that bind
integrins, leading to altered cell migration (Wang et al., 2006).
The most abundant IGFBP in circulation is IGFBP-3. Insulin-like binding protein-3 has a
very high affinity for both IGF-I and IGF-II (Cohick and Clemmons, 1993). Insulin-like growth
factor binding protein-3 is 46 to 53 kDa when glycosylated and 29 kDa just from its amino acid
sequence (Yamada and Lee, 2009). There are three potential N-glycosylated sites (Asn-XSer/Thr) located in the non-conserved mid-region of the IGFBP-3 sequence (Asn89, Asn109,
Asn172-sites 1, 2, 3 respectively; Firth and Baxter, 1999). In circulation, this binding protein is in
its glycosylated form. The glycosaminoglycan binding domains of IGFBP-3 allow localization
to the extracellular matrix and cell surfaces, decreasing the affinity of IGFBP-3 for IGF-I, thus
enhancing IGF action (Yamada and Lee, 2009). Two major phosphorylation sites of IGFBP-3
exist and dephosphorylation of the protein appears to enhance its binding to ALS and cell
surfaces. Acid labile subunit is a glycoprotein, ~ 85 kDa that contains several leucine rich
domains, known to facilitate protein-protein interactions and binding of IGFBP-3 (Boisclair et
al., 2001). It is capable of sequestering IGF from IGF type I receptor since it has greater affinity
for IGF than its receptor. This decreases IGF bioavailability and action (Yamada and Lee,
2009). In mammals, IGFBP-3 carries most circulating IGF-I and -II (> 90%) in a 150 kDa
ternary complex also made up of ALS (Boisclair et al., 2001). Like IGF, the liver is the main
source of IGFBP-3 and ALS. Growth hormone stimulates production of all three subunits of this
complex and regulates their concentrations in circulation (Kelly et al., 2002).
The second most abundant binding protein in circulation is IGFBP-2 (Wheatcroft and
Kearney, 2009). It is a ~36kDa protein and is not glycosylated or phosphorylated (Shimasaki
and Ling, 1991; Wheatcroft and Kearney, 2009). The distribution of cysteines in IGFBP-2 is
22

similar to IGFBP-1 (Shimasaki and Ling, 1991). The N-terminal of IGFBP-2 is 128 amino acids
in length and includes the first 12 cysteines. Exon 4 contains the coding region for the Cterminal and the 3’ non-coding region. Insulin-like growth factor binding protein-2 inhibits IGF
by hindering cell growth and proliferation (Jones and Clemmons, 1995). Insulin-like growth
factor, IGFBP-3, and IGFBP-2 concentrations in serum are age dependent. Concentrations of
IGF and IGFBP-3 are low at birth, peak at puberty and decrease thereafter, while IGFBP-2
concentrations are increased in infancy and decreased in adulthood (Cohen and Rosenfeld, 1994;
Govoni et al., 2003, 2004).
The other IGFBP bind with IGF in a smaller fraction. The liver and kidney express
IGFBP-1, which is a non-glycosylated 30 kDa protein (Shimasaki and Ling, 1991). Expression
of IGFBP-1 is regulated by insulin and glucocorticoids. Insulin inhibits IGFBP-1 expression and
glucocorticoids stimulate it (Kim et al., 1997). Concentrations of IGFBP-1 are dependent on
metabolic status (Collett-Solberg and Cohen, 1996). There is an increase in IGFBP-1 in the
fetal compartment. This along with the reduced IGFBP-3 in maternal circulation creates a
gradient that IGF can move down toward fetal circulation (Kim et al., 1997). Insulin-like growth
factor stimulated cell proliferation is inhibited by IGFBP-4 (Mohan et al., 1989). Bone cells
mainly express IGFBP-4, which has a role in bone growth (Kim et al., 1997). It acts to decrease
proliferation of bone cells (Mohan et al., 1989). The main role of IGFBP-5 is in ovarian function
(Kim et al., 1997). Insulin-like growth factor binding protein-5 is a 29 kDa phosphorylated and
glycosylated protein that is secreted by many cell types (Firth and Baxter, 2002). Mammary
gland development and other embryonic developmental processes involve IGFBP-5 (Flint et al.,
2000). Production of IGFBP-5 by mammary epithelial cells increases during involution of the
mammary gland in rodents. Insulin-like growth factor binding protein-6 is different than the
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other five binding proteins in that it is O-glycosylated and has greater affinity for IGF-II than
IGF-I. This binding protein antagonizes follicular development.
Insulin-like growth factor binding protein proteases
Three mechanisms can release IGF from their binding proteins so they can bind to
receptors and exert their mitogenic and metabolic effects (Bunn and Fowlkes, 2003). These
mechanisms include binding of IGFBP to extracellular matrix (ECM) molecules,
phosphorylation of IGFBP, and proteolytic degradation of IGFBP (Bunn and Fowlkes, 2003).
Proteolytic cleavage is the most predominant mechanism (Bunn and Fowlkes, 2003). Protease
activity regulates IGFBP, generating fragments of IGFBP that alter or decrease their
bioavailability. The IGFBP proteases can be serine proteases, metalloproteinases, or cathepsins
(Conover and De Leon, 1994).
Cathepsins are lysomal proteinases that are active at acidic pH 4 to 5.5 and cleave
IGFBP-1 and -5 (Conover and De Leon, 1994). Cathepsin D is an acid IGFBP protease and
regulates extracellular IGFBP. Zwad et al. (2002) showed that Cathepsin L degrades IGFBP-3.
Serine proteinases are the proteases responsible for cleavage of IGFBP-5 (Collett-Solberg and
Cohen, 1996). The metalloproteinases include the matrixins (MMP), the adamalysins, and the
pappalysins (Bunn and Fowlkes, 2003). The MMP are peptide hydrolases that require a metal
ion for their catalytic activity (Collett-Solberg and Cohen, 1996). This family of proteases
includes collagenases such as interstitial collagenase (MMP-1), gelatinase A (MMP-2),
stromolysis 1 (MMP-3), and gelatinase B (MMP-9; Collett-Solberg and Cohen, 1996).
Metalloproteinases may have a role in regulating cellular growth and proliferation through the
degradation of IGFBP-3 to enhance IGF bioavailability (Collett-Solberg and Cohen, 1996). The
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ADAM 12-S protein, a part of the adamalysin class of proteases, binds and degrades IGFBP-3
(Shi et al., 2000). It also can degrade IGFBP-5, suggesting that it requires the interaction with
the positively charged heparin-binding domain only found on these two binding proteins for
proteolysis to occur (Bunn and Fowlkes, 2003). Pregnancy-associated plasma protein A (PAPPA) is the IGF-dependent, IGFBP-4 protease and facilitates IGF release from this binding protein
(Bunn and Fowlkes, 2003). These IGFBP proteases are important for IGF action to be possible
since IGF cannot bind to receptors when their affinity for IGFBP is greater.
Effect of poor nutrition on the somatotropic axis
In normal growing animals, the concentration of GH declines with age and concentration
of IGF-I increases with age (Govoni et al., 2003, 2004). Concentrations of IGFBP-3 increase
with age and growth rate and IGFBP-2 concentrations vary depending upon species, but
normally decrease with age and growth rate (Rausch et al., 2002; Govoni et al., 2003, 2004).
Due to the association of IGFBP-2 and IGFBP-3 with changes in nutrition, these binding
proteins can be used as predictors of nutritional status in animals (Rausch et al., 2002). For these
reasons, we focused on studying changes in IGFBP-2 and IGFBP-3 concentrations.
Nutritional status plays a major role in determining concentrations of GH, IGF-I, IGFBP2 and -3. Fasting, nutrient-restriction, and over-nutrition can all alter the concentrations of
somatotropic axis hormones. These nutrition-induced changes in hormone concentrations in the
mother during gestation can cause inadequate nutrition for the fetus; leading to fetal
programming changes. These permanent metabolic changes that take place in-utero can lead to
disease later in life (Wu et al., 2006).

25

The primary adaptation of the fetus to nutrient-restriction late in gestation is to reduce
growth by altering its endocrine environment, particularly by reducing endocrine and paracrine
IGF-I, which is associated with a reduction of blood flow to protect vital organs (Gluckman and
Harding, 1997). Prolonged periods of maternal under-nutrition have been reported to lead to an
irreversible, permanent slowing of fetal growth rate in late gestation, which persists after birth, as
well as a degree of IGF-I, insulin, and GH resistance (Gluckman and Harding, 1997). Shorter
periods of poor maternal nutrition lead to a transient slowing of growth rate followed by catch-up
growth, suggesting that catch-up growth may be dependent on the length and severity of
substrate limitation in-utero (Mellor, 1979). Ewes undernourished between 60 d before and 30 d
after conception carry fetuses that grow slower in mid to late gestation and at 110 d of gestation
have abnormal regulation of IGFBP (Gluckman and Harding, 1997). This is compatible with the
development of insulin resistance (Gluckman and Harding, 1997). Maternal nutrient-restriction
and IUGR have been shown to alter insulin secretion and homeostasis (Hales and Barker, 2001;
Lobelo, 2005).
Growing animals, fed a restricted diet over an extended period of time have reduced
growth rate, reduced IGF-I and IGFBP-3, and increased GH and IGFBP-2 (Rausch et al., 2002).
The increase in GH associated with periods of under-nutrition, reflects stress, hypoglycemia, and
low serum free fatty acids (FFA; Breier, 1999). This is due to reduced metabolic clearance rate
of GH, facilitated by impaired GH mediated feedback due to altered properties of GHR (Breier,
1999). Growth hormone receptor concentrations positively correlate with nutritional status,
suggesting that under-nutrition induces a degree of GH resistance (Breier, 1999). Nutrition is
also an important regulator of IGF-I synthesis, and IGF-I has a major role in growth (Straus,
1994). There is a decrease in circulating IGF-I concentration as a result of both fasting and
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under-nutrition (Clemmons and Underwood, 1991). Reduced IGF-I during fasting is a result of
decreased binding of GH to its receptor (Cohick and Clemmons, 1993). There is also a decrease
in hepatic IGF-I and GHR mRNA (Bornfeldt et al., 1989; Straus and Takemoto, 1990). Reduced
IGF-I due to protein restriction is more likely in response to GH resistance (Clemmons and
Underwood, 1991). Nutritional restriction and post-partum negative energy balance generally
result in a decrease in the concentration of both circulating IGF-I and IGFBP-3, due to their
lower hepatic synthesis and an up-regulation of IGFBP-2, decreasing the bioavailability of IGF-I
for peripheral tissues (Breier, 1999). These changes exhibited in GH, IGF-I, IGFBP-2 and -3
results in a decrease in overall growth rate of an animal.
Over-nutrition, leading to obesity, normally leads to opposite hormonal changes than
under-nutrition. Obesity causes an increase in growth rate and increase in adipose deposition.
Growth hormone secretion is negatively and independently associated with age and the amount
of adiposity in normal animals (Iranmanesh et al., 1991). Increased adiposity causes a blunting
effect of GH secretion and the metabolic clearance rate of GH is accelerated (Veldhuis et al.,
1991). Insulin-like growth factor-I concentrations in obesity are variable. Different studies have
shown increased, normal, or decreased concentrations (Rudman et al., 1981; Marin et al., 1993;
Frystyk et al., 1995). Free IGF-I tend to be increased in obesity since IGF-I synthesis and
secretion depend on peripheral GH sensitivity, reflected by increased GHR and GHBP
concentrations (Frystyk et al., 1995). Concentrations of IGFBP-1 are reduced due to increased
peripheral sensitivity to GH as a result of hyperinsulinism (Brismar et al., 1994). Insulin inhibits
IGFBP-2 in obesity and IGFBP-3 concentrations are normal or increased in circulation (Argente
et al., 1997; Nam et al., 1997). Long et al. (2010) established maternal obesity, due to overnutrition, before gestation in sheep and the offspring of these obese ewes were insulin resistant
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and gained more adipose tissue than control offspring later in life. The offspring from these
overfed ewes also had increased feed intake compared with controls. Both under-nutrition and
over-nutrition can have major metabolic and physiological effects. Therefore, poor nutrition in
general, whether under-nutrition or over-nutrition can have severe effects on the growth and
survival of animals.
INSULIN-GLUCOSE HOMEOSTASIS
Overview
The regulation of feed intake and whole-body energy balance is important in livestock to
optimize animal reproduction, growth, lactation, and overall health. Therefore, altering body
composition by repartitioning of nutrients to favor lean protein accretion and improve production
efficiency is a major goal in animal agriculture (Houseknecht et al., 1998). For these reasons, a
clear understanding of energy metabolism, adipose accretion, and feed intake is important to
improve animal health and decrease the probability of obesity (Houseknecht et al., 1998).
Glucose homeostasis is required to regulate whole-body energy balance. For this to be
maintained, insulin must stimulate glucose uptake and storage in adipose and muscle tissue, and
stimulate glucose storage and inhibit gluconeogenesis in the liver. Disruptions in homeostasis,
due to factors such as changes in nutrient intake, can lead to insulin resistance, causing disorders
such as obesity and type 2 diabetes to develop in humans (Saltiel and Kahn, 2001).
Glucose homeostasis in embryonic and early fetal life depends on placental glucose
transfer and tissue glucose utilization (Mena et al., 2001). Understanding the changes in glucose
and insulin regulation associated with nutrient changes and IUGR is important to determine how
these changes to glucose homeostasis in fetal life can have lasting negative effects in post-natal
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life. In animal models of IUGR, early developmental shifts in fetal metabolism include
increased hepatic gluconeogenic gene expression, glucose production, and decreased pancreatic
insulin secretion (Limesand et al., 2006; Thorn et al., 2011). These changes can continue into
post-natal life, causing offspring to have increased hepatic glucose production, insulin resistance,
and altered insulin secretion (Owens et al., 2007; Park et al., 2008). The activation of
gluconeogenesis in IUGR fetuses may be a beneficial adaptive response to maintain glucose
supply to vital organs as placental glucose diminishes, but can cause permanent negative
consequences post-natally by promoting glucose production in excess of utilization capacity,
contributing to hyperglycemia (Thorn et al., 2011).
Blood glucose concentrations must be carefully maintained since mammalian cells
depend on a steady supply of glucose as a source of energy. The liver has a major role in blood
glucose homeostasis by maintaining the balance between uptake and storage of glucose through
glycogenesis and the release of glucose via glycogenolysis and gluconeogenesis (Nordlie et al.,
1999). In order for glucose homeostasis to be maintained, plasma glucose concentration is
regulated by actions of the pancreatic hormones, insulin and glucagon. These hormones control
glucose production and utilization in multiple tissues and organs (Bell and Bauman, 1997).
Insulin is the main metabolic regulator in ruminants, similar to other mammalian species
(Sasaki, 2002). The actions of insulin affect carbohydrate, lipid, and protein metabolism.
Insulin acts on a variety of tissues including muscle, adipose, liver, and pancreas by altering
processes including membrane translocation and enzyme activity. These actions make insulin
the major mediator of glucose homeostasis (Sasaki, 2002).
In muscle and adipose tissue, insulin signaling causes translocation of GLUT 4 and
increases glucose uptake into the tissues. Insulin acts on hepatocytes to stimulate the utilization
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and storage of glucose as lipid and glycogen as well as inhibit glucose production and release
(Saltiel and Kahn, 2001). Once plasma glucose concentrations decrease, glucagon release from
pancreatic α cells is stimulated (Layden et al., 2010). Glucagon acts in opposition to insulin and
stimulates hepatic gluconeogenesis to increase glucose concentrations in plasma (Layden et al.,
2010).
Glucose
Placental glucose transfer is important to fetal growth, and is required for regulation of
fetal insulin release, which then regulates fetal IGF-I (Gluckman and Harding, 1997). Therefore,
the somatotropic axis and the glucose-insulin axis are important in regulating fetal growth and
furthermore, post-natal growth. Altered glucose concentrations, due to IUGR, can have a
permanent effect on offspring. Glucose is an important carbohydrate required to meet the energy
requirements of the body. The main sources of glucose come from the diet and the liver.
Ruminants are different from monogastrics in that they depend mostly on hepatic glucose
production, whereas monogastrics can absorb glucose from their diet. From birth to about three
weeks of age, lambs are considered pre-ruminants and the reticular groove located in the
esophagus allows for milk to be transported directly to the abomasum, similar to a monogastric
animal (Parish et al., 2009). As these animals grow, rumen development occurs and instead of
the abomasum making up most of the stomach in the pre-ruminant, the reticulorumen makes up a
greater percentage of the stomach in the mature ruminant (Parish et al., 2009). Around two to
three months (mo) of age lambs are considered functional ruminants, as the reticular groove
reflux is lost (Parish et al., 2009). The change in dietary nutrient pattern and supply, due to
adaptation from pre-ruminant to functional ruminant, causes alterations in hepatic function and
energy requiring processes such as glucose synthesis (Seal and Reynolds, 1993). The fetal/pre30

ruminant lamb is able to utilize glucose as an energy source similar to a monogastric, but due to
the microbial fermentation of carbohydrates that occurs in the reticulorumen, mature ruminants
must use volatile fatty acids (VFA) that are produced in the rumen and converted to glucose via
hepatic gluconeogenesis (Bell and Bauman, 1997). Therefore, in the recently fed, postabsorptive state, ruminants must depend on gluconeogenesis in the liver and on the kidneys for
their tissue glucose requirements.
Propionate, one of the major VFA byproducts of pre-gastric fermentation, is the principle
precursor for hepatic gluconeogenesis in well-fed ruminants. Propionate is absorbed via the
ruminal epithelium into portal venous blood and removed by the liver (Elliot, 1980; Brockman,
1993). The production rate of ruminal propionate and other VFA is directly related to dietary
intake of fermentable substrate, suggesting ruminant whole-body glucose production is highly
correlated with digestible energy intake (Elliot, 1980). During meals, propionate is rapidly taken
up by the liver and converted into intermediates of the citric acid cycle (Allen et al., 2009).
Oxidation of propionate within a meal increases the energy state of hepatocytes more than
normal, generating a satiety signal to stop eating (Allen et al., 2009). Once gluconeogenesis
depletes the hepatic ATP pool, hunger is stimulated (Allen et al., 2009).
The importance of lactate, amino acids, and glycerol increases when the supply of
propionate decreases (Brockman, 1993). Insulin stimulates the utilization of these substrates
more than propionate (Brockman, 1993). Other VFA, such as acetate and butyrate, can be
substituted for glucose as a respiratory fuel or lipogenic substrate in adipose and muscle tissue
(Bergman et al., 1989). Insulin-responsive tissues, such as adipose and muscle tissues, are
dependent on insulin for promotion of glucose transport and metabolism (Jarrett et al., 1974).
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Glucose is a hydrophilic compound so it cannot pass through the lipid bilayer by simple
diffusion and requires specific carrier proteins to mediate its transport into the cytosol. All
mammalian cells contain one or more members of the GLUT gene family (Wood and Trayhurm,
2003). The function of GLUT proteins is to regulate the movement of glucose between the
extracellular and intracellular compartments maintaining a constant supply of glucose for
metabolism (Wood and Trayhurn, 2003). There are five main isoforms of GLUT (GLUT 1 to 5;
Sasaki, 2002). The isoform, GLUT 4, is considered the insulin-responsive glucose transporter
that is mainly found in muscle and adipose tissue and is responsible for most of the insulinstimulated glucose transport in adipose and muscle (Kasanicki and Pilch, 1990). It is also found
in hepatic tissue, but to a smaller degree. Insulin regulates glucose uptake in tissues through
GLUT 4 and GLUT4 is present in all insulin-responsive tissues in cattle (Abe et al., 1994).
Insulin
The protein insulin contains two polypeptide chains linked to each other by two disulfide
bridges (Mayer et al., 2007). These chains are homologous to the A and B chains of IGF-I and II (Mayer et al., 2007). Synthesis of insulin occurs in the β-cells of the islets of Langerhans in
the pancreas and is stored in β-granules of these cells (Mayer et al., 2007). Glucose
concentration in circulation regulates insulin secretion from β-granules. Glucose can be taken up
by pancreatic β-cells via GLUT 2, where it is metabolized, leading to an increase in ATP
(Layden et al., 2010). This increase results in K+ channels closing and the depolarization of the
cell. Calcium channels open and allow a flux of Ca2+ into the cell and this accumulation of Ca2+
causes insulin secretion to occur. Calcium has an essential role in insulin secretion since glucose
does not stimulate insulin secretion in the absence of extracellular Ca2+ (Grodsky and Bennett,
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1966). Secretion of insulin from β-cell granules occurs via exocytosis, expelling insulin into the
extracellular space.
In circulation, insulin acts on tissues, such as the liver, adipose, and muscle. Insulin
binds to an insulin receptor on the plasma membrane of these tissues and stimulates intracellular
signaling pathways. The insulin receptor has two purposes: to bind insulin with high affinity and
to transmit a transmembrane signal resulting in changes to intracellular metabolic pathways. The
insulin receptors are oligotetramers that consist of two α subunits, with a weight of 130 kDa, and
two β subunits that are each 90 kDa (White and Kahn, 1994). Each type of subunit is responsible
for one function of the receptor. The α subunit is the insulin binding subunit and is extracellular,
whereas the β subunit is a transmembrane protein and possesses insulin-sensitive tyrosine kinase
activity (Kahn, 1985). The insulin receptor is highly conserved among mammalian cell types
and species (Muggeo et al., 1979).
Once insulin binds to the α subunit of its specific cell surface receptor a signal is induced,
leading to rapid stimulation of tyrosine kinase activity of the β subunit (Patti and Kahn, 1998).
Autophosphorylation occurs, increasing the kinase activity of the receptor (Patti and Kahn,
1998). This results in tyrosine phosphorylation of cytosolic substrates such as members of the
IRS family, Shc and Cbl, an oncogene. These proteins interact with signaling molecules through
SH2 domains, which results in different signaling pathways including PI3K, Cbl/CAP (Cbl
associated protein) cascade, and the MAPK cascade, all acting to coordinate the regulation of
glucose metabolism and homeostasis (Saltiel and Kahn, 2001; Figure 3).
Insulin receptor substrate-I, is shown to mediate insulin-stimulated glucose transport in
related insulin target tissues (Kahn and White, 1988; Qunon et al., 1994). Tyrosine
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Figure 3. Insulin signal transduction pathways.

Insulin binds to the insulin receptor, causing tyrosine autophosphorylation, resulting in tyrosine
phosphorylation of insulin receptor substrate (IRS)-1 to 4, activating 3 different signal
transduction pathways: phosphatidylinositol 3-kinase (PI3K), CAP/Cbl, and mitogen activated
protein kinase (MAPK). The PI3K pathway mediated glucose/lipid/protein metabolism and
insulin stimulated glucose uptake through activation of protein kinase B (PKB)/Akt by
phosphoinositide-dependent kinase 1 (PDK-1). The CAP/Cbl pathway, also required for glucose
transporter (GLUT) 4 translocation, is activated by tyrosine phosphorylation of the Cbl gene and
CAP binding as well as the CrkII and C3G complex activating TC10 to signal GLUT4. The
third pathway, MAPK, results in cell proliferation/differentiation and is activated by binding
growth factor receptor-bound protein 2 (Grb2) and Shc, which binds son of Sevenless (SOS),
activating Ras then Mek (Modified and reprinted with permission from: Mlinar et al., 2006).
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phosphorylation of IRS-I induces its association with several protein containing SH2 domains,
including Grb2 and p85 regulatory subunit of PI3K. This leads to translocation of GLUT 4 from
intracellular vesicles to the plasma membrane (Greenfield and Campbell, 2004). The PI3K
inhibitors can block the stimulation of glucose transport and lipogenesis by insulin, suggesting
that PI3K may be necessary for these actions of the hormone (Evans et al., 2005). Insulin
activates PKB/AKT through phosphorylation of Thr308 and Ser473 by PDK-1 (Anderson et al.,
1998). Autophosphorylation of tyrosine residues of insulin receptor β subunit and
phosphorylation of IRS-1, PI3K, and PKB/Akt play a key role to regulate intracellular glucose
metabolism. The Cbl/CAP pathway involves tyrosine phosphorylation of the Cbl protooncogene
(Ribon et al., 1997). The adaptor protein, CAP, binds to the proline-rich sequences in Cbl
through its carboxyl-terminal SH3 domain (Ribon et al., 1998). Expression of CAP in insulin
sensitive tissues is induced by adipocyte differentiation (Ribon et al., 1998). The protein, CAP
contains three SH3 domains and once phosphorylation occurs, the Cbl-CAP complex
translocates to lipid raft domains in the plasma membrane. Translocation of phosphorylated Cbl
recruits the adaptor protein CrkII via its SH2 domain (Chiang et al., 2001). A complex is formed
between CrkII and guanyl nucleotide-exchange protein, C3G, which catalyzes the exchange of
GTP for GDP with the G protein TC10, activating it (Chiang et al., 2001). Once activated by
insulin, TC10 provides a second signal to GLUT 4 for translocation to occur.
The MAPK pathway involves the phosphorylation of IRS or Shc proteins that interact
with the adaptor protein Grb2 and recruit the SOS exchange protein to the plasma membrane,
activating Ras. Activation of Ras also requires stimulation of the tyrosine phosphatase SHP2,
through its interaction with receptor substrates such as Gab-1 or IRS-1/2. Activated Ras
stimulates a serine kinase cascade through stepwise activation of Raf, MEK, and ERK. The
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insulin signal transduction pathways mainly act to increase uptake and storage of glucose in
insulin sensitive tissues in order to maintain glucose homeostasis.
Glucose utilization
Glucose is needed in many tissues of the body for survival. In sheep, the brain accounts
for more than ten to fifteen percent of glucose utilization (Hocquette and Abe, 2000). Skeletal
muscle is a major consumer of glucose through oxidation and storage. Eighty percent of glucose
is stored as glycogen in sheep (Pethick, 1984). Adipose tissue in ruminants only accounts for
one percent of total glucose (Pethick, 1984). Glucose is taken up by muscle and adipose tissues
via the GLUT 4 transporter. Glucose transporter 4 is mainly found in the basal state inside the
cell and is translocated to the plasma membrane for insulin stimulation to increase the extraction
rate of glucose (Hocquette and Abe, 2000). Glucose oxidation and storage in muscles and
lipogenesis in adipose is also stimulated by insulin. Adipocytes are one of the most insulinresponsive cell types (Kahn and Flier, 2000). The role of insulin is to promote adipocyte
triglyceride storage by differentiation of pre-adipocytes, stimulating glucose transport and
lipogenesis, and inhibiting lipolysis (Kahn and Flier, 2000). In addition, insulin also increases
the uptake of fatty acids derived from circulating lipoproteins by stimulating lipoprotein lipase
activity in adipose tissue (Kahn and Flier, 2000). Skeletal muscle accounts for up to 75% of
insulin-dependent glucose disposal, where it is either stored as glycogen or oxidized (Saltiel and
Kahn, 2001).
Consequences of altered glucose homeostasis
A number of factors including insulin resistance can cause alterations in glucose
homeostasis. Insulin resistance is resistance to the effects of insulin on glucose uptake,
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metabolism, or storage. This is caused by decreased insulin-stimulated glucose transport and
metabolism in adipocytes and skeletal muscle as well as impaired suppression of hepatic glucose
output (Kahn and Flier, 2000). These defects may be caused by impaired insulin signaling in
target tissues as well as down regulation of GLUT 4 in adipocytes. Expression of GLUT 4 is
normal in skeletal muscle, but translocation and docking to the plasma membrane is impaired
(Kahn and Flier, 2000). There is a reduction in insulin binding to its receptor, receptor
phosphorylation and tyrosine kinase activity, and phosphorylation of IRS in both muscle and
adipocytes (Kahn and Flier, 2000). Reduced insulin binding and action leads to insulin
resistance, causing an increase in adiposity.
Increased adipose energy storage in obesity results in increased triglyceride storage in
these tissues, which promote insulin resistance and other adverse effects causing lipotoxicity
(Kahn and Flier, 2000). Increased plasma FFA impair the ability of insulin to suppress hepatic
glucose output, stimulate glucose uptake into skeletal muscle, and inhibit insulin secretion from
pancreatic β-cells. Normally functioning β-cells in the pancreas respond to insulin resistance by
secreting more insulin, causing hyperinsulinemia. Type 2 diabetes can result from insulin
resistance normally caused by obesity (Layden et al., 2010). In the case of type 2 diabetes, the
body is unable to increase insulin secretion to overcome the insulin resistance due to pancreatic
β-cell dysfunction and causes hyperglycemia (Layden et al., 2010). Glucagon concentrations
increase in individuals with type 2 diabetes, causing hyperglycemia to get worse since glucagon
increases hepatic glucose production (Layden et al., 2010). Hepatic lipogenesis and lipid storage
in adipose tissue could possibly be increased while other insulin effects of glucose homeostasis
are impaired (Kahn and Flier, 2000). In IUGR animals, changes in homeostasis can lead to
permanent consequences for the offspring in post-natal life such as insulin resistance and obesity.
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Overall, insulin acts to increase glucose uptake in muscle and adipose tissue through
stimulation of GLUT 4 translocation, increase glucogenesis in the liver, and inhibit glucose
production. Glucose stimulates insulin secretion from the pancreas in order for these actions to
occur. When plasma glucose concentrations are too low glucagon is released and increases
hepatic glucose production to increase circulating glucose concentrations (Layden et al., 2010).
Therefore, insulin and glucagon work together to tightly regulate plasma glucose concentrations
to insure glucose homeostasis is maintained.
LEPTIN
Leptin is another hormone required to maintain glucose homeostasis and energy balance.
Plasma concentrations of leptin are correlated with fat mass in humans and ruminants and are
also positively correlated to adipocyte volume (Chilliard et al., 2001; Delavaud et al., 2002).
Blache et al. (2000) found that plasma leptin concentration was highly correlated with backfat
thickness in sheep, Tokuda and Yano (2001), Tokuda (2003), and Altmann (2005) reported
similar findings. Concentrations of leptin are also positively correlated with insulin
concentrations (Tokuda and Yano, 2001). Leptin acts both in central and peripheral manners,
regulating central endocrinology and physiological processes as well as peripheral tissue activity
(Moran and Phillip, 2003). This shows that leptin is a major regulator of adipose deposition in
the body, demonstrating a relationship with insulin in regulating energy stores and maintaining
glucose homeostasis.
Leptin, a 16 kDa peptide hormone, is the product of the Ob gene and consists of 146
amino acids (Zhang et al., 1994). It is part of the type I helical cytokine family and is related to
prolactin, GH, and the interleukins (Huising et al., 2006). Leptin is encoded by two exons and

38

forms a four-helix bundle conformation. Leptin has a pair of conserved cysteine residues that
form a disulfide bridge required for full biological activity (Crespi and Denver, 2006). There are
three identified receptor binding sites with conserved amino acid sequences among species. The
leptin gene is expressed mainly in white adipose tissue and in smaller amounts in placental and
fetal tissues, mammary gland, stomach, muscles, and brown adipose tissue (Andrews, 1998).
The leptin mRNA abundance in adipose tissue has been shown to decrease significantly by food
deprivation or under-nutrition, and increase by re-feeding in sheep (Kumar et al., 1998).
Leptin is mainly secreted from white adipose tissue and the synthesis of leptin is
stimulated by insulin. Once in circulation, leptin can cross the blood-brain barrier and act on
receptors located in the ARC nucleus of the hypothalamus (Friedman and Halaas, 1998).
Neurons within the ARC nucleus are associated with obesity and respond directly to a variety of
hormonal and nutrient signals including leptin, insulin, and glucose (Elmquist, 2005). The
neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons promote feeding and are activated
by appetite stimulating signals. The ARC/pro-opiomelanocortin (POMC) neurons promote BW
loss through expression of alpha melanocyte-stimulating hormone (α-MSH), which acts at
melanocortin receptors to suppress food intake (Schwartz, 2001). Leptin acts to up regulate
POMC expression within the ARC nucleus, thereby limiting energy intake (Schwartz, 2001).
Leptin can also act directly on peripheral tissues by binding to receptors in the pancreas, liver,
skeletal muscle, or adipose tissue (Muoio and Dohm, 2002). The actions of leptin all work to
increase fatty acid oxidation and decrease triglyceride storage, to decrease adipose tissue mass.
The leptin receptor (Ob-R) is present in the hypothalamus and choroid plexus, as well as
various peripheral tissues and is encoded by the db gene (Tartaglia et al., 1995). It is similar in
function and structure to the class I cytokine receptors and exists in multiple isoforms; their
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intracellular domains varying in length due to alternative splicing of the db gene (Lee et al.,
1996; Bjorbaek et al., 1997). The isoforms of leptin have an identical extracellular ligandbinding domain at the N-terminus, but differ at the C-terminus.
The long form (OB-Rb), responsible for the central actions of leptin, contains a 302
amino acid intracellular domain and is abundantly expressed in specific nuclei of the
hypothalamus (Tartaglia et al., 1995; Mercer et al., 1996; Elmquist et al., 1997). The short forms
(OB-Ra, c, d, and e), contain 32 to 97 amino acids and are distributed throughout peripheral
tissues, but little is known about the physiological activity of this form (Wang et al. 1997; Szanto
and Kahn, 2000). The extracellular domain of both the long and short forms of the leptin
receptor contain two cytokine domains, each containing a single copy of the typical Trp-Ser-XTrp-Ser motif and a fibronectin III domain (White and Tartaglia, 1996).
Since leptin is considered a type I cytokine receptor, signal transduction is dependent on
ligand-induced phosphorylation of receptor tyrosine kinases in the JAK family, specifically
JAK2 (Huang and Cia, 2000). These kinases then phosphorylate tyrosine residues on the
receptor that serve as a docking site for SH2 domain proteins (Banks et al., 2000). Binding
initiates signal transduction and activated JAK2 phosphorylates tyrosine residues, Tyr985 and
Tyr1138 of the leptin receptor (Darnell, 1997; Banks et al., 2000). Once Tyr1138 is phosphorylated,
it serves as a binding site for STAT proteins, specifically STAT3 (Bendinelli et al., 2000). These
recruited STAT proteins become tyrosine-phosphorylated by JAK, causing dissociation from the
receptor to form homo- or heterodimers (Heim, 1996). Then STAT dimers translocate into the
nucleus and act as transcription factors by binding specific response elements (Bendinelli et al.,
2000). Leptin binds to an Ob-R homodimer with high affinity, causing activation of JAK2. The
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Ob-Rb is present in the hypothalamus and its actions are mediated by STAT3 and NPY
(Schwartz et al., 1996).
Another signaling pathway stimulated by leptin is the MAPK pathway. This pathway can
be stimulated by either the long or short isoforms (Banks et al., 2000; Figure 4.). The Tyr985
residue of the long leptin receptor form can induce full Erk activation, by becoming
phosphorylated and recruiting JAK2 (Banks et al., 2000). It provides a docking site for the SH2
domain containing protein tyrosine phosphatase, SHP-2. After binding to this specific tyrosine
residue, SHP-2 is phosphorylated at the C-terminus and with its adaptor molecule Grb2, activates
downstream signaling effects (Banks et al., 2000). The short form of the leptin receptor can also
activate this pathway by association of JAK2 with the SH2 domain-containing adaptor protein
Grb2 and SHP-2. This complex then activates further signaling steps (Banks et al., 2000).
Central actions
Leptin acts centrally through the nervous system to control food intake and energy
expenditure (Houseknecht et al., 1998). The major goal of leptin is to increase energy
expenditure, decrease food intake, and increase GH secretion, overall decreasing adipose
deposition in the body. Leptin has also been shown to regulate bone formation and resorption
indirectly through the hypothalamus (Cirmanova et al., 2008). Neuropeptide Y is considered a
major target of leptin action and acts as a strong stimulator of food intake and also inhibits brown
fat thermogenesis, increasing plasma insulin and steroid concentrations (Moran and Phillip,
2003). Leptin acts to inhibit NPY by binding to the leptin receptor of the NPY/AgRP neurons in
the ARC nucleus of the hypothalamus (Cusin et al., 1996; Bates et al., 2003). Suppression of
NPY release from the hypothalamus, results in inhibition of food intake, increasing
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Figure 4. Leptin signal transduction pathway activated through leptin binding with the long form
leptin receptor (Ob-Rb).

After leptin binds to the long form leptin receptor (Ob-Rb), intracellular signaling pathways are
activated, mainly though stimulation of tyrosine phosphorylation and activation of janus kinase
(JAK) 2. JAK2 then phosphorylates tyrosines within SHB2 and signal transducers and activators
of transcription (STAT) 3 binding sites. Signal transducer and activator of transcription-3 can be
transported into the nucleus, where it is involved in transcription of suppressor of cytokine
signaling 3 (SOCS-3). Once SHB2 is recruited, it binds to growth factor receptor-bound protein
2 (Grb2) and the extracellular signal-regulated kinase (ERK) 1/2 cascade is activated. JAK2 can
also activate insulin receptor substrate (IRS) and then phosphatidylinositol 3-kinase (PI3K) and
Akt, stimulating growth and survival. Leptin can also bind to short forms of its receptor, mostly
in peripheral tissues, which also activates intracellular pathways through the activation of JAK
(Modified and reprinted with permission from: Garofalo and Surmacz, 2006).
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thermogenesis and reducing adipose tissue mass (Stephens et al., 1995). Leptin can bind to
ARC/ POMC neurons and activate secretion of α-MSH, an anorexic neuropeptide (Bates et al.,
2003). This activation by leptin reduces food intake and increases energy expenditure
(Niswender and Schwartz, 2002).
Another central role of leptin is stimulating GH secretion from somatotrope cells of the
anterior pituitary gland, through stimulation of GHRH and inhibition of SRIF (Breier et al.,
2001; Moran and Phillip, 2003). Since actions of the somatotropic axis are known to be
inhibited in IUGR animals, the action of leptin on growth and organ weight may be mediated by
stimulation of the somatotropic axis (Djiane et al., 2008). The effect of leptin on GH secretion
may also involve NPY, since leptin suppresses NPY expression, and infusion of NPY is known
to suppress GH secretion (Kamegai et al., 1996). Increasing GH secretion increases GH
inhibitory action on adipose tissue, ultimately decreasing adipose tissue mass.
Peripheral actions
In addition to the central effects of leptin, leptin has peripheral effects on the pancreas,
skeletal muscle, liver, and possibly bone, and feeds back to inhibit excess leptin gene expression
in adipocytes. The peripheral actions of leptin occur mainly via the interaction of leptin with the
short forms of the leptin receptor l.found outside of the central nervous system, which activate
JAK signaling pathways (Tartaglia et al., 1995).
In muscle, leptin can increase fatty acid oxidation and decrease triglyceride storage,
promoting an increase in energy expenditure and insulin sensitivity (Muoio and Dohm, 2002).
Leptin also exhibits direct actions on insulin secretion, since both the long and short forms of the
leptin receptor are present in pancreatic β-cells (Kullkarni et al., 1997). Leptin inhibits insulin
biosynthesis and secretion by inhibiting glucose transport to the pancreas via GLUT 2,
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contributing to peripheral insulin resistance (Kieffer et al., 1997). Insulin stimulates leptin
secretion from adipose tissue, creating a hormonal regulatory feedback loop. In adipose, leptin
increases fatty acid oxidation and decreases triglyceride storage.
Leptin has been shown to have both insulin-like and insulin-antagonistic effects on the
liver, specifically hepatic glucose metabolism (Moran and Phillip, 2003). Leptin has been shown
to have a direct effect on glucose metabolism through leptin receptors identified in hepatocytes
(Zhao et al., 2000). Leptin, either alone or in combination with insulin, reduces hepatic glucose
production by decreasing the synthesis of the key enzyme of gluconeogenesis,
phosphoenolpyruvate carboxykinase (PEPCK; Moran and Phillip, 2003). The effects leptin has
on mediating insulin effects in the liver is not quite clear, especially in ruminants, and more
studies need to be done to determine the exact effects leptin has on the liver.
Bone marrow adipocytes can serve as a direct source of leptin and can stimulate
differentiation of bone marrow stromal cells (BMSC). Leptin is thought to stimulate BMSC
differentiation into osteoclasts and inhibit differentiation into adipocytes, but if leptin
concentrations are too great they can lead to BMSC apoptosis (Cirmanova et al., 2008). Normal
concentrations of leptin directly affect proliferation, differentiation, and mineralization of
osteoblasts by inhibiting apoptosis (Gordeladze et al., 2002). In addition to the interaction
between central and peripheral pathways, the overall effect of leptin on bone seems to be
modulated by serum concentration, where an increase in leptin stimulates bone formation.
However, when concentrations of serum leptin are too great, they can inhibit bone formation
(Cirmanova et al., 2008). Plasma leptin concentrations have also been shown to be associated
with bone mass. If leptin concentrations in plasma are reduced, then bone mass is suggested to
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be decreased (Hamrick, 2004). Yamauchi et al. (2001) reported that plasma leptin
concentrations were positively correlated with bone mineral density.
Overall, leptin centrally regulates whole-body energy homeostasis and mediates
peripheral metabolic processes such as controlling cellular lipid balance by promoting βoxidation and lipolysis as well as inhibiting synthesis of triacylglycerol. Leptin also plays a part
in regulation of insulin and glucose homeostasis. Leptin action in muscle, adipose, liver, and
pancreas tissues, requires signaling through the IRS-PI3K pathway, the same pathway insulin
uses for signal transduction in these tissues. Therefore, leptin may act in a synergistic manner
with insulin (Sivitz et al., 1997). Animals exhibiting leptin resistance or deficiency store
inappropriately increased concentrations of triacylglcerides in non-adipocyte cells, not adapted
for storing excess FA. These animals have been shown to have complications defined by
metabolic syndrome (Unger and Orci, 2001).
Influence of nutrition on leptin concentrations
Leptin response is stimulated by nutritional status, relating plasma leptin concentrations
to adipose deposition. In adult animals, including ruminants, plasma leptin concentrations are
shown to increase with the plane of nutrition (Ehrhardt et al., 2000; Ingvartsen and Boisclair,
2001). Energy expenditure and food intake are regulated by plasma leptin concentrations,
allowing for changes in leptin concentrations based on the amount of stored nutrients allocated
for energy (Morton, 2007).
In response to reduced nutrition, the brain initiates responses to promote positive energy
balance to restore and maintain energy and glucose homeostasis (Morton, 2007). In periods of
nutrient-restriction or starvation, there is a decrease in plasma leptin concentrations signaling to
increase feed intake and decrease energy expenditure to increase energy stores (Friedman, 2002).
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Reduced concentrations of leptin in circulation indicate an inadequate amount of fat, causing an
adaptive response to replenish theses energy stores (Friedman, 2002). Insulin is the major
stimulator of glucose storage in peripheral tissues. Decreased leptin concentrations allow insulin
to stimulate glucose uptake in these tissues, increasing energy stores.
It has been demonstrated that leptin concentration increases at the end of fetal life, but at
birth leptin concentrations are reduced in IUGR progeny (Djiane et al., 2008). In animals with
IUGR, active cell proliferation may continue after birth, more so than in normal situations,
suggesting that excess proliferation of fat cells in IUGR may be designed to improve long term
capacity for lipid storage to adapt in a restricted-food environment during fetal life. However, if
nutrients become abundant in post-natal life, this adaptation could promote obesity (Djiane et al.,
2008). Nutrition as well as adiposity regulates plasma leptin in early post-natal life of lambs
(Ehrhardt et al., 2003).
In instances of over-nutrition and excess energy storage, negative energy balance is
promoted. Impaired responses or resistance to hormonal nutrient signals, such as leptin could
lead to obesity and insulin resistance (Morton, 2007). Increased adiposity leads to increased
leptin concentrations, causing an increase in energy expenditure and decrease in food intake to
reduce adipose deposition. Overfeeding sheep throughout pregnancy has been determined to
increase maternal leptin concentrations (Thomas et al., 2001). In lambs born to ewes overfed
during late gestation, an increase in adipose tissue mass was reported to be associated with down
regulation of the leptin receptor in the ARC nucleus. This would result in decreased leptin
sensitivity (Muhlhausler et al., 2006). Furthermore, over-nutrition in pre-natal life may alter
responses of the central neural network to an increase in fat mass in post-natal life (Muhlhausler
et al., 2006). Long et al. (2010) observed that maternal over-nutrition can eliminate the leptin
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peak in lambs, demonstrating that over-nutrition can alter development of appetitive centers. In
obese individuals, increased leptin concentrations suggest leptin resistance and decreased
concentrations suggest decreased leptin production (Friedman, 2002).
Leptin has been shown to have a role in the regulatory action of adipose tissue on total
body sensitivity to insulin (Moran and Phillip, 2003). Along with insulin, leptin has been shown
to regulate glucose metabolism. Leptin increases insulin signaling by reducing intracellular lipid
concentrations. Hyperinsulinemia precedes the development of insulin resistance and obesity
(Le Stunff and Bougneres, 1994; Ferrannini et al., 1997). Leptin resistance seen in obesity could
be a result of inhibition of the JAK/STAT signaling pathway. Suppressor of cytokine signaling3 (SOCS-3) can bind to the phosphorylated tyrosine residues of signaling molecules and mediate
their degradation or inhibition, which inhibits leptin signal transduction (Hansen et al., 1999). In
obese individuals, there may be a failure of STAT signaling, causing a disruption in energy
homeostasis (Ghilardi et al., 1996).
Both leptin and insulin are critical for nutrient storage and maintenance of energy
balance. Changes to either one of these hormones could potentially alter glucose homeostasis,
adiposity, and whole-body energy balance. These changes could be caused by nutrientrestriction or over-nutrition and could lead to detrimental effects for offspring in post-natal life,
such as the development of obesity, and insulin and leptin resistance. Therefore, the relationship
between insulin and leptin and their involvement in regulating glucose homeostasis is important
for maintaining energy balance and metabolism.
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OBJECTIVES
The somatotropic axis is a known regulator of growth and development. This axis has
been shown to be altered due to insults such as poor maternal nutrition, with nutrient-restriction
and over-nutrition both leading to a similar outcome for the offspring. Given our knowledge of
this axis along with the role of both leptin and insulin in nutrient storage and glucose
homeostasis, we hypothesized that lambs born to nutrient-restricted or overfed ewes would have
reduced body weight, reduced growth rate, and increased adiposity, which would be associated
with changes in the somatotropic axis, leptin, and insulin-glucose homeostasis.
Variables including BW, body condition score (BCS), crown rump length (CRL), and
heart girth (HG) are considered to be determinants of growth rate. Circulating concentrations of
hormones involved in the somatotropic axis, including GH, IGF-I, and IGFBP-2 and -3, are
known to respond to nutrition (Rausch et al., 2002; Govoni et al., 2003, 2004). Therefore, these
hormones can be potentially used as predictors of nutritional status in animals. Of the six
IGFBP, IGFBP-2 and IGFBP-3 are specifically involved in changes in growth rate and response
to nutrient status (Govoni et al., 2003, 2004). The hormones insulin and leptin are critical for
nutrient storage, especially related to adiposity, and maintaining glucose homeostasis. Thus,
changes to either one of these hormones can lead to detrimental effects such as obesity, insulin
and leptin resistance.
Therefore, our objective was to determine the effects of poor maternal nutrition on postnatal growth rate and metabolism of offspring by studying the changes of the somatotropic axis,
insulin-glucose homeostasis, and leptin concentrations, as well as body composition of lambs.
Analyzing these body variables and metabolic hormones will provide us with insight to how poor
maternal nutrition can affect offspring in post-natal life.
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MATERIALS AND METHODS
Animals
Forty multiparous ewes from the University of Connecticut flock were selected for
synchronization of estrus during seasonal anestrus by intravaginally inserting a controlled
internal drug release (CIDR) device (EAZI-BREED CIDR, Pfizer, New York, NY) containing
300 mg progesterone for 12 days (Naderipour et al., 2012). Upon removal of CIDR device, ewes
were given a single 20 mg intramuscular (IM) injection of prostaglandin (PG) F2α (Knights et al.,
2003). After breeding, pregnancy was confirmed by ultrasound and 36 (25 Dorsets, 7
Shropshires, and 4 Southdowns) of the 40 ewes were selected for the study. Ewes were
individually housed in pens and acclimated to a control diet for one week. At d 31 ± 1.3 of
gestation, ewes were randomly assigned 1 of 3 treatment diets: control (CON, 100%), restricted
(RES, 60%), or overfed (OVER, 140%) of NRC (National Research Council, 1985) requirements
until the last four weeks of gestation when protein and energy intake were increased to maintain
restriction relative to the needs of the late gestating ewe (NRC, 1985; Table 1). Treatments were
balanced by breed (CON, 9 Dorsets, 2 Shropshires, 1 Southdown; RES, 8 Dorsets, 3 Shropshires,
1 Southdown; OVER, 8 Dorsets, 2 Shropshires, 2 Southdowns). Ewes were given a complete
pelleted feed diet (Table 2), which was offered each day based on BW of the ewe. Leftover feed
was removed and weighed to determine daily feed intake. Ewes had free access to water and
straw (Table 2) was provided in mornings. Body weight and BCS (Russel, 1991) of each ewe
was determined weekly and feed was adjusted accordingly.
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Table 1. Amount of complete pelleted diet in kilograms given to each ewe treatment group on
study based on NRC requirements for gestating sheep1
Amount fed during gestation
Acclimation week3, kg
During gestation4, kg
Last 4 weeks of gestation5, kg

Treatment2
Restricted
1.0
0.6
1.2

Control
1.0
1.0
1.6

Overfed
1.0
1.4
2.0

1

Amount of feed was calculated for each individual ewe based on body weight.
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
3
1 week prior to treatment, d 23 to 30 of gestation.
4
d 31 of gestation until d 119 of gestation.
5
d 120 of gestation until parturition.

2

Table 2. Feed analysis of diet fed to ewes.
Components
Crude protein, %
Acid detergent fiber, %
Neutral detergent fiber, %
TDN1, %
NEl2, mcal/kg
NEm3, mcal/kg
NEg4, mcal/kg

Feed Analysis
Complete Pelleted Diet
12.80
31.10
42.10
74.00
1.74
1.74
1.12

1

Total digestable nutrients.
Net energy lactation.
3
Net energy for maintenance.
4
Net energy for growth.
2
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Straw
15.60
43.80
66.70
53.00
0.26
0.26
0.05

Following parturition, lambs remained with the ewes for up to 24 h to ensure sufficient
colostrum consumption then one lamb was removed from each ewe, for the study. There were a
total of 35 lambs selected for the study (one dorset, restricted ewe had stillborn lambs and was
not used). The largest male was selected if there were two males, the male was selected if there
was a male and female, or the largest female was selected if there were two females. We
selected males since males are usually marketed for meat, whereas ewes are kept as flock for
reproduction. This resulted in 6 rams and 6 ewes in the control group, 8 rams and 3 ewes in the
restricted group, and 7 rams and 5 ewes in the overfed group. Eighteen lambs [CON, n = 6 (3
rams, 3 ewes); RES, n = 6 (3 rams, 3 ewes); OVER, n = 6 (4 rams, 2 ewes)] were euthanized
with an intravenous injection of Beuthanasia-D solution within 24 h of birth. The remaining 17
lambs were fed a control diet until 3 mo of age and then euthanized. Birth and 3 mo necropsy
groups were balanced by breed and birth status. The 17 lambs were group housed (4 to 5/pen)
until 3 mo of age [CON, n = 6 (3 rams, 3 ewes); RES, n = 5 (all rams); OVER, n = 6 (3 rams, 3
ewes)]. The control diet consisted of milk replacer (Land O’Lakes Animal Milk Product
Company; Shoreview, MN) fed at 1.7% of BW until weaning at 56 d of age, and ad libitum
creep feed (Lamb BT, Blue Seal Feeds; Litchfield, CT) and second cutting hay at beginning of
weaning [4 weeks (wk) of age] until 3 mo of age. Lambs also had free access to water. Lambs
were weighed every 2 d to determine growth rate and milk replacer amounts were adjusted
accordingly.
Sample Collection
Body weight and BCS of ewes were recorded once per week during gestation, until
parturition. The average BW gain of each treatment group during gestation was: CON = 22.8 kg,
RES = 10.3 kg, OVER = 29.3 kg, which demonstrates the effectiveness of the ewe diets. Lamb
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BW was measured at birth and 3 times per wk until weaning then once a wk thereafter. Crown
rump length and HG were measured at birth and once a wk until slaughter. Lamb BCS were
determined once per week starting at 4 wk of age until slaughter. Ewe blood samples (20 mL)
were collected once a week via jugular venipuncture using an 18 G needle with syringe. Lamb
blood samples (10 mL) were collected at birth and one week of age; then 20 mL were collected
once a week until slaughter. Blood was collected in serum BD (Franklin Lakes, NJ) vacutainer
tubes and plasma heparin and EDTA BD vacutainer tubes. Serum tubes were kept at room
temperature for 4 to 6 hours to allow blood to clot then stored overnight at 4°C and centrifuged
the next morning. Plasma tubes were inverted several times after blood collection and kept on
ice until centrifugation, which was done within one hour of collection. Blood was centrifuged
for 30 minutes at 1,800 x g (Sorval RT7; Kendro Laboratory Products, Newtown, CT) at 4°C and
serum and plasma were harvested and stored at -20° C until hormone and metabolite analyses
were performed.
Animals were euthanized with intravenous injection of Beuthanasia-D solution
containing 390 mg/mL sodium pentobarbital and 50 mg/mL phentoin calculated based on BW
measured the day of euthanasia. Crown rump length and HG were measured and blood samples
(20 mL) were collected. Organ weights were recorded from the heart, liver, kidneys, adipose,
quadracep muscle and loin muscle. Loin eye area (LEA; cm2), the cross section of the
longissimus dorsi muscle, was measured at birth and 3 mo using a grid. Backfat thickness (cm)
was measured only at 3 mo since there was no measurable amount present at birth. Tissue
samples were collected from the heart, liver, adipose, muscle, pancreas, and kidney and frozen in
liquid nitrogen then stored at -80°C for later RNA extraction.
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Intravenous Glucose Tolerance Test (IVGTT)
An IVGTT was performed on the lambs at 1 and 3 mo of age. Twelve hours before the
test, all feed was removed. Lambs were provided water ad libitum. The neck areas of the lambs
were shaved and cleaned with 70% ethanol and betadine. A catheter (Abbocath 18 g x 2.5 in
long) was inserted into a jugular vein of lambs 1 hour before the challenge to allow lambs time to
recover. The catheters were held in place by bandage tape and vet wrap (Johnson & Johnson;
Arlington, TX). Blood samples (3 mL) were taken at -30, -15, 0, 2, 5, 10, 15, 30, 60, and 120
minutes relative to glucose infusion. Blood samples were immediately placed in BD vacutainer
lithium heparinized plasma tubes for later insulin and glucose analysis. A single bolus injection
of glucose (50% dextrose solution; Vedco, St. Joseph, MO) was given via the jugular catheter,
which was calculated based on 0.25g/kg of BW (Ford et al., 2007).
Hormone and Metabolite Analyses
Serum IGF-I concentrations were determined by radioimmunoassay as described by
Govoni et al. (2002). Insulin-like growth factor binding proteins were separated using a
glycylglycine hydrochloric acid extraction method (Govoni et al., 2003). A standard curve was
prepared by serial dilution of IGF-I standard (5 ng/mL) using assay buffer. All samples were run
in duplicate. Anti-human IGF-1 rabbit antiserum (NIDDK, Parlow; Torrance, CA) was used at
1:100,000 dilution. Secondary antibody, goat anti-rabbit G-globulin (EMD Millipore, Billerica,
MA), was used at a dilution of 1:4. The amount of 125I-IGF-I (Perkin Elmer, Shelton, CT) added
was adjusted to 10,000 cpm per tube. Bound radioactivity was determined by a gamma counter
(GMI Iso-Data 20/20 series). Intra-assay coefficients of variation averaged 8.9% for low and
7.4% for high pools, respectively. Inter-assay coefficients of variation averaged 26.6% for low
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(52.9 ng/mL) and 16.7% for high (156.3 ng/mL). The large inter-assay coefficient for the low
pool is due to few samples used (n = 3) and large standard deviation (20.1) ..
Serum concentrations of GH were determined by radioimmunoassay as described by
Kazmer et al. (1992). Preparation and purification of 125I-GH was performed using the Iodogen
method (Pierce, Rockford, IL) as described by Cohick et al. (1989), using 5 µg ovine GH and 1
mCi 125I. The standard curve was prepared by serial dilution of GH standard (NIDDK Parlow;
Torrance, CA) containing 40 ng/mL using assay buffer. Samples were run in duplicate. There
was 20,000 cpm of 125I-GH added to each tube. Rabbit antiserum ovine GH (NIDDK-anti-oGH2, Parlow, Torrance, CA) was used at a dilution of 1:20,000. The secondary antibody, goat antirabbit G-Globulin (EMD Millipore, Billerica, MA) was used at a dilution of 1:40. The bound
radioactivity was determined using a gamma counter (GMI Iso-Data 20/20 series). Intra-assay
and inter-assay coefficients of variation averaged 7.4 and 32.3% for low (0.88 ng/mL) and 9.5
and 13.4% for high (1.13 ng/mL) pools, respectively. Inter-assay coefficients of variation were
high due to number of samples used (n = 4) and standard deviation of low (0.28) and high (0.15)
pools.
Plasma leptin concentrations were determined by a multi-species leptin RIA kit
(Millipore Corporation, Billerica, MA). This assay used 125I labeled human leptin and a multispecies leptin antiserum to determine the leptin concentrations in serum. The sensitivity of this
assay is 0.801 ng/mL + 2 SD HE (100 µL sample size). Intra-assay and inter-assay coefficients
of variation averaged 12.5 and 14.7% for Quality Control 1 (2.75 ng/mL) and 10.12 and 8.1% for
Quality Control 2 (17.5 ng/mL), respectively.
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Serum insulin concentrations were determined by an ovine insulin ELISA kit from
ALPCO Diagnostics. The microplate (96-well) was coated with monoclonal antibody specific
for insulin. A 5 parameter logistic (pl) fit was used to optimize the accuracy and precision of the
sigmoidal curve. The sensitivity of this assay was 0.14 ng/mL. Inter-assay coefficients of
variation averaged 3.24% for control 1 (3.22 ng/mL) and 5.72% for control 2 (0.88 ng/mL).
Plasma glucose concentrations from the IVGTT were determined by a glucose
colorimetric assay kit (Cayman Chemical, Ann Arbor, MI). This glucose assay used the glucose
oxidase-peroxide reaction for the determination of glucose concentrations. The range of this
assay is 0 to 25 mg/dL. As stated in this assay kit, the intra-assay coefficient of variance was
4.6% and inter-assay coefficient of variance was 1.7%.
Concentrations of IGFBP-3 and -2 in serum were determined by Western ligand blot after
gel electrophoresis as described by Freake et al. (2001) and Govoni et al. (2002). Proteins were
separated by gel electrophoresis on a gradient SDS-polyacrylamide gel, made using 30%
acrylamide. A bovine IGFBP-3 standard, human recombinant IGFBP-3 standard (Petrotech),
and six serum samples (2 µL) were run in eight lanes on a Mini Protean II (BioRad, Richmond,
CA) for 30 min at 100 V then 1 h at 150 V. Gels were then transferred to nitrocellulose
membrane at 45 V for 1 h and 30 min in a transfer tank. Membranes were blocked with 3%
Igepal (Sigma Aldrich Corp., St. Louis, MO) in Tris-buffered saline (TBS) then washed for 2 h
with 1% Tween 20 (Fisher Scientific). Membranes were then incubated over night with 300,000
cpm of

125

I -IGF-I (PerkinElmer, Shelton, CT) in 0.1% Tween 20. After 15 h incubation

membranes were washed with Tween 20 and TBS to remove any unbound radiolabel. After
washing, the membrane was exposed to a multipurpose phosphor screen (PerkinElmer) for 18 h
and imaged with a Cyclone Storage Phosphor System (PerkinElmer). Both IGFBP-2 and -3
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were quantified using OptiQuant acquisition and analysis Software (PerkinElmer). Each binding
protein was measured as digital light units (DLU)/mm2 and expressed as a percentage of the
signal of a bovine standard IGFBP-3 to account for variation between gels. Each band was
measured twice per gel and the four measurements were averaged together then expressed as
arbitrary units (AU).
Serum total cholesterol (TC) was determined by enzymatic analysis using cholesterol
reagents from Pointe Scientific (Canton, MI). Serum triglyceride (TG) concentration was
determined using Wako Chemical USA triglyceride kit (Richmond, VA). This kit uses the Ltype triglyceride M method, an enzymatic method, to analyze triglyceride concentrations (Kim et
al., 2013).
Statistical Analysis
Statistical analysis was done using the mixed model analysis of variance procedure (SAS
Inst. Inc., Cary, NC) to determine changes in age. Five covariant structures [CS, VC, AR (1),
TOEP, Huynh-Feldt], were examined. A goodness of fit statistic was used to determine which
covariate adequately fit the data. Variance components for all analyses were estimated
comparing variance components and least square means. All data are expressed as least square
means ± standard error of the mean.
The birth time point, for all variables, included measurements of all 35 lambs. The
weekly time points after birth, until 3 mo of age, include measurements of the lambs that
remained on study for 3 mo (n = 4 to 6/ treatment).
For all variables overtime; treatment, week, and treatment by week were included in the
final model. The subject in the repeated statement was animal and the repeated variable was
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week. For ADG, BW, CRL, HG, and BCS the covariate model used was VC, AR (1), AR (1),
TOEP, and VC, respectively. For IGF-I, GH, leptin, insulin, IGFBP-2, and IGFBP-3 the
covariate model used was TOEP, CS, CS, AR (1), VC, and CS, respectively. Pre-weaning (wk 0
to 8) and post-weaning (wk 9 to 12) were analyzed for all body variables and hormones using the
covariate model previously mentioned for each variable. Total cholesterol and TG were
analyzed by ANOVA at birth and 3 mo time points with treatment in the final model.
Analysis of a gender effect was performed for BW, CRL, HG, IGF-I, GH, IGFBP-2,
IGFBP-3, TC, and TG at the birth time point by ANOVA with treatment, gender, and treatment
by gender in the final model. Gender was not analyzed for variables at 3 mo since there was not
enough experimental units of each gender per treatment. There were no differences in gender at
birth for any variables measured.
For the IVGTT, glucose and insulin concentrations were analyzed overtime by TOEP and
AR (1), respectively. Baseline concentrations of each were determined from blood samples
collected at -30, -15 and 0 time points relative to glucose infusion. Area under the curve (AUC)
was determined using the trapezoidal method (Weber et al., 2005). Peak, baseline, and AUC
concentrations for glucose and insulin were analyzed by a variance components covariance
structure. First phase insulin response was calculated as the sum of the glucose concentration at
2 and 5 minutes relative to glucose infusion divided by the average baseline glucose
concentration (Ford et al. 2007). Insulin to glucose ratio was determined overtime and analyzed
by variance component covariance structure using a between-within method, with time being the
repeated measure.
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For organ weights at birth and 3 mo, necropsy an analysis of covariance was done using
the GLM procedure with the organ as the dependent variable and BW as the covariate. This
analysis was done for the heart, kidney, liver, quadracep muscle, loin muscle, various fat depots,
as well as measurements of loin eye area and backfat.

58

RESULTS
Body Variables
Body weight, averaged across all time points, from birth until 3 mo of age tended to be
greater in lambs born to overfed ewes than lambs born to control (P = 0.09) and restricted (P =
0.05) ewes (15.45 ± 0.64, 15.07 ± 0.64, 16.97 ± 0.64 kg, control, restricted, overfed,
respectively; Figure 5). At birth, overfed offspring were heavier (P < 0.01) than control and
restricted offspring and continued to maintain this heavier weight until 3 mo of age (P ≤ 0.05;
Table 3). The greatest BW gain (P ≤ 0.05) in overfed offspring vs. control and restricted
offspring was observed after weaning, from wk 9 to 12. There were no differences in BW of
restricted lambs when compared with control lambs during the study (P = 0.7).
Average daily gain was calculated for each lamb throughout the study. Lambs born to
overfed ewes had greater (P = 0.01) ADG, averaged across all time points from wk 1 until 3 mo
of age, when compared with control and restricted offspring (0.21 ± 0.01, 0.21 ± 0.01, 0.23 ±
0.01 kg, control, restricted, overfed, respectively; Table 3). The greatest ADG in the overfed vs.
control and restricted offspring was observed post-weaning from week 9 to 12 (P ≤ 0.004; Figure
6). There were no differences among treatment groups during the pre-weaning period (wk 1 to
8) when analyzed separately from post-weaning (P = 0.9).
At birth, overfed offspring had 10% greater (P = 0.01) CRL than control offspring and
tended to have greater (P = 0.07) CRL than restricted offspring (46.46 ± 1.20, 48.14 ± 1.20,
51.27 ± 1.20 cm, control, restricted, overfed, respectively). Averaged across time points, from
birth until 3 mo of age, overfed offspring had greater (P ≤ 0.03) average CRL than control and
restricted offspring, and restricted offspring tended to have reduced (P = 0.08) average CRL than
control offspring (66.14 ± 0.85, 64.02 ± 0.85, 68.86 ± 0.85 cm, control, restricted, overfed,
59

Figure 5. The effect of maternal diet on body weight (BW; kg) of lambs measured weekly from
birth until three months of age.
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Body weight of lambs born to ewes given 1 of 3 diets from 31d of gestation until parturition
(Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were fed a control
diet in post-natal life. Body weight at the birth time point was analyzed in all 35 lambs on study.
After birth, BW was analyzed in lambs monitored for another 3 months (Control, n = 6;
Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Body weight treatment differences between
overfed and control at that specific time point; * P ≤ 0.05, # P ≤ 0.1. Birth SEM = 0.19, Week 1
to 12 largest SEM = 0.64.
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Table 3. Body variables of lambs measured weekly from birth until 3 months (mo) of age from
ewes given 1 of 3 diets.
Item
Body weight, kg
Birth
3 mo
Pre-weaning3
Post-weaning 4, 5
Average from birth to 3 mo5, 6
Average daily gain, kg
Pre-weaning3
Post-weaning4
Average from wk 1 to 3 mo
Crown rump length, cm
Birth6
3 mo
Pre-weaning3
Post-weaning4
Average from birth to 3 mo7
Heart girth, cm
Birth
3 mo6
Pre-weaning3
Post-weaning4
Average from birth to 3 mo7
Body condition score8
3 mo
Pre-weaning3
Post-weaning4, 5
Average from wk 5 to 3 mo

Treatment1
Control

Restricted

4.82a
29.67a
10.73
26.07a
15.45

4.65a
28.41a
10.35
25.58a
15.07

SEM2

Overfed
5.78b
33.51b
11.71
29.37b
16.97

0.19
1.37
0.69
1.13
0.64

0.18
0.28a
0.21a

0.17
0.29a
0.21a

0.18
0.33b
0.23b

0.01
0.01
0.01

46.46a
84.03
60.40a
79.06
66.14a

48.14ab
81.60
57.93a
77.70
64.02a

51.27b
85.10
63.83b
80.00
68.86b

1.20
1.89
0.86
1.72
0.85

38.43a
73.66ab
50.49
71.01
56.81

37.98a
73.03a
50.02
69.61
56.05

41.72b
78.11b
51.81
72.87
58.06

0.90
1.60
0.90
1.14
0.91

2.91
2.94
2.90ab
2.92a

2.89
2.92
2.88a
2.90a

2.95
2.97
2.96b
2.96b

0.04
0.02
0.02
0.02

a, b

Means within a row with different superscripts differ (P ≤ 0.05).
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
2
Largest SEM across treatments for variable.
3
Average of weeks 0 to 8 of age
4
Average of weeks 9 to 12 of age.
5
Control vs. Overfed, (P ≤ 0.1).
6
Overfed vs. Restricted, (P ≤ 0.1).
7
Control vs. Restricted, (P ≤ 0.1).
8
Body condition score based on scale from (Russel, 1991).
1
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Figure 6. Effect of maternal diet on average daily gain (ADG; kg/d) of lambs, calculated weekly
from week 1 to 12 of age.
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Average daily gain of lambs born to ewes given 1 of 3 diets from 31d of gestation until
parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were
fed a control diet in post-natal life. Average daily gain was analyzed in lambs monitored for 3
months (Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Average daily gain
treatment differences between overfed and control at that specific time point; * P ≤ 0.05, # P ≤
0.1. Largest SEM = 0.01.
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respectively; Figure 7). There were no differences among treatment groups at 3 mo of age (P =
0.4). Overfed offspring (63.83 ± 0.86 cm) had greater (P = 0.01) CRL during the pre-weaning
period than control (60.40 ± 0.86 cm) and restricted (57.93 ± 0.86 cm) offspring, but not during
post-weaning (P = 0.5; Table 3).
At birth, overfed offspring had greater HG (P ≤ 0.01) than control and restricted offspring
(38.43 ± 0.90, 37.98 ± 0.90, 41.72 ± 0.90 cm, control, restricted, overfed, respectively; Figure 8).
They maintained this greater (P ≤ 0.06) HG until 3 mo of age (Table 3). There were no
differences in restricted versus control lambs at birth (P = 0.7) or 3 mo of age (P = 0.7). There
were no differences among treatment groups during pre or post weaning (P ≤ 0.3). When
averaged across all time points, HG tended to be greater (P = 0.1) in overfed vs. restricted
offspring.
Body condition score was measured starting at week 5 of age until 3 mo of age (Figure
9). Week 5 was the first week after weaning began and the lambs were given ad libitum creep
feed and hay. Averaged across all time points, from week 5 until 3 mo of age, overfed offspring
had greater (P ≤ 0.04) average BCS than control and restricted offspring (2.92 ± 0.02, 2.90 ±
0.02, 2.96 ± 0.02, control, restricted, overfed, respectively; Table 3). There were no differences
in average BCS across all time points from week 5 to 3 mo of age in restricted versus control
offspring (P = 0.4). During post-weaning, overfed offspring tended to have greater (P = 0.07)
BCS than control offspring and had significantly greater (P = 0.05) BCS than restricted
offspring.

63

Figure 7. Effect of maternal nutrition on crown rump length (CRL; cm), measured from birth to
3 months of age in lambs.
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Crown rump length of lambs born to ewes given 1 of 3 diets from 31d of gestation until
parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were
fed a control diet in post-natal life. Crown rump length at the birth time point was analyzed in all
35 lambs on study. After birth, CRL was analyzed in lambs monitored for 3 months (Control, n
= 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Crown rump length treatment differences
between overfed and control at that specific time point; * P ≤ 0.05, # P ≤ 0.1. Largest SEM at
birth = 1.20. Week 1 to 12 largest SEM = 0.85.
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Figure 8. Effect of maternal nutrition on heart girth (HG; cm) of lambs from birth to 3 months
of age.
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Heart girth of lambs born to ewes given 1 of 3 diets from 31d of gestation until parturition
(Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were fed a control
diet in post-natal life. Heart girth at the birth time point was analyzed in all 35 lambs on study.
After birth, HG was analyzed in lambs monitored for 3 months (Control, n = 6; Restricted, n = 4
to 5; Overfed, n = 4 to 6/ week). Heart girth treatment differences between overfed and control
at that specific time point; * P ≤ 0.05. Heart girth treatment differences between restricted and
control at that specific time point; ϯ P ≤ 0.05. Largest SEM at birth = 0.90. Week 1 to 12
largest SEM = 0.91.
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Figure 9. Effect of maternal nutrition on body condition scores (BCS) of lambs from week 5
(first week after start of weaning) until 3 months of age.
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Body condition scores of lambs born to ewes given 1 of 3 diets from 31d of gestation until
parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were
fed a control diet in post-natal life. Body condition scores were measured from week 5 until 3
months of age (Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Week 5 was
the first week lambs were given ad libitum creep feed and hay. Body condition score treatment
differences between overfed and control at that specific time point; # P ≤ 0.1. Largest SEM =
0.02.
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Organ Weights
Heart weight was quantified at birth and 3 mo necropsy (Figure 10). When heart weight
is expressed with BW as a covariate, at 3 mo, the restricted offspring have greater (P = 0.04)
heart weights than the control offspring, and overfed offspring tend to have greater (P = 0.1)
heart weights than control offspring (0.15 ± 0.01, 0.18 ± 0.01, 0.17 ± 0.01, control, restricted,
overfed, respectively; Table 4). There were no differences in heart weight at birth (P = 0.4).
Liver weight, analyzed with BW as a covariate at birth tended to be greater in overfed
offspring than control offspring (P = 0.08; Table 4). At 3 mo necropsy there were no differences
in liver weight among treatment groups (P = 0.6; Figure 11). Using a grid, LEA, the cross
section of the longissimus dorsi muscle, was measured at birth and 3 mo necropsy (Figure 12).
When expressed with BW as a covariate at birth, restricted offspring had reduced LEA than
control offspring (P = 0.01; Table 4). At 3 mo there was no difference when adjusted for BW
among treatment groups (P = 0.4). Backfat thickness was measured only at 3 mo necropsy
(Figure 13). When analyzed with BW as a covariate, the restricted offspring had reduced backfat
versus the control offspring at 3 mo of age (P = 0.05; Table 4).
Metabolic Hormones
Hormone concentrations were measured at birth and once per week until 3 mo of age.
There were no differences among treatment groups in GH at birth (P = 0.3) or averaged across
time points from birth until 3 mo of age (P = 0.6; Figure 14). At 3 mo of age overfed offspring
tended to have greater GH concentrations than control offspring (P = 0.1). Average GH
concentrations tended to be greater (P = 0.1) in restricted (12.25 ± 1.78 ng/mL) versus control
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Figure 10. Lamb heart weights at birth and 3 month necropsy, expressed with body weight
(BW) as a covariate.
0.25
*

#

Heart weight, kg

0.20
0.15
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0.00
Birth
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3 Months
Restricted
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Heart weight of lambs quantified at birth (n = 6/treatment) and 3 month (Control, n = 6;
Restricted, n = 4; Overfed, n = 4) necropsy. Heart weight was analyzed with BW as a covariate.
Heart weight treatment differences between treatments indicated by * P ≤ 0.05 vs. Control and #
P ≤ 0.1 vs. Control. Values are means ± SEM.
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Table 4. Lamb organ weights, loin eye area, and backfat thickness measurements at birth and 3
month (mo) necropsy expressed with body weight (BW) as a covariate.
Item2
Heart weight, kg
Birth
3 mo3
Liver weight, kg
Birth3
3 mo
Loin eye area, cm2
Birth
3 mo
Backfat thickness, cm
Birth
3 mo

Control

Treatment1
Restricted

Overfed

SEM

0.03
0.15a

0.03
0.18b

0.03
0.17ab

0.01
0.02

0.11
0.75

0.11
0.70

0.12
0.73

0.01
0.07

7.57a
23.11

6.27b
21.01

7.49ab
20.10

0.77
3.00

ND4
0.20a

ND
0.11b

ND
0.26ab

0.06

a, b

Means within a row with different superscripts differ (P ≤ 0.05).
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
2
Expressed with BW as a covariate.
3
Control vs. Overfed, (P ≤ 0.1).
4
Not Detectable.
1
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Figure 11. Lamb liver weights from birth and 3 month necropsy expressed with body weight
(BW) as a covariate.
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Liver weight of lambs quantified at birth (n = 6/treatment) and 3 month (Control,
(Control n = 6;
Restricted, n = 4; Overfed, n = 4) necropsy. Liver weight was analy
analyzed
zed with BW as a covariate.
Liver weight treatment differences indicated by # P ≤ 0.1 vs. Control. Values are means ± SEM.
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Figure 12. Loin eye area (LEA), cross section of the longissimus dorsi muscle, measured in
lambs at birth and 3 month necropsy expressed with body weight (BW) as a covariate.

30
25

LEA, cm2

20
15
10

*

5
0
Birth
Control

3 Months
Restricted

Overfed

Loin eye area of lambs measured, using a grid, at birth (n = 6/treatment) and 3 month (Control, n
= 6; Restricted, n = 4; Overfed, n = 4) necropsy. Loin eye area was analyzed with BW as a
covariate. Loin eye area treatment differences indicated by * P ≤ 0.05 vs. Control. Values are
means ± SEM.
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Figure 13. Backfat thickness of lambs measured at 3 month necropsy, expressed with body
weight (BW) as a covariate.
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Backfat thickness of lambs was measured at 3 month (Control, n = 6; Restricted, n = 4; Overfed,
n = 4) necropsy. Backfat was analyzed with BW as a covariate. * Indicates backfat treatment
difference P ≤ 0.05 vs. Control. Values are means ± SEM.
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Figure 14. Serum growth hormone (GH; ng/mL) concentrations measured from birth until 3
months of age.
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Growth hormone (GH) concentrations of lambs born to ewes given 1 of 3 diets from 31d of
gestation until parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC).
All lambs were fed a control diet in post-natal life. Growth hormone at the birth time point was
analyzed in all 35 lambs on study. After birth, GH was analyzed in lambs monitored for 3
months (Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Growth hormone
treatment differences between overfed and control at that specific time point; # P ≤ 0.1. Largest
SEM at birth = 3.71. Week 1 to 12 largest SEM = 1.61.
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(8.49 ± 1.78 ng/mL) and overfed (8.42 ± 1.78 ng/mL) lambs pre-weaning (wk 0 to 8), but were
not different post-weaning (P = 0.7; Table 5).
Insulin-like growth factor-I concentrations were greater in overfed offspring (334.67 ±
65.93 ng/mL) than control offpsring (149.51 ± 65.93 ng/mL; P = 0.05) and tended to be greater
in overfed versus restricted (155.07 ± 65.93 ng/mL) offspring at 3 mo of age (P = 0.08; Figure
15). There were no differences among treatment groups at birth (P = 0.9) or averaged across
time points, from birth until 3 mo of age (P = 0.2). During pre-weaning there was an overall
treatment by time effect (P = 0.1), but there were no differences among treatment groups during
post-weaning (P =0.3; Table 5). Concentrations of IGF-I decreased at wk 4 due to fasting in
preparation for an IVGTT. After wk 4, IGF-I concentrations increased since lambs were given
free access to creep feed and hay beginning at wk 4 through the remainder of the study.
Insulin-like growth factor binding protein-3 concentrations at birth were not different
among treatment groups (P = 0.6). At 3 mo of age, overfed offspring had greater IGFBP-3
concentrations than control offspring (P = 0.01; Table 5). When averaged across time points,
IGFBP-3 was greater (P = 0.04) in overfed (121.99 ± 6.24 AU) versus restricted lambs (103.10 ±
6.24 AU). Post-weaning, week 9 through 12 of age, average IGFBP-3 concentrations were
greater (P ≤ 0.05) in overfed (175.27 ± 12.19 AU) versus control (140.56 ± 12.19 AU) and
restricted (125.79 ± 12.19 AU) lambs (Figure 16). The only difference in IGFBP-2 among
treatments was observed at 3 mo of age (Figure 17), when overfed (18.49 ± 1.52 AU) lambs had
greater (P = 0.01) concentrations than control (11.91 ± 1.52 AU) lambs (Table 5).
There were no significant differences in leptin concentrations (Table 6) at birth (P = 0.9)
or across time points from birth until 3 mo (P = 0.5), among treatment groups (Figure 18).
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Table 5. Serum concentrations of somatotropic axis hormones [growth hormone (GH), insulinlike growth factor (IGF)-1, IGF binding protein (IGFBP) -3 and -2] measured in lambs from
birth until 3 months of age.
Item
GH, ng/mL
Birth
3 mo3
Pre-weaning4
Post-weaning 5, 6, 7
Average birth to 3 mo
IGF-I, ng/mL
Birth
3 mo6
Pre-weaning4
Post-weaning5
Average birth to 3 mo
IGFBP-3, AU8
Birth
3 mo
Pre-weaning4
Post-weaning5
Average birth to 3 mo
IGFBP-2, AU8
Birth
3 mo
Pre-weaning4
Post-weaning5
Average birth to 3 mo

Treatment1
Restricted
Overfed

Control
5.47
2.16
8.49a
4.74
7.35

12.35
5.33
12.25b
6.46
10.36

SEM2

5.12
6.03
8.42a
5.46
7.53

3.71
1.75
1.78
1.71
1.61

110.42
149.51a
129.98
187.78
147.68

107.87
155.07ab
119.85
161.19
130.72

105.18
334.67b
123.82
253.02
161.31

22.10
65.93
21.46
49.08
25.33

68.15
120.16a
98.16
140.56a
111.20ab

66.07
140.48ab
92.78
125.79a
103.10a

73.42
189.24b
98.51
175.27b
121.99b

5.13
12.13
5.66
12.19
6.24

11.05
11.91a
15.49
15.14
15.38

12.32
13.73ab
15.01
14.52
14.86

10.04
18.49b
14.60
16.38
15.15

1.06
1.52
0.63
1.30
0.58

a, b

Means within a row with different superscripts, differ (P ≤ 0.05).
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
2
Largest SEM across treatments for variable.
3
Control vs. Overfed, (P ≤ 0.1).
4
Average of weeks 0 to 8 of age.
5
Average of weeks 9 to 12 of age.
6
Control vs. Restricted, (P ≤ 0.1).
7
Restricted vs. Overfed, (P ≤ 0.1).
8
Arbitrary units.
1
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Figure 15. Serum insulin-like growth factor-I (IGF-I; ng/mL) concentrations measured from
birth until 3 months of age.
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Insulin-like growth factor-I (IGF-I) concentrations of lambs born to ewes given 1 of 3 diets from
31d of gestation until parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140%
NRC). All lambs were fed a control diet in post-natal life. At the birth time point, IGF-I was
analyzed in all 35 lambs on study. After birth, IGF-I was analyzed in lambs monitored for 3
months (Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Insulin-like growth
factor treatment differences between overfed and control at that specific time point; *P ≤ 0.05, #
P ≤ 0.1. Largest SEM at birth = 22.10. Week 1 to 12 largest SEM = 25.33.
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Figure 16. Serum insulin-like growth factor binding protein-3 (IGFBP-3) concentrations
measured in arbitrary units (AU) from birth until 3 months of age.
250

#
*

IGFBP-3, AU

200
150
100

ϯ

ϯ

50
0
0

1

2

3

Control

4

5

6

7

8

Restricted

9

10 11 12
Overfed

Insulin-like growth factor binding protein-3 (IGFBP-3) concentrations of lambs born to ewes
given 1 of 3 diets from 31d of gestation until parturition (Control, 100% NRC; Restricted, 60%
NRC; Overfed, 140% NRC). All lambs were fed a control diet in post-natal life. At the birth
time point, IGFBP-3 was analyzed in all 35 lambs on study. After birth, IGFBP-3 was analyzed
in lambs monitored for 3 months (Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/
week). Insulin-like growth factor binding protein-3 treatment differences between overfed and
control at that specific time point; *P ≤ 0.05, # P ≤ 0.1. Insulin-like growth factor binding
protein-3 treatment differences between restricted and control at that specific time point; ϯ P ≤
0.05. Largest SEM at birth = 5.13. Week 1 to 12 largest SEM = 6.24.
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Figure 17. Serum concentrations of insulin-like growth factor binding protein-2
2 (IGFBP-2)
(
measured in arbitrary units (AU) from birth until 3 months of age in lambs.
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Insulin-like
like growth factor binding protein
protein-3 concentrations of lambs born to ewes given 1 of 3
diets from 31d of gestation
ion until parturition (Control, 100% NRC; Restricted, 60% NRC;
Overfed, 140% NRC). All lambs were fed a control diet in post-natal life. At th
he birth time
point, IGFBP-3 was
as analyzed in all 35 lambs on study. After birth, IGFBP-3 was analyzed in
lambs monitored for 3 months (Control
Control, n = 6; Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week).
Insulin-like
like growth factor binding protein
protein-2 treatment differences between overfed and control at
that specific time point; *P ≤ 0.05
0.05, # P ≤ 0.1. Insulin-like
like growth factor binding protein-2
protein
+
treatment differences between restricted and control at that specific time point; ϯ P ≤ 0.05, P ≤
0.1. Largest SEM at birth = 1.06
1.06. Week 1 to 12 largest SEM = 0.58.
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Leptin, ng/mL

Figure 18. Plasma leptin concentrations measured in ng/mL of lambs from birth until 3 months
of age.
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Plasma leptin concentrations of lambs born to ewes given 1 of 3 diets from 31d of gestation until
parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were
fed a control diet in post-natal life. At the birth time point, leptin was analyzed in all 35 lambs
on study. After birth, leptin was analyzed in lambs monitored for 3 months (Control, n = 6;
Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Leptin treatment differences between overfed
and control at that specific time point; *P ≤ 0.05. Leptin treatment differences between overfed
and restricted at that specific time point; # P ≤ 0.05. Largest SEM at birth = 0.20. Week 1 to 12
largest SEM = 0.09.
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Table 6. Plasma leptin and serum insulin measured in ng/mL, and serum total cholesterol (TC)
and triglyceride (TG) concentrations measured in mg/dL from lamb birth until 3 months (mo) of
age.
Item
Leptin, ng/mL
Birth
3 mo
Pre-weaning3
Post-weaning4
Average birth to 3 mo
Insulin, ng/mL
Birth
3 mo
Pre-weaning 3, 5
Post-weaning 4, 5
Average birth to 3 mo
TC, mg/dL
Birth
3 mo
TG, mg/dL
Birth
3 mo

Treatment1
Restricted
Overfed

Control

SEM2

1.22
1.03ab
1.15
1.01
1.11

1.17
0.78a
1.30
0.98
1.21

1.32
1.24b
1.29
1.08
1.23

0.20
0.13
0.11
0.08
0.09

1.17a
0.41
0.34a
0.33
0.33a

1.95b
0.50
0.49b
0.50
0.49b

1.06a
0.66
0.47ab
0.61
0.49b

0.36
0.24
0.05
0.14
0.05

35.13
30.18

38.42
37.70

30.28
28.70

4.39
9.78

22.52
15.31

15.52
16.86

23.96
15.38

5.22
2.73

a, b

Means within a row, with different superscripts, differ (P ≤ 0.05).
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
2
Largest SEM across treatments for variable.
3
Average of weeks 0 to 8 of age.
4
Average of weeks 9 to 12 of age.
5
Control vs. Overfed, (P < 0.01).
1
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At 3 mo of age, overfed offspring (1.24 ± 0.13 ng/mL) had greater (P = 0.03) leptin
concentrations than restricted offspring (0.78 ± 0.13 ng/mL).
Averaged across all time points, from birth until 3 mo of age, both overfed (0.49 ± 0.05
ng/mL) and restricted (0.49 ± 0.05 ng/mL) offspring had increased (P ≤ 0.05) serum insulin
concentrations when compared with the control (0.33 ± 0.05 ng/mL) offspring (Figure 19). At
birth, restricted offspring had greater (P = 0.1) insulin concentrations than control and overfed
offspring. There were no differences in insulin concentrations at 3 mo (P = 0.7) of age (Table 6).
During pre-weaning control offspring had reduced (P ≤ 0.1) insulin concentrations compared
with overfed and restricted offspring. During post-weaning, overfed offspring tended to have
greater (P = 0.1) insulin concentrations than control offspring.
Total cholesterol was measured from lambs at birth and 3 mo of age. There were no
differences among treatment groups at birth (P = 0.4) or at 3 mo of age (P = 0.8) due to the
variation among lambs within a treatment (Table 6). Total cholesterol concentrations decreased
with age (Figure 20). Triglyceride concentration was measured from lambs at birth and 3 mo of
age (Table 6). Triglyceride concentrations decreased with age, but there were no significant
differences among treatment groups at either time point, birth (P = 0.5) or 3 mo of age (P = 0.9;
Figure 21).
Intravenous Glucose Tolerance Test
Plasma glucose and insulin concentrations (Table 7) were measured from an IVGTT
performed on lambs at 3 mo of age. There were no differences (P = 0.7) in glucose
concentrations (Figure 22) over the 2 h 30 min challenge among treatments, but insulin
concentration ( Figure 23) in overfed offspring tended to be greater than control
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Insulin, ng/mL

Figure 19. Serum insulin concentrations measured in ng/mL of lambs from birth until 3 months
of age.
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Serum insulin concentrations of lambs born to ewes given 1 of 3 diets from 31d of gestation until
parturition (Control, 100% NRC; Restricted, 60% NRC; Overfed, 140% NRC). All lambs were
fed a control diet in post-natal life. At the birth time point, insulin was analyzed in all 35 lambs
on study. After birth, insulin was analyzed in lambs monitored for 3 months (Control, n = 6;
Restricted, n = 4 to 5; Overfed, n = 4 to 6/ week). Insulin treatment differences between overfed
and control at that specific time point; *P ≤ 0.05, # P ≤ 0.1. Insulin treatment differences
between restricted and control at that specific time point; ϯ P ≤ 0.1. Largest SEM at birth =
0.36. Week 1 to 12 largest SEM = 0.05.
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TC, mg/dL

Figure 20. Total cholesterol (TC; mg/dL) concentrations measured from lambs at birth and 3
months of age.
50
45
40
35
30
25
20
15
10
5
0
Birth
Control

3 Months
Restricted

Overfed

Total cholesterol was measured from birth and 3 month serum samples collected from lambs.
There was no difference observed among treatment groups at birth or 3 month time points.
Values are means ± SEM.
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Figure 21. Triglyceride (TG; mg/dL) concentrations measured from lambs at birth and 3 months
of age.
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Triglyceride concentrations were measured in mg/dL, from serum samples collected from lambs
at birth and 3 months of age. There was no difference among treatment groups at either time
point. Values are means ± SEM.
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Table 7. Plasma glucose and insulin concentrations from the intravenous glucose tolerance test
(IVGTT) performed on lambs at 3 months of age.
Item
Glucose
Average of all time points, mg/dL
Baseline, mg/dL
Peak concentration, mg/dL3
AUC, AU4
Insulin
Average of all time points, ng/mL3
Baseline, ng/mL3
Peak concentration, ng/mL5
AUC, AU4
1st phase response, ng/mL
Insulin:glucose ratio, ng/mL, mg/dL

Control
137.08
91.08
219.44
18,201.90
0.84
0.30a
1.75a
106.31
1.69
0.005a

a, b, c

Treatment1
Restricted
Overfed
128.88
97.16
211.28
15,717.20
1.17
0.61b
2.46ab
149.06
2.20
0.009b

127.48
88.42
180.54
16,916.30

SEM2
10.19
8.46
16.75
1467.69

1.41
0.42ab
3.66b
200.50
1.75
0.01c

Means within a row with different superscripts, differ (P ≤ 0.05).
Treatments: Control = 100% NRC; Restricted = 60% NRC; Overfed = 140% NRC.
2
Largest SEM across treatments for variable.3 Control vs. Overfed, (P ≤ 0.1).4 Expressed in
arbitrary units (AU).
5
Overfed vs. Restricted, (P ≤ 0.1).

1
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0.27
0.09
1.00
47.37
0.49
0.001

Figure 22. Plasma glucose concentrations and glucose area under the curve (AUC) from
intravenous glucose tolerance test (IVGTT) performed on lambs at 3 months of age.
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Plasma glucose concentrations were analyzed from samples collected during the intravenous
glucose tolerance test (IVGTT) from 30 minutes before glucose infusion to 120 minutes after
glucose infusion. The glucose tolerance test was performed at 3 months of age on 14 lambs
[Control (CON), n = 6; Restricted (RES), n = 4; Overfed (OVER), n = 4]. Baseline glucose
concentrations were calculated by the average of -30, -15, and 0 time points. Glucose peak
concentrations were measured during the tolerance test. Inset shows AUC expressed in arbitrary
units (AU). Glucose treatment differences between overfed and control at that specific time
point; # P ≤ 0.1. Glucose treatment differences between restricted and control at that specific
time point; *P ≤ 0.05. Largest SEM = 10.19. AUC largest SEM = 1467.69.
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Figure 23. Plasma insulin concentrations and insulin area under the curve (AUC) from
intravenous glucose tolerance test (IVGTT) performed on lambs at 3 months of age.

*
*
*

Plasma insulin concentrations were analyzed from samples collected during the intravenous
glucose tolerance test (IVGTT) from 30 minutes before glucose infusion to 120 minutes after
glucose infusion. The glucose tolerance test was performed at 3 months of age on 14 lambs
[Control (CON), n = 6; Restricted (RES), n = 4; Overfed (OVER), n = 4]. Baseline insulin
concentrations were calculated by the average of -30, -15, and 0 time points. Insulin peak
concentrations were analyzed at 10 minutes relative to glucose infusion and AUC were measured
during the tolerance test. Inset shows AUC expressed in arbitrary units (AU). First phase insulin
response was calculated by the sum of concentrations at 2 and 5 min minus the average baseline
concentration. Insulin treatment differences between overfed and control at that specific time
point; * P ≤ 0.05. Largest SEM = 0.27. AUC largest SEM = 47.37.
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offspring ( P = 0.1). There were also no significance differences in glucose baseline or AUC
among treatments (P > 0.1). Overfed (180.54 ± 16.75 mg/dL) offspring tended to have reduced
(P = 0.1) glucose peak concentration than control (219.44 ± 16.75 mg/dL) offspring. Insulin
baseline concentrations were greater in restricted offspring than control (P = 0.02) and overfed
(P = 0.1) offspring. There was no difference in AUC or first phase insulin response among
treatment groups (P = 0.4). Ten minutes after glucose infusion, insulin peak concentration was
reached and was greater in overfed offspring than control (P = 0.003) and restricted (P = 0.07)
offspring (Figure 24). Both overfed and restricted offspring exhibited a greater insulin:glucose
ratio than the control offspring (P ≤ 0.05; Figure 24).
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Insulin:Glucose, ng/mL, mg/dL

Figure 24. Plasma insulin:glucose ratio from the intravenous glucose tolerance test (IVGTT)
performed on lambs at 3 months of age.
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The insulin to glucose ratio was significantly greater in overfed and restricted offspring than
control offspring. Ten minutes after glucose infusion overfed lambs had a greater
insulin:glucose ratio than the control offspring and maintained this greater ratio until 30 minutes
after infusion. Insulin:glucose treatment differences between overfed and control at that specific
time point; * P ≤ 0.05. Largest SEM = 0.001.
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DISCUSSION
Maternal nutrition has been implicated in developmental programming associated with
pre- and post-natal changes affecting health and performance of offspring (Barker, 2004; Wu et
al., 2006). Fetal growth restriction and maternal under-nutrition result in negative impacts on
growth efficiency and body composition (Greenwood et al., 2000; Wu et al., 2006; Larson et al.,
2009; Neville et al., 2010). This current study focused on determining the effects poor maternal
nutrition, during gestation, has on post-natal growth of offspring. Specifically studying the
changes in concentrations of hormones involved in growth and differences in organ size and
body composition. These changes could potentially be linked to altered fetal programming as a
result of poor maternal nutrition. Adverse consequences, such as these, can become more
evident with increasing age as compensatory adaptations in other tissues and organ systems fail
(McMillen and Robinson, 2005).
Reed et al. (2007) and Swanson et al. (2008) demonstrated that maternal nutrientrestriction during the last two-thirds of gestation in sheep reduced birth weights. However,
Gardner et al. (2005) and Ford et al. (2007) have reported that maternal restriction significantly
altered composition of growth and metabolism in the absence of birth weight differences of
offspring born to ewes nutrient-restricted in either early gestation, early to mid gestation, or late
gestation, which support the data from the current study where there were no differences in birth
weight observed in lambs born to nutrient-restricted ewes from d 31 of gestation until parturition.
However, developmental programming can occur independently of birth weight (Barker, 2004).
Thus, long-term insults of poor maternal nutrition can occur even when BW is not different at
birth.
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In the current study, we observed heavier birth weight and BW throughout the 3 mo in
lambs born to ewes overfed from 31 d of gestation until parturition. Similar to our data, Meyer
et al. (2010) reported at 20 d of age, BW was greater in lambs born to overfed ewes versus
control-fed ewes. However, these data are not consistent with several studies using an obese or
over-nourished sheep model, who reported reduced birth weight of lambs born to ewes overfed
during mid to late or late gestation (Muhlhausler et al., 2006; Swanson et al., 2008) or no
differences in birth weight when ewes were overfed from 60 d before conception (Long et al.,
2010). These differences between these studies and the current study are possibly attributed to
different timing of changes in nutrition. All three of these studies began overfeeding ewes either
before conception or later (d 50 or d 90) in gestation than the current study.
A number of studies have reported a U-shaped relationship between birth weight and
adult fat mass, with a greater prevalence of obesity occurring at lighter and heavier birth weights
(McMillen and Robinson, 2005). Since we observed a greater increase in BW after weaning in
lambs born to overfed ewes, this could suggest that if these lambs had been monitored for a
longer period of time, development of obesity would have been likely, especially given that
maternal obesity at conception is associated with an increased risk of obesity in the offspring
(Shankar et al., 2008; Long et al., 2010).
Low and high planes of maternal nutrition can impact growth of fetal organs (Reed et al.,
2007; Carlson et al., 2009; Caton et al., 2009). Since the heart is fairly mature at birth, any
environmental stimulus that alters the timing of the transition from hyperplastic to hypertrophic
growth of cardiomyocytes may have long lasting consequences for heart growth and function.
This includes effects in post-natal life of offspring exposed to poor maternal nutrition (Li et al.,
2003). Studies have reported changes in cardiac morphometry and function in fetuses of
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nutrient-restricted ewes (Vonnahme et al., 2003) and overfed (Dong et al., 2008; Fan et al., 2011;
Wang et al., 2011) ewes and rats. Vonnahme et al. (2003) observed cardiac ventricular
hypertrophy in fetuses of nutrient restricted ewes. These data support our findings that lambs
born to restricted and overfed ewes exhibited increased heart weight compared with lambs born
to control-fed ewes. This could suggest cardiovascular dysfunction and hypertrophy were
programmed in-utero.
Lambs born to overfed ewes tended to have increased liver weight at birth compared with
lambs born to control ewes, when expressed with BW as a covariate. This may suggest an
increase in liver metabolic function due to nutrient repartitioning to allow for proper
development based on findings reported in Vonnahme et al. (2003). It could also suggest an
increase in hepatic triglyceride concentrations, which are associated with maternal over-nutrition
and lead to fatty liver disease as observed in rats and nonhuman primates (Buckley et al., 2005;
McCurdy et al., 2009). Vonnahme et al. (2003) reported that fetuses from nutrient-restricted
ewes (fed 50% NRC) at 78 d of gestation had increased liver weight. In the current study we
observed an increase in liver weight in lambs born to overfed ewes. Therefore, both maternal
over-nutrition and nutrient-restriction can lead to altered fetal organ growth, although offspring
of restricted mothers did not differ in liver weight in the current study.
Loin eye area, a predictor of muscularity, was reduced in lambs born to nutrient-restricted
ewes at birth when compared with lambs born to control-fed ewes, which could indicate that
offspring from nutrient-restricted mothers at birth exhibited reduced muscularity. Decreased
muscularity is a normal result of maternal under-nutrition due to the decrease in available energy
(Wu et al., 2006). These lambs are also expected to have increased adiposity (Greenwood and
Thompson, 2007; Ford et al., 2007). However, the lambs born to restricted ewes on our study
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did not exhibit increased adiposity. Backfat thickness, a predictor of adiposity, was reduced in
lambs born to restricted ewes at 3 mo of age compared with those born to control and overfed
ewes. The lambs exposed to under-nutrition in fetal life could have still been recovering from
this restriction at 3 mo of age since this is still an early time point in post-natal life. This could
potentially explain why we observed a reduction in backfat thickness of these lambs. However,
at 3 mo of age we did observe an up regulation of factors involved in adipogenesis (Bush et al.,
2013), suggesting that if we had monitored these lambs for a longer period of time they would
have exhibited an increase in adiposity. Reduced nutrient intake at various time points before
mating and during gestation can result in offspring with increased adipose depot weights at term
or later in life (Gardner et al., 2005; Ford et al., 2007). This supports our hypothesis that these
lambs would have exhibited increased adiposity if studied until a later time point.
Measures of the somatotropic axis are known to be predictive of nutritional status, energy
balance, and growth rate (Freake et al., 2001; Rausch et al., 2002). Many of the studies
analyzing the relationship between hormones of the somatotropic axis and poor maternal
nutrition focused on changes in these hormones during fetal development. Few studies have
been done determining if these changes persist in post-natal life and most of these studies used a
model of maternal under-nutrition (Greenwood et al., 2000; Wu et al., 2006; Caton et al., 2007;
Ford et al., 2007; Larson et al., 2009; Neville et al., 2010). We are now beginning to determine
that maternal over-nutrition has similar negative consequences associated with the somatotropic
axis of offspring in post-natal life. Thus, our objective was to design an experiment consisting of
both a maternal under-nutrition model and a maternal over-nutrition model and study changes
associated with the somatotropic axis of the offspring.
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Intrauterine growth retardation is normally observed in animals with reduced birth weight
and body composition. In the current study, lambs born to nutrient restricted ewes did not differ
in BW from lambs born to control ewes at any time point during the study. However, this does
not necessarily mean that these lambs did not exhibit IUGR. The reduced LEA at birth and
reduced backfat at 3 months of age suggests that body composition of these lambs was altered.
Therefore, these lambs could have exhibited IUGR.
Circulating concentrations of somatotropic hormones in the mother and the fetus are
under strong nutritional regulation from mid to late gestation (Oliver et al., 1999). In fetal sheep,
fetal plasma IGF-I, IGF-II, IGFBP-3, insulin, and glucose are decreased during severe maternal
nutrient-restriction, while IGFBP-2 concentrations are increased (Gallaher et al., 1994). Growth
hormone in fetal sheep is increased in response to under-nutrition and exhibits a pattern of
response similar to that seen during post-natal life (Bauer et al., 1995). Growth hormone
concentrations in normal growing animals are known to decrease with age (Govoni et al., 2003,
2004) and in nutrient-restricted animals concentrations are known to increase (Rausch et al.,
2002). Growth hormone concentrations in lambs born to nutrient-restricted ewes in the current
study tended to be greater than control lambs before bottle weaning at week 8 of age,
demonstrating that the somatotropic axis of these lambs in post-natal life was affected by their
exposure to maternal nutrient-restriction in-utero.
Most IGF-I in circulation is bound in a complex with IGFBP-3 (Breier, 1999), so it was
expected that IGFBP-3 concentrations would be parallel to IGF-I concentrations and both are
known to increase with age and growth rate (Govoni et al., 2003, 2004). Both IGF-I and IGFBP3 concentrations decreased at week 4 of age, which was indicative of fasting in preparation for a
glucose tolerance test (Katz et al., 2002). Concentrations of IGFBP-3 are known to increase with
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growth rate, similar to IGF-I, which was demonstrated in this study with lambs born to overfed
ewes exhibiting increased concentrations of IGFBP-3 and IGF-I that parallel increases in BW.
We observed an increase in IGFBP-2 concentrations at 3 mo of age in lambs born to overfed
ewes, which was not expected since IGFBP-2 concentrations are normally opposite that of
IGFBP-3 concentrations (Govoni et al., 2003, 2004). This was the only time point IGFBP-2 was
different among treatments and this may be because IGFBP-2 concentrations were variable and
are known to be greater at birth and decrease with age (Govoni et al., 2003, 2004).
Of interest is the comparison of these hormonal concentrations between pre-weaning and
post-weaning, since weaning occurred at the same time that the rumen was fully developing
(Parish et al., 2009). The difference in GH concentrations among treatments was observed preweaning, but not post-weaning. However, the prominent differences in IGF-I and IGFBP-3 were
observed in lambs born to overfed ewes post-weaning. These changes in hormone
concentrations may demonstrate differences in intake, digestion and nutrient utilization due to
adaptation from pre-ruminant to functional ruminant (Seal and Reynolds, 1993). Muhlhausler et
al. (2006) and Samuelsson et al. (2008) have demonstrated that pre-natal overfeeding in mice and
sheep leads to altered appetite regulation in post-natal offspring. Altered response of the central
appetite regulatory system can signal to increase feed intake and adiposity after birth
(Muhlhusler et al., 2006). Long et al. (2010) demonstrated, that feed intake was increased by
10% in lambs born to obese ewes compared with offspring of control ewes. These data show
that the appetitive regulation system of lambs exposed to over-nutrition in pre-natal life is
altered, causing an increase in appetite. This could explain the differences in hormone
concentrations between pre-and post-weaning of lambs born to overfed ewes in the current study.
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Most of the changes in these hormones were exhibited by lambs born to overfed ewes,
not lambs born to restricted ewes, similar to BW differences observed in the current study. This
may suggest that concentrations of IGF-I may be related more to size at birth and current weight
rather than maternal nutritional group (Oliver et al., 2002). This suggests that the factors that
program post-natal phenotype are more closely related to size at birth than to maternal nutrition
in late gestation (Oliver et al. 2002). This is in agreement with the current study since overfed
lambs at 3 mo of age had greater BW and greater IGF-I and IGFBP-3 concentrations than control
lambs. However, the increase in BW and IGF-I concentrations after weaning in lambs born to
overfed ewes could be due to an increase in feed intake; however we did not measure intake of
these lambs. We expected overfed offspring to have greater IGF-I and IGFBP-3 concentrations,
but another experiment would need to be done to determine if these changes are due to BW or
maternal nutrition.
Hyperinsulinemia can be caused by compensation for insulin resistance, which is one of
the many conditions associated with metabolic syndrome. Hyperinsulinemia has been reported in
lambs and rats exposed to poor maternal nutrition (Ford et al., 2007, 2009; Shankar et al., 2008;
Samuelsson et al., 2008). In the current study, lambs born to both overfed and restricted ewes
had greater insulin concentrations than control born lambs throughout their life time, suggesting
insulin-glucose homeostasis was altered during fetal life. Increased insulin concentrations may
also indicate impaired insulin signaling pathways leading to insulin resistance, which has been
shown as another long-term effect of poor maternal nutrition (Thorn et al., 2011). In normal
growing lambs, insulin secretion, sensitivity and action are known to decrease with age (Gatford
et al., 2004), but we did not observe this decrease in lambs from the current study, which also
indicates an impairment in homeostasis. This could suggest compensatory changes to insulin
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secretion in the current study to maintain glucose tolerance. Maturation of the ovine pancreas
does not occur until two mo of age (Titlbach et al., 1985); therefore, poor maternal nutrition
could contribute to pancreatic dysfunction. This could be a result of fetal programming, and
thus alter insulin regulatory and signaling mechanisms (Armitage et al., 2004; Ford et al., 2009).
We performed an IVGTT on all lambs at 1 and 3 mo of age to assess glucose tolerance
and insulin sensitivity and we observed that lambs born to overfed ewes had greater insulin
response to glucose than lambs born to control-fed ewes. Lambs born to overfed ewes exhibited
reduced glucose peak and increased insulin peak concentrations, but no significant difference in
glucose or insulin AUC. Insulin AUC was increased in lambs born to overfed ewes, but was not
significant due to variation among animals, agreeing with the increase in insulin AUC in lambs
born to nutrient-restricted ewes at 63 d of age observed in Ford et al. (2007).
A study performed by Gatford et al. (2004) established post-natal ontogeny of glucose
homeostasis and insulin action in lambs through IVGTT at different ages. This study determined
glucose homeostasis of lambs from pre-weaning to adulthood by assessing insulin secretion,
insulin sensitivity, and glucose tolerance. They concluded that glucose homeostasis, insulin
secretion, insulin sensitivity, and insulin action decrease with maturation and age from before
weaning to early adulthood in sheep. Insulin secretion in young lambs was predictive of insulin
secretion in young adults, suggesting that events in early life may permanently determine the
capacity for glucose-stimulated insulin secretion (Gatford et al., 2004). Findings in the current
study, along with Ford et al. (2007), could suggest that both maternal over-nutrition and undernutrition result in lambs with deficits in insulin regulation of glucose, more so than what would
have been observed with increasing age.

This could lead to problems such as insulin resistance

and obesity.
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We did not observe differences in leptin concentrations among treatment groups
throughout the study. Leptin decreases feed intake and increases energy expenditure. Therefore
we expected to observe an increase in leptin concentration associated with the increase in
adiposity, known to result from exposure to poor maternal nutrition (Long et al., 2010).
However, we did not observe an increase in adiposity in any treatment group, nor did we observe
a difference in leptin concentrations due to maternal treatment. At 3 mo of age, lambs born to
restricted ewes tended to have reduced leptin concentrations compared with lambs born to
overfed ewes. This same time point is when we observed a reduction in backfat of lambs born to
restricted ewes, suggesting that the reduced leptin concentrations are in response to reduced
adiposity which allows for increased intake and increased accumulation of energy stores
(Friedman, 2002). This is in agreement with Blache et al. (2000) who reported that plasma leptin
concentrations were highly correlated with backfat thickness in sheep. Tokuda and Yano (2001),
Tokuda (2003), and Altmann (2005) reported similar findings.
The current study demonstrates that growth, development, and metabolism are altered in
offspring exposed to poor maternal nutrition. Most changes in body composition and the
somatotropic axis observed were in lambs exposed to maternal over-nutrition, specifically larger
body size, greater heart weight, increased concentrations of IGF-I, IGFBP-3, and insulin. These
changes, along with the greater insulin response to glucose observed in lambs born to overfed
ewes, demonstrates that both the somatotropic axis and insulin-glucose homeostasis were altered
during fetal life and could be a result of fetal programming. The data we reported are similar to
changes observed in humans who develop metabolic syndrome later in life, which is
characterized by conditions such as cardiovascular disease, insulin resistance, and obesity.
These findings suggest that this study, if carried out until lambs reached adult life, could have
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resulted in lambs exhibiting deficits that parallel with metabolic syndrome in humans. We now
know how poor maternal nutrition alters hormones involved in metabolic function, but we still
need to investigate possible metabolic control mechanisms that lead to these changes.
Understanding this will give us more insight into how the development of diseases in adult life
are associated with changes in these hormones in early post-natal life, as a consequence of fetal
programming.

99

REFERENCES
Abe, H., M. Moritmatsu, M. Aso, H. Shimizu, Y. Nikami, H. Kosaka, K. Syuto and M. Saito.
1994. Tissue distribution of major insulin-responsive glucose transporter (GLUT4)
protein in cattle. Proc Soc Nutr Physiol. 3: 214.
Adams, N. R. and J. R. Briegel. 2005. Multiple effects of an additional growth hormone
gene in adult sheep. J Anim Sci. 83:1868-1874.
Allen, M. S., B. J. Bradford, and M. Oba. 2009. BOARD-INVITED REVIEW: The hepatic
oxidation theory of the control of feed intake and its application to ruminants. J Anim
Sci. 87:3317-3334.
Altmann, M., H. Sauerwein, and E. Von Borell. 2005. Relationship between plasma leptin
concentrations and carcass composition in fattening mutton: a comparison with
ultrasound results. J Anim Physiol Anim Nutr. 89: 326-330.
Anderson, K. E., J. Coadwell, L. R. Stephens, and P. T. Hawkins. 1998. Translocation of PDK-1
to the plasma membrane is important in allowing PDK-1 to activate protein kinase B.
Current Biology. 8:684-691.
Andrews, J. F. 1998. Leptin: energy regulation and beyond to a hormone with pan-physiological
function. In Proceedings-Nutrition Society of London . 57:409-411. Cambridge
University Press.
Annunziata, M., R. Granata, and E. Ghigo. 2011. The IGF System. Acta. Diabetol. 48:1-9.
Argente, J., N. Caballo, V. Barrios, J. Pozo, M. T. MunÄoz, J. A. Chowen, and M. Hernandez.
1997. Multiple endocrine abnormalities of the growth hormone and insulin-like growth
factor axis in prepubertal children with exogenous obesity: effect of short and long-term
weight reduction. J Clin Endocrinol Metab. 82:2076-2083.
Armitage, J. A., I. Y. Khan, P. D. Taylor, P. W. Nathanielsz, and L. Poston. 2004.
Developmental programming of the metabolic syndrome by maternal nutritional
imbalance: how strong is the evidence from experimental models in mammals? J
Physiol. 561: 355-377.
Bach, L. A. 2005. IGFBP-6 five years on; not so ‘forgotten’?. Growth Hor IGF Res. 15:185-192.
Banks, A. S., S. M. Davis, S. H. Bates, and M. G. Myers. 2000. Activation of downstream
signals by the long form of the leptin receptor. J. Biol. Chem. 275: 14563-14572.
Barker, D. 2004. Developmental origins of adult health and disease. J. Epidemiol. 58:114.

100

Barker, D. J. P., and P. M. Clark. 1997. Fetal undernutrition and disease in later life. Rev.
Reprod. 2:105-112.
Barker, D. J., S. P. Bagby, and M. A. Hanson. 2006. Mechanisms of disease: in utero
programming in the pathogenesis of hypertension. Nat Clin Pract Nephr. 2:700-707.
Barta, A., R. Richards, J. D. Baxter, and J. Shine. 1981. Primary structure and evolution
of rat growth hormone gene. Proc Nat Acad Sci. 78:4867-71.
Baserga, R., M. Resnicoff, and M. Dews. 1997. The IGF-I receptor and cancer.
Endocrine. 7.1:99-102.
Bates, S. H., W. H. Stearns, T. A. Dundon, M. Schubert, A. W. K. Tso, Y. Wang, A. S. Banks,
H. J. Lavery, A. K. Haq, E. Maratos-Flier, B. G. Neel, M. W. Schwartz, and M. G.
Myers. 2003. STAT3 signalling is required for leptin regulation of energy balance but not
reproduction. Nature. 421: 856-859.
Bauer, M. K., B. H. Breier, J. E. Harding, J. D. Veldhuis, and P. D. Gluckman. 1995. The fetal
somatotropic axis during long term maternal undernutrition in sheep: evidence for
nutritional regulation in utero. Endocrinol. 136: 1250-1257.
Bauman, D. E. 1999. Bovine somatotropin and lactation: from basic science to commercial
application. Domest Anim Endocrin. 17:101-116.
Baumann, G. 1994. Growth hormone-binding proteins: state of the art. J Endocrinology. 141:1-6.
Baumann, G. 2001. Growth hormone binding protein. J Pediatr Endocrinol Metab. 14:355-375.
Baumann, G., K. Amburn, and M. A. Shaw. 1988. The circulating growth hormone (GH)binding protein complex: a major constituent of plasma GH in man. Endocrinol.
122:976-984.
Bazan, J. F. 1990. Structural design and molecular evolution of a cytokine receptor
superfamily. Proc Natl Acad Sci. 87:6934-6938.
Bell, A. W. and D. E. Bauman. 1997. Adaptations of glucose metabolism during pregnancy and
Lactation. J Mammary Gland Biol. 2:265-278.
Benali, N., G. Ferjoux, E. Puente, L. Buscail, and C. Susini. 2000. Somatostatin receptors.
Digestion. 62:27-32.
Bendinelli, P., P. Maroni, F. P. Giraldi, and R. Piccoletti. 2000. Leptin activates Stat3, Stat1 and
AP-1 in mouse adipose tissue. Mol Cell Endocrinol. 168:11-20.
Bergman, E. N., S. S. Reulein, and R. E. Corlett. 1989. Effects of obesity on insulin sensitivity
and responsiveness in sheep. Am J Physiol. 257:E772-E781.
101

Bikle, D. D. 2008. Integrins, insulin like growth factors, and the skeletal response to load.
Osteoporosis Int. 19:1237-1246.
Bjorbaek, C., S. Uotani, B. Da Silva, and J. S. Flier. 1997. Divergent signaling capacities of the
long and short isoforms of the leptin receptor. J Biol Chem. 272: 32686-32695.
Blache, D., R. L. Tellam, L. M. Chagas, M. A. Blackberry, P. E. Vercoe, and G. B. Martin. 2000.
Level of nutrition affects leptin concentrations in plasma and cerebrospinal fluid in sheep.
J Endocrinol. 165: 625-637.
Bloomfield, H., A. Spiroski, and J. E. Harding. 2013. Fetal growth factors and fetal nutrition.
Semin Fetal Neonat M.. WB Saunders.
Boisclair, Y. R., R. P. Rhoads, I. Ueki, J. Wang, and G. T. Ooi. 2001. The acid-labile subunit
(ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten
component of the circulating IGF system. J Endocrinol. 170: 63-70.
Bornfeldt, K. E., H. J. Arnqvist, B. Enberg, L. S. Mathews, and G. Norstedt. 1989. Regulation of
insulin-like growth factor-I and growth hormone receptor gene expression by diabetes
and nutritional state in rat tissues. J Endocrinol. 122: 651-656.
Breier, B. H. 1999. Regulation of protein and energy metabolism by the somatotropic axis.
Domes Anim Endocrinol.17:209-18.
Breier, B. H., M. H. Vickers, B. A. Ikenasio, K. Y. Chan, and W. P. S. Wong. 2001. Fetal
programming of appetite and obesity. Mol Cell Endocrinol. 185: 73-79.
Brismar, K., E. Fernqvist-Forbes, I. Wahren, and K. Hall. 1994. Effect of insulin on the hepatic
production of insulin-like growth factor binding protein-1 (IGFBP-1), IGFBP-3 and
IGF-I in insulin-dependent diabetics. J Clin Endocr Metab. 79:872-878.
Brissenden, J.E., A. Ullrich, and U. Francke. 1984. Human chromosomal mapping of genes for
insulin-like growth factors i and ii and epidermal growth factor. Nature. 310:781-784.
Brockman, R. P. 1993. Glucose and short-chain fatty acid metabolism. In: J. M. Forbes and J.
France, editors, Quantitative Aspects of Ruminant Digestion and Metabolism, CAB
International, Wallingford, United Kingdom, p. 247-265.
Brooks, A. J., J. W. Wooh, K. A. Tunny, and M. J. Waters. 2008. Growth hormone
receptor; mechanism of action. The Int J Biochem Cell B. 40:1984-1989.
Buckley, A. J., A. L. Jaquiery, and J. E. Harding. 2005. Nutritional programming of adult
disease. Cell Tissue Res. 322: 73-79.
Bunn, R. C. and J. L. Fowlkes. 2003. Insulin-like growth factor binding protein proteolysis.
Trends Endocrin Met. 14:176-181.
102

Bush, A. M., M. L. Hoffman, K. N. Peck, S. A. Zinn, and K. E. Govoni. (2013, July). Effects of
poor maternal nutrition during gestation on gene expression in renal adipose tissue of
lambs. Poster presented at the ADSA – ASAS Joint Annual Meeting, Indianapolis, IN.
(Abstract W173).
Butler, A. and D. Le Roith. 2001. Control of growth by the somatotropic axis: grow
hormone and the insulin-like growth factors have related and independent roles.
Annu Rev Physiol. 63:141-164.
Campbell, R. M. and C. G. Scanes. 1995. Endocrine peptides' moonlighting'as immune
modulators: roles for somatostatin and GH-releasing factor. Endocrinol. 147:383-396.
Canton, J. G., and J. A. Quintal. 2007. Evaluation of growth and carcass characteristics of pure
Pelibuey sheep and their cross with Dorper and Katahdin breeds. J Dairy Sci.
90:571-571. 360 Park Ave South, New York, NY 10010-1710 USA: ELSEVIER
SCIENCE INC.
Carlson, D. B., J. J. Reed, P. P. Borowicz, J. B. Taylor, L. P. Reynolds, T. L. Neville, D. A.
Redmer, K. A. Vonnahme, and J. S. Caton. 2009. Effects of dietary selenium supply and
timing of nutrient-restriction during gestation on maternal growth and body composition
of pregnant adolescent ewes. J Anim Sci. 87: 669-680.
Caton, A. R., E. M. Bell, C. M. Druschel, M. M. Werler, A. E. Lin, M. L. Browne, L. McNutt, P.
A. Romitti, A. A. Mitchell, R. S. Olney, and A. Correa. 2009. Antihypertensive
medication use during pregnancy and the risk of cardiovascular malformations.
Hypertension. 54: 63-70.
Cella, S. G., V. De Gennaro Colonna, V. Locatelli, G. E. Bestetti, G. L. Rossi, A. Torsello, W. B.
Wehrenberg, and E. E. Muller. 1994. Somatotropic dysfunction in growth hormonereleasing hormone-deprived neonatal rats: effect of growth hormone replacement therapy.
Pediatr Res. 36:315–322.
Chiang, S. H., C. A. Baumann, M. Kanzaki, D. C. Thurmond, R. T. Watson, C. L. Neudauer, I.
G. Macara, J. E. Pessin, and A. R. Saltiel. 2001. Insulin-stimulated GLUT4 translocation
requires the CAP-dependent activation of TC10. Nature. 410: 944-948.
Chilliard, Y., M. Bonnet, C. Delavaud, Y. Faulconnier, C. Leroux, J. Djiane, and F. Bocquier.
2001. Leptin in ruminants. Gene expression in adipose tissue and mammary gland, and
regulation of plasma concentration. Domest Anim Endocrin. 21: 271-295.
Cirmanova, V., M. Bayer, L. Starka, and K. Zajickova. 2008. The effect of leptin on bone: an
evolving concept of action. Physiol Res. 57: S143-S151.
Clemmons, D. R. 2006. Involvement of insulin-like growth factor-i in the control of glucose
homeostasis. Curr Opin Pharmacol. 6:620-625.

103

Clemmons, D. R. 2009. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrin
Met. 20:349-356.
Clemmons, D. R. and L. E. Underwood.1991. Nutritional regulation of IGF-Iand IGF binding
proteins. Annu Rev Nutr. 1:393-394.
Cohen, P. and R. G. Rosenfeld. 1994. Physiologic and clinical relevance of the insulin-like
growth factor binding proteins. Curr Opin Pediatr. 6:462-467.
Cohick, W. S., and D. R. Clemmons. 1993. The insulin-like growth factors. Annu
Rev Physiol. 55:131-153.
Cohick, W. S., K. Plaut, S. J. Sechen, and D. E. Bauman. 1989. Temporal pattern of insulin-like
growth factor-I response to exogenous bovine somatotropin in lactating cows. Domest
Anim Endocrin. 6: 263-273.
Cole, D. J. A. 1990. Nutritional strategies to optimize reproduction in pigs. J Reprod
Fertil Suppl. 40:67-82.
Collett-Solberg, P. F. and P. Cohen. 1996. The role of the insulin-like growth factor binding
proteins and the IGFBP proteases in modulating IGF action. Endocrin Metab Clin
25:591-614.
Conover, C. A. and D. D. De Leon. 1994. Acid-activated insulin-like growth factor-binding
protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem
269:7076-7080.
Coverley, J. A., J. L. Martin, and R. C. Baxter. 2000. The effect of phosphorylation by casein
kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinol.
141: 564-570.
Coverley, J.A. and R. C. Baxter. 1997. Phosphorylation of insulin-like growth factor binding
proteins. Mol Cell Endocrinol. 128:1-5.
Crespi, E. J., and R. J. Denver. 2006. Leptin (ob gene) of the South African clawed frog Xenopus
Laevis. P Natl Acad Sci. 103: 10092-10097.
Cunningham, B. C., M. Ultsch, A. M. de Vos, M. G. Mulkerrin, K. R. Clauser, and J. A.
Wells. 1991. Dimerization of the extracellular domain of the human growth hormone
receptor by a single hormone molecule. Science. 254:821-825.
Cusin, I., F. Rohner-Jeanrenaud, A. Stricker-Krongrad, and B. Jeanrenaud. 1996. The weightreducing effect of an intracerebroventricular bolus injection of leptin in genetically obese
fa/fa rats: reduced sensitivity compared with lean animals. Diabetes. 45: 1446-1450.

104

Da Silva, P., R. P. Aitken, S. M. Rhind, P. A. Racey, and J. M. Wallace. 2001. Influence of
placentally mediated fetal growth restriction on the onset of puberty in male and female
lambs. Reproduction. 122: 375-383.
Da Silva, P., R. P. Aitken, S. M. Rhind, P. A. Racey, and J. M. Wallace. 2002. Impact of
maternal nutrition during pregnancy on pituitary gonadotrophin gene expression and
ovarian development in growth-restricted and normally grown late gestation sheep
fetuses. Reproduction. 123:769-777.
Darnell, J. E. 1997. STATs and gene regulation. Science. 277: 1630-1635.
Dasen, J. S., and M. G. Rosenfeld. 2001. Signaling and transcriptional mechanisms in pituitary
development. Annu Rev Neuro Sci. 24: 327-355.
Davey, H. W., R. J. Wilkins, and D. J. Waxman. 1999. STAT5 signaling in sexually
dimorphic gene expression and growth patterns. Am J Hum Genet. 65:959-965.
Delavaud, C., A. Ferlay, Y. Faulconnier, F. Bocquier, G. Kann, and Y. Chilliard. 2002. Plasma
leptin concentration in adult cattle: effects of breed, adiposity, feeding level, and meal
intake. J Anim Sci. 80: 1317-1328.
Denley, A., L. J. Cosgrove, G. W. Booker, J. C. Wallace, and B. E. Forbes. 2005. Molecular
interactions of the IGF system. Cytokine Growth F R. 16: 421-439.
DeNoto, F. M., D. D. Moore, and H. M. Goodman. 1981. Human growth hormone DNA
sequence and mRNA structure: possible alternative splicing. Nucl Acids Res.
9:3719-30.
Devesa, J., L. Lima, and J.A.F. Tresguerres. 1992. Neuroendocrine control of growth
hormone secretion in humans. Trends in Endocrin Met. 3:175-183.
Dickson, M. C., J. C. Saunders, and R. S. Gilmour. 1991. The ovine insulin-like growth factor-I
gene: characterization, expression and identification of a putative promoter. J Mol
Endocrinol. 6: 17-31.
Djiane, J., and L. Attig. 2008. Role of leptin during perinatal metabolic programming and
obesity. J Physiol Pharmacol. 59: 55-63.
Dong, F., S. P. Ford, M. J. Nijland, P. W. Nathanielsz, and J. Ren. 2008. Influence of maternal
undernutrition and overfeeding on cardiac ciliary neurotrophic factor receptor and
ventricular size in fetal sheep. J Nutr Biochem. 19: 409-414.
Duan, C. 2002. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins.
J Endocrinol. 175: 41-54.

105

Ehrhardt, H., S. Fulda, I. Schmid, J. Hiscott, K. Debatin, and I. Jeremias. 2003. TRAIL induced
survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis
mediated by NF-κB. Oncogene. 22: 3842-3852.
Ehrhardt, R. A., R. M. Slepetis, J. Siegal-Willott, M. E. Van Amburgh, A. W. Bell, and Y. R.
Boisclair. 2000. Development of a specific radioimmunoassay to measure physiological
changes of circulating leptin in cattle and sheep. J Endocrinol. 166: 519-528.
Elliot, J. M. 1980. Propionate metabolism and vitamin B12. In: Y. Ruckebusch and P. Thivend,
editors, Digestive Physiology and Metabolism in Ruminants. MTP Press, Lancaster,
United Kingdom. p. 485-503.
Elmquist, J. K., R. Coppari, N. Balthasar, M. Ichinose, and B. B. Lowell. 2005. Identifying
hypothalamic pathways controlling food intake, body weight, and glucose homeostasis.
J Comp Neurol. 493: 63-71.
Elmquist, J. K., R. S. Ahima, E. Maratos-Flier, J. S. Flier, and C. B. Saper. 1997. Leptin
activates neurons in ventrobasal hypothalamus and brainstem. Endocrinol.
138: 839-842.
Evans, J. L., B. A. Maddux, and I. D. Goldfine. 2005. The molecular basis for oxidative stressinduced insulin resistance. Antioxidants and Redox Signaling. 7:1040-1052.
Fan, X., S. Turdi, S. P. Ford, Y. Hua, M. J. Nijland, M. Zhu, P. W. Nathanielsz, and J. Ren.
2011. Influence of gestational overfeeding on cardiac morphometry and hypertrophic
protein markers in fetal sheep. J Nutr Biochem. 22: 30-37.
Fang, Y. Z., S. Yang, and G. Wu. 2002. Free radicals, antioxidants, and nutrition. Nutrition.
18:872-879.
Ferguson, J. D. 2005. Nutrition and reproduction in dairy herds. Vet Clin Food Anim.
21:325-347.
Ferrannini, E., A. Natali, P. Bell, P. Cavallo-Perin, N. Lalic, and G. Mingrone. 1997. Insulin
resistance and hypersecretion in obesity. European Group for the Study of Insulin
Resistance (EGIR). J Clin Invest. 100: 1166.
Firth, S. M. and R. C. Baxter. 2002. Cellular actions of the insulin-like growth factor binding
proteins. Endocr Rev. 23:824-854.
Firth, S. M., and R. C. Baxter. 1999. Characterisation of recombinant glycosylation variants of
insulin-like growth factor binding protein-3. J Endocrinol. 160: 379-387.
Flint, D. J, E. Tonner, G. J. Allan. 2000. Insulin-like growth factor binding proteins: IGFdependent and –independent effects in the mammary gland. J Mammary Gland Biol
Neoplasia. 5:65–73.
106

Fontaneli, R. S., L. E. Sollenberger, R. C. Littell, and C. R. Staples. 2005. Performance of
lactating dairy cows managed on pasture based or in freestall barn-feeding systems. J.
Dairy Sci. 88:1264-1276.
Ford, S. P., B. W. Hess, M. M. Schwope, M. J. Nijland, J. S. Gilbert, K. A. Vonnahme, W. J.
Means, H. Han, and P. W. Nathanielsz. 2007. Maternal undernutrition during early to
mid-gestation in the ewe results in altered growth, adiposity, and glucose tolerance in
male offspring. J Anim Sci. 85: 1285-1294.
Ford, S. P., L. Zhang, M. Zhu, M. M. Miller, D. T. Smith, B. W. Hess, G. E. Moss, P. W.
Nathanielsz, and M. J. Nijland. 2009. Maternal obesity accelerates fetal pancreatic β-cell
but not α-cell development in sheep: pre-natal consequences. Am J Physiol-Reg I. 297:
R835-R843.
Frank, S. J. and J. L. Messina. 2002. Growth Hormone Receptor. Cytokine reference
on-line. London: Academic Press, Harcourt. 121.
Freake, H. C., K. E. Govoni, K. Guda, C. Huang, and S. A. Zinn. 2001. Actions and interactions
of thyroid hormone and zinc status in growing rats. J Nutr. 131:
1135-1141.
Friedman, J. M. 2002. The function of leptin in nutrition, weight, and physiology. Nutr Rev.
60: S1-S14.
Friedman, J. M., and J. L. Halaas. 1998. Leptin and the regulation of body weight in mammals.
Nature. 395: 763-770.
Frystyk, J., E. Skjaerbaek, C. E. Mogensen, H. Orskov. 1995. Free Insulin-like growth factor in
human obesity. Metabolism. 44:37-44.
Gallaher, B. W., M. H. Oliver, K. Eichhorn, U. Kessler, W. Kiess, J. E. Harding, P. D.
Gluckman, and B. H. Breier. 1994. Circulating insulin-like growth factor II/mannose-6phosphate receptor and insulin-like growth factor binding proteins in fetal sheep plasma
are regulated by glucose and insulin. Eur J Endocrinol. 131: 398-404.
Gardner, D. S., K. Tingey, B. W. M. Van Bon, S. E. Ozanne, V. Wilson, J. Dandrea, D. H.
Keisler, T. Stephenson, and M. E. Symonds. 2005. Programming of glucose-insulin
metabolism in adult sheep after maternal undernutrition. Am J Physiol Regul Integr
Comp Physiol. 289:R947-954.
Garofalo, C. and E. Surmacz. 2006. Leptin and cancer. J Cell Physiol. 207: 12-22.

107

Gatford, K. L., M. J. De Blasio, P. Thavaneswaran, J. S. Robinson, I. C. McMillen, and J. A.
Owens. 2004. Post-natal ontogeny of glucose homeostasis and insulin action in sheep.
Am J Physiol Endocrinol Metab. 286: E1050-E1059.
Gaylinn, B. D., J. K. Harrison, J. R. Zysk, C. E. Lyons, K. R. Lynch, and M. O. Thorner.
1993. Mol. Endocrinol. 7:77-84.
Gerrard D. E., A. L. 2006. Principles of animal growth & development. Dubuque, IA: Kendall
Hunt Publishing Co. p 189–192.
Ghilardi, Nico, Sandra Ziegler, Adrian Wiestner, Ruedi Stoffel, Markus H. Heim, and Radek C.
Skoda. 1996. Defective STAT signaling by the leptin receptor in diabetic mice. P Nat
Acad Sci. 93: 6231-6235.
Gluckman, P. D., and J. E. Harding. 1997. The physiology and pathophysiology of intrauterine
growth retardation. Horm Res Pediatr. 48: 11-16.
Goffin, V., K.T. Shiverick, P.A. Kelly, and J.A. Martial. 1996. Sequence–function
relationships within the expanding family of prolactin, growth hormone, placental
lactogen, and related proteins in mammals. Endocr Rev. 17:385-410.
Gondret, F., L. Lefaucheur, I. Louveau, and B. Lebret. 2005. The long-term influence of birth
weight on muscle characteristics and eating meat quality in pigs individually reared and
fed during fattening. Arch Tierz Dummerstorf. 48:68-73.
Gootwine, E., A. Rozov, A. Bor, and S. Reicher. 2006. Carrying the FecB (Booroola)
mutation is associated with lower birth weight and slower post-weaning growth
rate for lambs, as well as a lighter mature BW for ewes. Reprod Fertil Dev.
18:433-437.
Gootwine, E., J. A. Sise, J. M. Penty, and G. W. Montgomery. 1993. The duplicated gene
copy of the ovine GH gene contains a PvuII polymorphism in the second intron.
Anim Gen. 24:319-321.
Gootwine, E., S. Yossefi, A. Zenou, A. Bor. 1998. Marker assisted selection for FecB
carriers in Booroola Awassi crosses. In: Procedings of the Sixth World Congres. Genet.
Appl. Livest. Prod. Armidale, Australia. 24:161-164.
Gordeladze, J. O., C. A. Drevon, U. Syversen, and J. E. Reseland. 2002. Leptin stimulates
human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization:
Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem.
85: 825-836.
Govoni, K. E., D. Goodman, R. M. Maclure, L. M. Penfold, and S. A. Zinn. 2011. Serum
concentrations of insulin‐like growth factor‐i and insulin‐like growth factor binding
protein‐2 and‐3 in eight hoofstock species. Zoo Biol. 30: 275-284.
108

Govoni, K. E., T. A. Hoagland, and S. A. Zinn. 2003. The ontogeny of the somatotropic axis in
male and female Hereford calves from birth to one year of age. J Anim Sci. 81: 28112817.
Govoni, K. E., T. A. Hoagland, and S. A. Zinn. 2004. The ontogeny of the somatotropic axis in
Hereford calves from birth to one year of age and its response to administration of
exogenous bovine somatotropin. J Anim Sci. 82: 1646-1655.
Govoni, K. E., X. C. Tian, G. W. Kazmer, M. Taneja, B. P. Enright, A. L. Rivard, X. Yang, and
S. A. Zinn. 2002. Age-related changes of the somatotropic axis in cloned Holstein calves.
Biol Reprod. 66: 1293-1298.
Greenfield, J. R. and L. V. Campbell. 2004. Insulin resistance and obesity. Clin Dermatol.
22:289-295.
Greenwood, P. L., A. S. Hunt, J. W. Hermanson, and A. W. Bell. 2000. Effects of birth
weight and post-natal nutrition on neonatal sheep: II. Skeletal muscle growth and
development. J Anim Sci. 78:50-61.
Greenwood, P. L., and A. N. Thompson. 2007. Consequences of maternal nutrition during
pregnancy and of foetal growth for productivity of sheep. Recent Adv Anim Nutr.
185-196.
Grodsky, G. M. and L. L. Bennett. 1966. Cation requirements for insulin secretion in the isolated
perfused pancreas. Diabetes. 15:910–913.
Guillemin, R., P. Brazeau, P. Bohlen, F. Esch, N. Ling, and W. B. Wehrenberg. 1982. Growth
hormone-releasing factor from a human pancreatic tumor that caused acromegaly.
Science. 218: 585-587.
Hadsell, D. L. 2004. Genetic manipulation of mammary gland development and lactation. Adv.
Exp Med Biol. 554:229-251.
Hales, C. Nicholas, and David JP Barker. 2001. The thrifty phenotype hypothesis Type 2
diabetes. Brit Med Bull. 60: 5-20.
Hamrick, Mark W. 2004. Leptin, bone mass, and the thrifty phenotype. J Bone Miner Metab. 19:
1607-1611.
Han, I. K., P. Bosi, Y. Hyun, J. D. Kim, K. S. Sohn, and S. W. Kim. 2000. Recent advances
in sow nutrition to improve reproductive performance. Asian-australas. J Anim Sci.
13:335-355.
Hankins, G. R., A. T. De Souza, R. C. Bentley, M. R. Patel, J. R. Marks, J. D. Iglehart, and R. L.
Jirtle. 1996. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene.
12:9:2003-2009.
109

Hansen, Barbara Caleen. 1999. The metabolic syndrome X. Ann NY Acad Sci. 892: 1-24.
Headey, S. J., D. W. Keizer, S. Yao, J. C. Wallace, L. A. Bach, and R. S. Norton. 2004. Binding
site for the C-domain of insulin-like growth factor (IGF) binding protein-6 on IGF-II;
implications for inhibition of IGF actions. FEBS letters. 568: 19-22.
Heim, M. H. 1996. The Jak–STAT pathway: specific signal transduction from the cell membrane
to the nucleus. Eur J Clin Invest. 26: 1-12.
Himpe, E., and R. Kooijman. 2009. Insulin‐like growth factor‐I receptor signal transduction and
the Janus Kinase/Signal Transducer and Activator of Transcription (JAK‐STAT)
pathway. Biofactors. 35: 76-81.
Hoaglund, C. M., V. M. Thomas, M. K. Petersen, and R. W. Kott.1992. Effects of
Supplemental protein source and metabolizable energy intake on nutritional
status in pregnant ewes. J Anim Sci. 70:273-280.
Hocquette, J. F. and H. Abe. 2000. Facilitative glucose transporters in livestock species. Reprod
Nutr Dev. 40:517-533.
Holt, R. I. G., H. L. Simpson, and P. H. Sönksen. 2003. The role of the growth hormone–
insulin‐like growth factor axis in glucose homeostasis. Diabetic medicine. 20: 3-15.
Honegger, A., and R. E. Humbel. 1986. Insulin-like growth factors I and II in fetal and adult
bovine serum. Purification, primary structures, and immunological cross-reactivities.
J Biol Chem. 261: 569-575.
Houseknecht, K. L., C. A. Baile, R. L. Matteri, and M. E. Spurlock. 1998. The biology of leptin:
a review. J Anim Sci. 76:1405-1420.
Huang, L. U., and L. I. Cai. 2000. Leptin: a multifunctional hormone. Cell research 10: 81-92.
Huising, M. O., E. J. W. Geven, C. P. Kruiswijk, S. B. Nabuurs, E. H. Stolte, F. A. T. Spanings,
B. M. L. Verburg-van Kemenade, and G. Flik. 2006. Increased leptin expression in
common carp (Cyprinus carpio) after food intake but not after fasting or feeding to
satiation. Endocrinol. 147: 5786-5797.
Humbel, R. E. 1989. Insulin-like growth factors I and II. Eur J Biochem. 190:445-462.
Hwa, V., Y. Oh, and R. G. Rosenfeld. 1999. The insulin-like growth factor binding protein
(IGFBP) superfamily. Endocr Rev. 20:761-787.
Ikezu, T., T. Okamoto, U. Giambarella, T. Yokota, and I. Nishimoto. 1995. In vivo coupling of
insulin-like growth factor II/mannose 6-phosphate receptor to heteromeric G proteins.
Distinct roles of cytoplasmic domains and signal sequestration by the receptor. J Biol
Chem. 270:29224-29228.
110

Ingvartsen, K. L., and Y. R. Boisclair. 2001. Leptin and the regulation of food intake, energy
homeostasis and immunity with special focus on periparturient ruminants. Domest Anim
Endocrin. 21: 215-250.
Iranmanesh, A., G. Lizarralde, J. D. Veidhuis . 1991. Age and relative adiposity are specific
negative determinants of the frequency and amplitude of growth hormone (GH) secretory
bursts and the half-life of endogenous GH in healthy man. J. Clin Endocr Metab.
73:1081-1088.
Isaksson, O.G., A. Lindahl, A. Nilsson, and J. Isgaard. 1987. Mechanism of the stimulatory
effect of growth hormone on longitudinal bone growth. Endocr Rev. 8:426-438.
Jarrett, I. G., O. H. Filsell, and F. J. Ballard. 1974. Metabolic and endocrine interrelationships in
normal and diabetic sheep. Horm Metab Res. 4:111-116.
Jones, J.I. and D. R. Clemmons. 1995. Insulin-like growth factors and their binding proteins:
biological actions. Endocr Rev. 16:3-34.
Jones, J.I., A. J. D’Ercole, C. Camacho-Hubner, and D. R. Clemmons. 1991. Phosphorylation of
insulin-like growth factor (IGF)-binding protein-1 in cell culture and in vivo: effects on
affinity for IGF-I. Proc Natl Acad Sci. 88:7481-7485.
Kahn, B. B. and J. S. Flier. 2000. Obesity and insulin resistance. J Clin Invest.106:473-481.
Kahn, C. R. 1985. The molecular mechanism of insulin action. Annu Rev Med. 36:429-451.
Kahn, C. R. and M. White. 1988. The insulin receptor and the molecular mechanism of insulin
action. Journal of Clin Invest. 82:1151.
Kamegai, J., S. Minami, H. Sugihara, O. Hasegawa, H. Higuchi, and I. Wakabayashi. 1996.
Growth hormone receptor gene is expressed in neuropeptide Y neurons in hypothalamic
arcuate nucleus of rats. Endocrinol. 137: 2109-2112.
Kanaka‐Gantenbein, Christina. 2010. Fetal origins of adult diabetes. Ann NY Acad Sci.
1205: 99-105.
Kaplan, S. A. and P. Cohen. 2007. The somatomedin hypothesis 2007:50 years later. J Clin
Endocrin Metab. 92:4529-4535.
Kasanicki, M. A. and P. F. Pilch. 1990. Regulation of glucose-transporter function. Diabetes
Care. 13:219-227.
Katz, L. E. L., D. D. DeLeón, H. Zhao, and A. F. Jawad. 2002. Free and total insulin-like growth
factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding
protein-1. J Clin Endocr Metab. 87: 2978-2983.

111

Kazmer, G. W., S. A. Zinn, and L. D. Strausbaught. 2000. Short communication: growth
hormone response to somatostatin-28 and growth hormone-releasing factor in dairy
heifers. J Dairy Sci. 83: 2282-2284.
Kazmer, G. W., S. A. Zinn, H. Rycroft, and R. M. Campbell. 1992. Serum growth hormone in
and semen characteristics of proven AI dairy sires after administration of growth
hormone-releasing factor. Can J Anim Sci. 72: 959-963.
Kelly, P. A., A. Bachelot, C. Kedzia, L. Hennighausen, C. J. Ormandy, J. J. Kopchick, and N.
Binart. 2002. The role of prolactin and growth hormone in mammary gland
development. Mol Cell Endocrinol. 197:127-131.
Kelly, P. A., J. E. L. Finidori, S. E. P. Moulin, C. E. C. Kedzia, and N. Binart. 2001. Growth
hormone receptor signalling and actions in bone growth. Horm Res Paediatr. 55(Suppl.
2):14-17.
Kieffer, T. J., R. S. Heller, C. A. Leech, G. G. Holz, and J. F. Habener. 1997. Leptin suppression
of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic β-cells.
Diabetes. 46: 1087-1093.
Kim, B., C. S. Ku, T. X. Pham, Y. Park, D. A. Martin, L. Xie, R. Taheri, J. Lee, and B. W.
Bolling. 2013. Aronia melanocarpa (chokeberry) polyphenol–rich extract improves
antioxidant function and reduces total plasma cholesterol in apolipoprotein E knockout
mice. Nutr Res. 33: 406-413.
Kim H-S, R. G. Rosenfeld, and Y. Oh. 1997. Biological roles of insulin-like growth factor
binding proteins. Exp Mol Med. 29: 85–96.
Kim, Y. B., S. E. Nikoulina, T. P. Ciaraldi, R. R. Henry, and B. B. Kahn. 1999. Normal insulindependent activation of Akt/protein kinase B,with diminished activation of
phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest. 104:733–741.
Knights, M., Q. S. Baptiste, A. B. Dixon, J. L. Pate, D. J. Marsh, E. K. Inskeep, and P. E. Lewis.
2003. Effects of dosage of FSH, vehicle and time of treatment on ovulation rate and
prolificacy in ewes during the anestrous season. Small Ruminant Res. 50: 1-9.
Koch, B. D., J. B. Blalock, and A. Schonbrunn. 1988. Characterization of the cyclic AMPindependent actions of somatostatin in GH cells. I. An increase in potassium
conductance is responsible for both the hyperpolarization and the decrease in
intracellular free calcium produced by somatostatin. J Biol Chem. 263:216-225.
Krantic, S., I. Goddard, A. Saveanu, N. Giannetti, J. Fombonne, A. Cardoso, P. Jaquet, and A.
Enjalbert. 2004. Novel modalities of somatostatin actions. Eur J Endocrinol.
151: 643-655.

112

Kulkarni, R. N., Z. Wang, R. Wang, J. D. Hurley, D. M. Smith, M. A. Ghatei, D. J. Withers, J.
V. Gardiner, C. J. Bailey, and S. R. Bloom. 1997. Leptin rapidly suppresses insulin
release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest.
100: 2729.
Kumar, B., S. M. Francis, J. M. Suttie, and M. P. Thompson. 1998. Expression of obese mRNA
in genetically lean and fat selection lines of sheep. Comp Biochem phys B. 120: 543-548.
Larsen, L. U., E. Sloth, O. B. Petersen, T. F. Pedersen, K. Sorensen, and N. Uldbjerg. 2009.
Systolic myocardial velocity alterations in the growth‐restricted fetus with
cerebroplacental redistribution. Ultrasound Obst Gyn. 34: 62-67.
Layden, B. T., V. Durai, and W. L. Lowe Jr. 2010. G-Protein-Coupled Receptors, Pancreatic
Islets, and Diabetes. Nature Education. 3:13.
Le Roith, D. 1996. Insulin-like growth factor receptors and binding proteins. Bailliere Clin
Endoc. 10: 49-73.
Le Roith, D. 2003. The insulin-like growth factor system. Exp. Diabesity Res. 4:205-212.
Le Stunff, C., and P. Bougnères. 1994. Early changes in postprandial insulin secretion, not in
insulin sensitivity, characterize juvenile obesity. Diabetes. 43: 696-702.
Lee, G., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee, and J. M.
Friedman. 1996. Abnormal splicing of the leptin receptor in diabetic mice. Nature.
632-635.
Li, P., J. Li, X. Feng, Z. Li, R. Hou, C. Han, and Y. Zhang. 2003. Gene expression profile of
cardiomyocytes in hypertrophic heart induced by continuous norepinephrine infusion in
the rats. Cell Mol Life Sci. 60: 2200-2209.
Limesand, S. W., P. J. Rozance, G. O. Zerbe, J. C. Hutton, and W. W. Hay. 2006. Attenuated
insulin release and storage in fetal sheep pancreatic islets with intrauterine growth
restriction. Endocrinol. 147: 1488-1497.
Lin-Su, K., and M. P. Wajnrajch. 2002. Growth hormone releasing hormone (GHRH)
and the GHRH receptor. Rev Endocr Metab Disord. 3:313-323.
Lobelo, F. 2005. Fetal programming and risk of metabolic syndrome: prevention efforts for highrisk populations. Pediatrics. 116: 519-519.
Long, N. M., L. A. George, A. B. Uthlaut, D. T. Smith, M. J. Nijland, P. W. Nathanielsz, and S.
P. Ford. 2010. Maternal obesity and increased nutrient intake before and during gestation
in the ewe results in altered growth, adiposity, and glucose tolerance in adult offspring. J
Anim Sci. 88:3546-3553.
113

Marin, P., H. Kvist, G. Lindstedt, L. Sjostrom, and P. Bjorntorp. 1993. Low concentrations of
insulin-like growth factor-I in abdominal obesity. Int J Obes. 17:83-89.
Marinaro, J. A., G. M. Neumann, V. C. Russo, K. S. Leeding, and L. A. Bach. 2000.
O‐glycosylation of insulin‐like growth factor (IGF) binding protein‐6 maintains high
IGF‐II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to
proteolysis. Eur J Biochem. 267: 5378-5386.
Mayer, J. P., F. Zhang, and R. D. DiMarchi. 2007. Insulin structure and function.
Peptide Science. 88: 687-713.
Mayo, K. E. 1992. Molecular cloning and expression of a pituitary-specific receptor for growth
hormone-releasing hormone. Mol Endocrinol. 6:10:1734-1744.
Mayo, K. E., P. A. Godfrey, S. T. Suhr, D. J. Kulik, and J. O. Rahal. 1995. Growth
hormone-releasing hormone: Synthesis and signaling. Rec Prog Horm Res. 50:35-73.
Mayo, K. E., T. Miller, V. DeAlmeida, P. Godfrey, J. Zheng, and S. R. Cunha. 2000.
Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog
Horm Res. 55:237-266.
McCurdy, C. E., J. M. Bishop, S. M. Williams, B. E. Grayson, M. S. Smith, J. E. Friedman, and
K. L. Grove. 2009. Maternal high-fat diet triggers lipotoxicity in the fetal livers of
nonhuman primates. J Clin Invest. 119: 323.
McMillen, I. C., and J. S. Robinson. 2005. Developmental origins of the metabolic syndrome:
prediction, plasticity, and programming. Physiological Rev. 85: 571-633.
Mellor, D. J., and I. C. Matheson. 1979. Daily changes in the curved crown-rump length of
individual sheep fetuses during the last 60 days of pregnancy and effects of different
levels of maternal nutrition. Exp Physiol. 64: 119-131.
Mellor, D. J., R. A. Dingwall, and T. J. King. 1993. Successful fostering of orphan lambs by
nonpregnant ewes induced to lactate using exogenous hormone treatment. New Zeal Vet
J. 41: 200-204.
Mena, P., A. Llanos, and R. Uauy. 2001. Insulin homeostasis in the extremely low birth weight
infant. Semin Perinatol. 25: 436-446. WB Saunders.
Mercer, J. G., N. Hoggard, L. M. Williams, C. B. Lawrence, L. T. Hannah, and P. Trayhurn.
1996. Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in
mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Letters.
387: 113-116.

114

Meyer, A. M., J. J. Reed, T. L. Neville, J. B. Taylor, C. J. Hammer, L. P. Reynolds, D. A.
Redmer, K. A. Vonnahme, and J. S. Caton. 2010. Effects of plane of nutrition and
selenium supply during gestation on ewe and neonatal offspring performance, body
composition, and serum selenium. J Anim Sci. 88: 1786-1800.
Mlinar, B., J. Marc, and M. Pfeifer. 2006. Molecular Mechanisms of Insulin Resistance, Obesity
and Metabolic Syndrome. Biochemia Medica 16: 8-24.
Mohan, S., C. M. Bautista, J. Wergedal, and D. J. Baylink. 1989. Isolation of an inhibitory
insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium, a
potential local regulator of IGF action. Proc. Natl. Acad. Sci. USA. 86: 8338-8342.
Monzavi, R., and P. Cohen. 2002. IGFs and IGFBPs: role in health and disease. Best
Pract Res Cl En. 16:433-447.
Moran, O., and M. Phillip. 2003. Leptin: obesity, diabetes and other peripheral effects–a review.
Pediatric Diabetes. 4: 101-109.
Morton, G. J. 2007. Hypothalamic leptin regulation of energy homeostasis and glucose
metabolism. J Physiol. 583: 437-443.
Muggeo, M., B. H. Ginsberg, J. Roth, D. M. Jr. Neville, P. DeMeyts.1979. The insulin receptor
in vertebratesis functionally more conserved during evolution than insulin itself.
Endocrinol. 104: 1393-1402.
Muhlhausler, B. S., C. L. Adam, P. A. Findlay, J. A. Duffield, and I. C. McMillen. 2006.
Increased maternal nutrition alters development of the appetite-regulating network in the
brain. The FASEB Journal. 20: 1257-1259.
Muller, E. E., V. Locatelli, and D. Cocchi. 1999. Neuroendocrine control of growth
hormone secretion. Physiol Rev. 79:511-607.
Muoio, Deborah M., and G. Lynis Dohm. 2002. Peripheral metabolic actions of leptin. Best
Pract Res Cl En. 16: 653-666.
Murakami, M., M. Narazaki, M. Hibi, H. Yawata, K. Yasukawa, M. Hamaguchi, T. Taga,
and T. Kishimoto. 1991. Critical cytoplasmic region of the interleukin 6 signal
transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci.
88:11349-11353.
Naderipour, H., J. Yadi, A. G. Shad, and M. A. Sirjani. 2012. The effects of three methods of
synchronization on estrus induction and hormonal profile in Kalkuhi ewes: A comparison
study. Afr J Biotechnol. 11: 530-533.

115

Nam, S.Y., E. J. Lee, K. R. Kim, B. S. Cha, Y. D. Song , S. K. Lim, H. C. Lee, and K. B. Huh.
1997. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their
relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth
hormone. Int J Obes. 21:355-359.
National Research Council (NRC). 1985. Subcommittee on Sheep Nutrition. Nutrient
requirements of sheep. National Academies Press, Washington DC.
Neumann, G. and L. Bach. 1999. The N-terminal disulfide linkages of human insulin-like growth
factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass
spectrometry. J Biol Chem. 274:14587-14594.
Neville, T. L., J. S. Caton, C. J. Hammer, J. J. Reed, J. S. Luther, J. B. Taylor, D. A. Redmer, L.
P. Reynolds, and K. A. Vonnahme. 2010. Ovine offspring growth and diet digestibility
are influenced by maternal selenium supplementation and nutritional intake during
pregnancy despite a common post-natal diet. J Anim Sci. 88: 3645-3656.
Nissen, P. M., V. O. Danielsen, P. F. Jorgensen, and N. Oksbjerg. 2003. Increased
maternal nutrition of sows has no beneficial effects on muscle fiber number or post-natal
growth and has no impact on the meat quality of the offspring. J Anim Sci.
81:3018-3027.
Nissley, P. W. Lopaczynski. 1991. Insulin-like growth factor receptors. Growth Factors. 5:29-43.
Niswender, K. D., and M. W. Schwartz. 2003. Insulin and leptin revisited: adiposity signals with
overlapping physiological and intracellular signaling capabilities. Front Neuroendocrin.
24: 1-10.
Nordlie, R. C., J. D. Foster, and A. J. Lange. 1999. Regulation of glucose production by the
liver. Annu Rev Nutr. 19:379-406.
O’Gorman, D. B., J. Weiss, A. Hettiaratchi, S. M. Firth, and C. D. Scott. 2002. Insulin-like
growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of
choriocarcinoma cells in vitro and in vivo. Endocrinol. 143:4287-4294.
Oliver, M. H., B. H. Breier, P. D. Gluckman, and J. E. Harding. 2002. Birth weight rather than
maternal nutrition influences glucose tolerance, blood pressure, and IGF-I levels in
sheep. Pediatr Res. 52:516-524.
Oliver, M. H., F. H. Bloomfield, J. E. Harding, B. H. Breier, N. S. Bassett, and P. D. Gluckman.
1999. The maternal, fetal and post-natal somatotrophic axes in intrauterine growth
retardation. Biochem Soc Trans.

116

Owens, J. A., K. L. Gatford, M. J. De Blasio, L. J. Edwards, I. C. McMillen, and A. L. Fowden.
2007. Restriction of placental growth in sheep impairs insulin secretion but not sensitivity
before birth. J Physiol. 584: 935-949.
Parish, J. A., J. D. Rivera, and H. T. Boland.1914. Understanding the Ruminant Animal
Digestive System. Extension Service of Mississippi State University, cooperating with
U.S. Department of Agriculture.
Park, S., S. M. Hong, S. R. Sung, and H. K. Jung. 2008. Long-term effects of central leptin and
resistin on body weight, insulin resistance, and β-cell function and mass by the
modulation of hypothalamic leptin and insulin signaling. Endocrinol. 149: 445-454.
Patel, Y. C., and W. O'Neil. 1988. Peptides derived from cleavage of prosomatostatin at
carboxyl-and amino-terminal segments. Characterization of tissue and secreted
forms in the rat. J Biol Chem. 263:745-751.
Patti, M. and C. R. Kahn. 1998. The insulin receptor-a critical link in glucose homeostasis and
insulin action. JBCPP. 9: 89-110.
Petersenn, S., and H. M. Schulte. 2000. Structure and function of the growth hormonereleasing hormone receptor. Vitam Horm. 59:35-69.
Pethick, D.W. 1984. Energy metabolism of skeletal muscle. In: Gawthorne J.M., Baker S.K.,
Mac Kintosh J.B., Purser D.B., editors, Ruminant Physiology. Concepts and
Consequences, Symposium held at University of Western Australia,7–10 May 1984,
Nedlands, Australia. p. 277–287.
Pollak, M. 2008. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer.
8:915-928.
Postel-Vinay, M., and P. A. Kelly. 1996. Growth hormone receptor signaling. Baillieres clin
endocrinol metab. 10: 323-336.
Qunon, M. J., A. T. Butte, M. J. Zarnowsky, G. Sesti, S. W. Cushman, S. I. Taylor. 1994. Insulin
receptor substrate mediated the stimulatory effects of insulin on GLUT-4 translocation in
transfected rat adipose cells. J Biol Chem. 269:27920–27924.
Rausch, M. I., M. W. Tripp, K. E. Govoni, W. Zang, W. J. Webert, B. A. Crooker, T. A.
Hoagland, and S. A. Zinn. 2002. The influence of level of feeding on growth and serum
insulin-like growth factor I and insulin-like growth factor-binding proteins in growing
beef cattle supplemented with somatotropin. J Anim Sci. 80: 94-100.
Redmer, D. A., J. M. Wallace, and L. P. Reynolds. 2004. Effect of nutrient intake during
pregnancy on fetal and placental growth and vascular development. Domest Anim
Endocrin. 27:199-217.

117

Reed, J. J., M. A. Ward, K. A. Vonnahme, T. L. Neville, S. L. Julius, P. P. Borowicz, J. B.
Taylor et al. 2007. Effects of selenium supply and dietary restriction on maternal and
fetal body weight, visceral organ mass and cellularity estimates, and jejunal vascularity in
pregnant ewe lambs. J Anim Sci. 85: 2721-2733.
Renaville, R., M. Hammadi, and D. Portetelle. 2002. Role of the Somatotropic Axis in the
Mammalian Metabolism. Domest Anim Endocrin. 23:351-60.
Reynolds, L. P., C. L. Ferrell, J. A. Nienaber, and S. P. Ford. 1985. Effects of chronic
environmental heat stress on blood flow and nutrient uptake of the gravid bovine uterus
and foetus. J Agric Sci Camb. 104:289-297.
Reynolds, L. P. and D. A. Redmer. 1995. Utero-placental vascular development and
placental function. J Anim Sci. 73:1839-1851.
Ribon, V., and A. R. Saltiel. 1997. Insulin stimulates tyrosine phosphorylation of the protooncogene product of c-Cbl in 3T3-L1 adipocytes. Biochem J. 324: 839.
Ribon, V., J. A. Printen, N. G. Hoffman, B. K. Kay, and A. R. Saltiel. 1998. A novel,
multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes.
Mol Cell Biol.18:872-879.
Rondinone, C. M., L. Wang, P. Lonnroth, C. Wesslau, J. H. Pierce, and U. Smith. 1997. Insulin
receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for
phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent
diabetes mellitus. P Nat Acad Sci. 94: 4171-4175.
Rotwein, P., K. M. Pollock, D. K. Didier, and G. G. Krivi. 1986. Organization and sequence of
the human insulin-like growth factor i gene. Alternative RNA processing produces two
insulin-like growth factor i precursor peptides. J Biol Chem. 261:4828-4832.
Rudman, D., M. H. Kutner, C. M. Rogers, M. F. Lubin, G. A. Fleming, and R. P. Bain. 1981.
Impaired growth hormone secretion in the adult population: relation to age and adiposity.
J Clin Invest. 67:1361-1369.
Saltiel, A. R. and C.R. Kahn. 2001. Insulin signalling and the regulation of glucose and lipid
metabolism. Nature. 414:799-806.
Samuelsson, A., P. A. Matthews, M. Argenton, M. R. Christie, J. M. McConnell, E. H. Jansen,
A. H. Piersma, S. E. Ozanne, D. F. Twinn, C. A. Rowlerson, L. Poston, P. D. Taylor.
2008. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity,
hypertension, and insulin resistance A novel murine model of developmental
programming. Hypertension. 51: 383-392.
Sasaki, S. 2002. Mechanism of insulin action on glucose metabolism in ruminants. Anim
Sci J. 73: 423-433.
118

Schneider, H. 1996. Ontogenic changes in the nutritive function of the placenta.
Placenta. 17:15-26
Schwartz, M. W. 2001. Brain pathways controlling food intake and body weight. Exp Biol Med.
226: 978-981.
Schwartz, M. W., R. J. Seeley, L. A. Campfield, P. Burn, and D. G. Baskin. 1996. Identification
of targets of leptin action in rat hypothalamus. J Clin Invest. 98: 1101.
Seal, C. J., and C. K. Reynolds. 1993. Nutritional implications of gastrointestinal and liver
metabolism in ruminants. Nutr Res Rev. 6: 185-208.
Shankar, K., A. Harrell, X. Liu, J. M. Gilchrist, M. J. J. Ronis, and T. M. Badger. 2008.Maternal
obesity at conception programs obesity in the offspring. Am J Physiol-Reg I. 294, no.
2: R528-R538.
Shi, Z., W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy. 2000. ADAM 12, a disintegrin
metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem.
275: 18574-18580.
Shimasaki, S. and N. Ling. 1991. Identification and molecular characterization of insulin-like
growth factor binding proteins (IGFBP-1,-2,-3,-4,-5 and-6). Prog Growth Factor
Res. 3:243-266.
Sivitz, W. I., S. A. Walsh, D. A. Morgan, M. J. Thomas, and W. G. Haynes. 1997. Effects of
leptin on insulin sensitivity in normal rats. Endocrinol. 138: 3395-3401.
Siwanowicz, I., G. M. Popowicz, M. Wisniewska, R. Huber, K. Kuenkele, K. Lang, R. A. Engh,
and T. A. Holak. 2005. Structural basis for the regulation of insulin-like growth factors
by IGF binding proteins. Structure. 13: 155-167.
Skaar, T. C., C. R. Baumrucker, D. R. Deaver, and J. W. Blum. 1994. Diet effects and ontogeny
of alterations of circulating insulin-like growth factor binding proteins in newborn dairy
calves. J Anim Sci. 72: 421-427.
Smith, P.J., E. L. Spurrell, J. Coakley, C. J. Hinds, R. J. Ross, A. R. Krainer, S. L. Chew. 2002.
An exonic splicing enhancer in human igf-i pre-mrna mediates recognition of alternative
exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor.
Endocrinol. 143:146-154.
Soos, M. A., C. E. Field, and K. Siddle. 1993. Purified hybrid insulin/insulin-like growth factor-I
receptors bind insulin-like growth factor-i, but not insulin,with high affinity. Biochem J.
290:419-426.

119

Sosa. C., J.A. Albecia, M. Carriquiry, F. Forcada, G.B. Martin, I. Palacin, and A. Meikle. 2009.
Early pregnancy alters the metabolic responses to restricted nutrition in sheep. Domest
Anim Endocrinol. 36:13-23.
Stegeman, J. H. J. 1974. Placental development in the sheep and its relation to fetal development:
a qualitative and quantitative anatomic and histologic study. Universiteit van Amsterdam,
1974.
Stephens, T. W., M. Basinski, P. K. Bristow, J. M. Bue-Valleskey, S. G. Burgett, L. Craft, J.
Hale, J. Hoffmann, H. M. Hsiung, A. Kriauciunas, W. Mackellar, P. R. Rosteck, B.
Schoner, D. Smith, F. C. Tinsley, X. Zhang, and M. Heiman. 1995. The role of
neuropeptide Y in the antiobesity action of the obese gene product. Nature. 377: 530-532.
Straus, D. S. 1994. Nutritional regulation of hormones and growth factors that control
mammalian growth. FASEB. 8:7-12.
Straus, D. S. and C. D. Takemoto. 1990. Effect of fasting on insulin-like growth factor-I (IGF-I)
and growth hormone receptor rnRNA levels and IGF-I gene. Mol Endocrinol. 4:91-100.
Swanson, T. J., C. J. Hammer, J. S. Luther, D. B. Carlson, J. B. Taylor, D. A. Redmer, T. L.
Neville et al. 2008. Effects of gestational plane of nutrition and selenium supplementation
on mammary development and colostrum quality in pregnant ewe lambs. J Anim Sci.
86: 2415-2423.
Szanto, I. and C. R. Kahn. 2000. Selective interaction between leptin and insulin signaling
pathways in a hepatic cell line. P Nat Acad Sci. 97: 2355-2360.
Tartaglia, L. A., M. Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards, L. A.
Campfield, F. T. Clark, J. Deeds, C. Muir, S. Sanker, A. Moriarty, K. J. Moore, J S.
Smutko, G. G. Mays, E. A. Wool, C. A. Monroe, and R. I. Tepper. 1995. Identification
and expression cloning of a leptin receptor, OB-R. Cell. 83: 1263-1271.
Tavakkol, A., F. A. Simmen, and R. C. M. Simmen. 1988. Porcine insulin-like growth factor-I
(pIGF-I): complementary deoxyribonucleic acid cloning and uterine expression of
messenger ribonucleic acid encoding evolutionary conserved IGF-I peptides. Mol
Endocrinol. 2: 674-681.
Thomas, T., B. Burguera, L. J. Melton III, E. J. Atkinson, W. M. O’Fallon, B. L. Riggs, and S.
Khosla. 2001. Role of serum leptin, insulin, and estrogen levels as potential mediators of
the relationship between fat mass and bone mineral density in men versus women. Bone
29: 114-120.
Thomas, V. M., and R. W. Kott. 1995. A review of Montana winter range ewe nutrition
research. Sheep Goat Res. J. 11:17-24.

120

Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence weighting,
position-specific gap penalties and weight matrix choice. Nucleic Acids Res.
22:4673-4680.
Thorn, S. R., P. J. Rozance, L. D. Brown, and W. W. Hay Jr. 2011. The intrauterine growth
restriction phenotype: fetal adaptations and potential implications for later life insulin
resistance and diabetes. Semin Reprod Med. 29: 225. NIH Public Access.
Titlbach, M., K. Fält, and S. Falkmer. 1985. Post-natal maturation of the islets of Langerhans in
sheep. Light microscopic, immunohistochemical, morphometric, and ultrastructural
investigations with particular reference to the transient appearance of argyrophil insulin
immunoreactive cells. Diabetes Res. (Edinburgh, Scotland) 2: 5.
Tokuda, T., and H. Yano. 2001. Blood leptin concentrations in Japanese Black cattle. Anim Sci.
72: 309-313.
Tokuda, T., C. Delavaud, and Y. Chilliard. 2003. Plasma leptin concentration in pre-and postweaning lambs. Anim Sci. 76: 221-227.
Tricoli, J. V., L. B. Rall, J. Scott, G. I. Bell, T. B. Shows. 1984. Localization of insulin-like
growth factor genes to human chromosomes 11 and 12. Nature. 310:784-786.
Tuggle, C.K. and A. Trenkle. 1996. Control of growth hormone synthesis. Domest Anim
Endocrinol. 13:1-33.
Unger, R. H., and L. Orci. 2001. Diseases of liporegulation: new perspective on obesity and
related disorders. The FASEB Journal. 15: 312-321.
Valinsky, A., M. Shani, and E. Gootwine. 1990. Restriction fragment length polymorphism in
sheep at the growth hormone locus is the result of variation in gene number.
Anim Biotechnol. 1:135-144.
Veldhuis, J. D., A. Iranmanesh, K. Ky Ho, M. J. Waters, M. L. Johnson, and G. Lizarralde. 1991.
Dual defects in pulsatile growth hormone secretion and clearance subserve the
hyposomatotropism of obesity in man. J Clin Endocr Metab. 72:51-9.
Vincent, A. M. and E. L. Feldman. 2002. Control of cell survival by IGF signaling pathways.
Growth Horm IGF Res. 12:193-197.
Vonnahme, K. A., B. W. Hess, T. R. Hansen, R. J. McCormick, D. C. Rule, G. E. Moss, W.
J. Murdoch, M. J. Nijland, D. C. Skinner, P. W. Nathanielsz, and S. P. Ford. 2003.
Maternal undernutrition from early to mid-gestation leads to growth retardation, cardiac
ventricular hypertrophy and increased liver weight in the fetal sheep. Biol Reprod.
69:133-140.
121

Vonnahme, K. A., J. S. Luther, L. P. Reynolds, C. J. Hammer, D. B. Carlson, D. A. Redmer, and
J. S. Caton. 2010. Impacts of maternal selenium and nutritional level on growth,
adiposity, and glucose tolerance in female offspring in sheep. Domest Anim Endocrin.
39: 240-248.
Wallace, A. L. C., and J. M. Bassett. 1966. Effect of sheep growth hormone on plasma
insulin concentration in sheep. Metabolism. 15:95-97.
Wallace, J. M., J. S. Milne, and R. P. Aitken. 2004. Maternal growth hormone treatment
from day 35 to 80 of gestation alters nutrient partitioning in favor of uteroplacental
growth in the overnourished adolescent sheep. Biol Reprod. 70:1277-1285.
Wang, M., L. Chen, G. O. Clark, Y. Lee, R. D. Stevens, O. R. Ilkayeva, B. R. Wenner, J. R.
Bain, M. J. Charron, C. B. Newgard, and R. H. Unger. 2010. Leptin therapy in insulindeficient type I diabetes. P Nat Acad Sci. 107: 4813-4819.
Wang, P., F. Yang, H. Du, Y. Guan, T. Xu, X. Xu, D. Su, and C. Miao. 2011. Involvement of
Leptin Receptor Long Isoform (LepRb)-STAT3 Signaling Pathway in Brain Fat Mass–
and Obesity-Associated (FTO) Downregulation during Energy Restriction. Mol Med.
17: 523.
Wang, Y., K. K. Kuropatwinski, D. W. White, T. S. Hawley, R. G. Hawley, L. A. Tartaglia,
and H. Baumann. 1997. Leptin receptor action in hepatic cells. J Biol Chem.
272: 16216-16223.
Wang, S., Y. Yeh, S. Yang, C. Chai, and K. Lee. 2006. Potential role of leptin expression in
hepatocellular carcinoma. J Clin Pathol. 59: 930-934.
Weber, W. J., L. H. Baumgard, G. W. Kazmer, S. A. Zinn, L. B. Hansen, H. Chester-Jones, and
B. A. Crooker. 2005. Growth hormone response to growth hormone releasing hormone in
calves that differ in genetic merit for milk yield. J Dairy Sci. 88: 1723-1731.
Wheatcroft, S. B., and M. T. Kearney. 2009. IGF-dependent and IGF-independent actions of
IGF-binding protein-1 and-2: implications for metabolic homeostasis. Trends Endocrin
Met. 20: 153-162.
White, D. W., and L. A. Tartaglia. 1996. Leptin and OB-R: body weight regulation by a cytokine
receptor. Cytokine Growth F. 7: 303-309.
White, M. F., and C. R. Kahn. 1994. The insulin signaling system. J Biol Chem. 269.
Wilson, M. E. 2002. Role of placental function in mediating conceptus growth and
survival. J Anim Sci. 80:E195-E201.
Wood, I.S. and P. Trayburn. 2003. Glucose transporters (GLUT and SGLT): expanded
families of sugar transport proteins. Br J Nutr. 89: 3–9.
122

Wootton, R., P. A. Flecknell, J. P. Royston, and M. John. 1983. Intrauterine growth
retardation detected in several species by nonnormal birth weight distributions. J Reprod.
Fertil. 69:659-663.
Wu, G., F. W. Bazer, J. M. Wallace, and T. E. Spencer. 2006. Intrauterine Growth
Retardation: Implications for the Animal Sciences. J Anim Sci. 84:2316-337.
Yamada, P. M. and K. W. Lee. 2009. Perspectives in mammalian IGFBP-3 biology: local vs.
systemic action. Am J Physiol-Cell Ph. 296:C954-C976.
Yamauchi, T., J. K., H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami,
N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M. L.
Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura,
M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin
reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med.
7: 941-946.
Yoshida, M., Y. Iwasaki, M. Asai, S. Takayasu, T. Taguchi, K. Itoi, K. Hashimoto, and Y. Oiso.
2006. Identification of a functional AP1 element in the rat vasopressin gene promoter.
Endocrinol. 147: 2850-2863.
Zhang, L., N. M. Long, S. M. Hein, Y. Ma, P. W. Nathanielsz, and S. P. Ford. 2011. Maternal
obesity in ewes results in reduced fetal pancreatic β-cell numbers in late gestation and
decreased circulating insulin concentration at term. Domest Anim Endocrin. 40: 30-39.
Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman. 1994. Positional
cloning of the mouse obese gene and its human homologue. Nature. 372: 425-432.
Zhao, A. Z., M. M. Shinohara, D. Huang, M. Shimizu, H. Eldar-Finkelman, E. G. Krebs, J. A.
Beavo, and K. E. Bornfeldt. 2000. Leptin induces insulin-like signaling that antagonizes
cAMP elevation by glucagon in hepatocytes. J Biol Chem. 275: 11348-11354.
Zhu, M. J., M. Du, P. W. Nathanielsz, and S. P. Ford. 2010. Maternal obesity up-regulates
inflammatory signaling pathways and enhances cytokine expression in the mid-gestation
sheep placenta. Placenta. 31: 387-391.
Zhu, T., E. L. K. Goh, and P. E. Lobie. 1998. Growth hormone stimulates the tyrosine
phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2 Fak is
not required for stat-mediated transcription. J Biol Chem. 273: 10682-10689.
Zwad, O., B. Kubler, W. Roth, J. Scharf, P. Saftig, C. Peters, and T. Braulke. 2002. Decreased
intracellular degradation of insulin-like growth factor binding protein-3 in cathepsin Ldeficient fibroblasts. FEBS Letters. 510:211-215.

123

